SA01, Systemic and Topical Delivery of Anti-HIV Monoclonal Antibodies to Prevent HIV Transmission

This workshop will present an overview of anti-HIV monoclonal antibody (mAb) production platforms, nonhuman primate research on HIV mabs and SIV/SHIV infection, research on mAb function in mucosal tissues, and ongoing clinical trials employing the systemic and topical delivery of mabs to prevent HIV transmission. The workshop will end with a panel discussion on future directions of the field.

Chairs:
Deborah Anderson (Boston University School of Medicine, United States)
Kevin Whaley (Mapp Biopharmaceutical, United States)
Ruth Ruprecht (Texas Biomedical Research Institute, United States)
Francois Villinger (University of Louisiana at Lafayette, United States)
Kenneth H. Mayer (Fenway Health, United States)
Galit Alter (Ragon Institute of MGH, MIT and Harvard, United States)
SA05, Advocates Pre-conference Workshop: Strengthening Advocacy for Research to Rollout

The current landscape in HIV prevention offers new opportunities and challenges to advocates across the world involved and/or interested in biomedical HIV prevention research and development as well as the implementation of positive results into policies and programs. Advocates are at the forefront of advocating for the rollout of PrEP as well as helping to develop guidelines and implementation plans to roll it out. They are key collaborators in efforts to monitor rollout of early treatment and VMMC, as well contribute to the important dialogues on how research for new interventions for women’s prevention meet women’s needs. Advocates have championed the voices of key groups whose access to new interventions is imperative if they are to be successful and, as a result, have helped bring them to the table. At the same time, they are engaged in discussions around trials of vaccines, long-acting injectables, antibody mediated prevention and multipurpose prevention technologies.

International and national advocacy partners will hold a day-long pre-conference workshop to equip advocates, new investigators, community liaison officers at trials and other interested stakeholders to more fully participate in biomedical HIV prevention research and the HIV R4P conference. The workshop will provide an overview of the field to contextualize the themes and issues that will be presented at HIV R4P; will connect research and advocacy priorities and explore common goals; and build the capacity of advocates and trial staff to better engage with emerging issues in the field.

The pre-conference workshop will feature seasoned advocates and researchers from the HIV prevention research field who will provide new and experienced advocates, community representatives and trial staff with latest updates and previews on topics to be presented at the conference.

Please click here to view the full session agenda, and click the link below to register for the Advocates pre-conference workshop.
https://www.surveymonkey.com/r/ZHZNDVP

Chairs:
Sallie Permar (Duke University Medical Center)

Advocates Pre-conference Workshop: Strengthening Advocacy for Research to Rollout
SA03, The Next Wave in HIV Prevention: Multipurpose Prevention Technologies (MPTs)

Multipurpose prevention technologies (MPTs) are an important class of prevention options for women offering combinations of HIV protection, other STI protection, and contraception. MPTs have high potential for public health impact, and achieving this potential can be attained only through optimized funding and objective and informed consideration of market drivers and technical aspects of MPT development and delivery. Building from the key recommendations from the IMPT’s technical meeting on MPT clinical trial evaluation and design (CTED) Clinical Evaluation Workshop for MPTs in September, the objective of this satellite is to further the development of a consensus strategy unifying funders, developers, and market entities in the product neutral assessment of relevant MPT market drivers and technical options, and eliminate impediments to appropriate MPT development define the technical, clinical and market data required to justify progressing an appropriately optimal MPT product through regulatory licensure and into a successful commercial launch. This session will 1) examine the value and impact potential of MPTs; 2) assess key MPT market drivers and data needs; and 3) identify relevant technical considerations that are responsive to MPT market drivers. Panels of product development, advocacy, social-behavioral, and market evaluation experts will report back on CTED clinical trial meeting recommendations and participate in focused discussions of these critical issues. Session attendees will be directly engaged in structured discussions to inform multi-faceted strategies to achieve successful development and uptake of MPTs.

Chairs:
Elizabeth Bukusi (KEMRI, Kenya)
Bethany Young-Holt (Initiative for Multipurpose Prevention Technologies (IMPT), United States)

The Next Wave in HIV Prevention: Multipurpose Prevention Technologies (MPTs)
Mike Chirenje (University of Zimbabwe, Zimbabwe)
Joseph Romano (NW Group, LLC, United States)
Andrea Ries Thurman (CONRAD Eastern Virginia Medical School, United States)
Kavita Nanda (FHI 360)
Amy Lin (USAID)
Martha Brady (Population Council)
SA02, Addressing the Leading Edge of the HIV Epidemic in the U.S.: Advancing Prevention Programs for Urban YMSM

Experts in social, biomedical, and network sciences will present research on the HIV prevention needs of urban young men who have sex with men (YMSM). The session will detail recent trends in the domestic HIV epidemic among men who have sex with men (MSM), provide insight into structures that determine HIV risk, and discuss the path forward as existing and future interventions are implemented.

Keynote. Kenneth Mayer, MD will present recent survey and epidemiologic data on the state of the HIV epidemic in YMSM. The keynote will discuss ongoing prevention efforts and identify opportunities for expanding prevention initiatives.

Panel 1. Social and network factors that drive the HIV epidemic. Scientists will examine HIV risk through the lens of interpersonal relationships at multiple levels (sexual/romantic dyads, families, and social/sexual networks).

Panel 2. Engagement and adherence strategies for biomedical prevention. Experts will present up-to-the-minute results on biomedical prevention acceptability, uptake, adherence, and outcomes for YMSM.

Chairs:
Alida Bouris (University of Chicago, United States)
Sybil Hosek (Stroger Hospital of Cook County, United States)
Brian Mustanski (Northwestern University, United States)

Addressing the Leading Edge of the HIV Epidemic in the US: Advancing Prevention Programs for Urban YMSM
Kenneth H. Mayer (Fenway Health, United States)
Brian Mustanski (Northwestern University, United States)
Aditya Khanna (University of Chicago, United States)
Alida Bouris (University of Chicago, United States)
Sybil Hosek (Stroger Hospital of Cook County, United States)
Michael Newcomb (Northwestern University, United States)

SA04, HIV Vaccine Design and Development Partnerships in Africa: Showcasing African-led Basic HIV Prevention Science Research

Despite impressive capacity strengthening for HIV research in Africa, there are still gaps. Many of the efforts were directed toward epidemiological and clinical studies, but basic science research capacity is still low. New partnership models are beginning to increase the engagement of Africans in Africa in basic HIV prevention research. This brings novel opportunities for South-South and South-South collaborations for discovery and innovation and promotes multidisciplinary approaches. The coming wave of change facilitates more initiatives addressing these gaps while harnessing the role African scientists and institutions play in basic research. We will bring together African scientists, policy makers, advocates, and institutions involved in HIV prevention research to share success stories, identify gaps and challenges, and propose opportunities for enhanced collaborations with a focus on discovery and innovation, as well as young scientists. The session will feature design and development partnership models, each with a brief overview from a leadership representative and short presentations by two junior investigators. In advance and during the session, presenters, participants, and those who can't attend will be invited to share their ideas of the next priorities for African research. These will be discussed in a final panel discussion on the way forward.

Chairs:
Pontiano Kaleebu (UVRI, Uganda)
Tumani Corra (Africa Research Development, Medical Research Council (MRC), The Gambia)
Margaret Mccluskey (USaid, United States)
William Snow (Global HIV Vaccine Enterprise, United States)
HIV Vaccine Design and Development Partnerships in Africa: Showcasing African-led Basic HIV Prevention Science Research

Satellites
09:00 - 11:00
Sheraton Ballroom II

SA07, Engagement from All Angles: Advocates, Sponsors, and Implementers Discuss GPP in Action

The Good Participatory Practice Guidelines (GPP) provide implementers with a framework for broad stakeholder engagement throughout research processes. GPP is increasingly becoming the gold standard of engagement practices, especially since the release of the second edition of the guidelines in 2011. As GPP implementation continues, predominantly at trial site level, some debate has emerged over who is responsible for supporting and implementing GPP, whose role it is to involve various stakeholder groups, and when to begin and end trial and/or research engagement. This satellite session will provide an update on global GPP implementation and an interactive discussion around roles and responsibilities of various research entities and advocacy groups, such as AVAC. Case studies will be presented to highlight organizational approaches, successes, and challenges around implementing GPP, including in research studies involving vulnerable populations. A sponsor perspective will articulate how GPP is being implemented beyond individual trial sites and will explore the benefit of an institutional approach to GPP. Finally, session leaders and participants will reflect on the value of monitoring the impact of GPP and how GPP indicators can inform effective stakeholder engagement processes at all levels.

Chairs:
Stacey Hannah (AVAC)
Deborah Baron (Wits Reproductive Health and HIV Institute)

Engagement from All Angles: Advocates, Sponsors, and Implementers Discuss GPP in Action

Sinazo Pato (Wits Reproductive Health and HIV Institute)
Mitchell Warren (AVAC, United States)

SA06, From Basic to Population Sciences: How to Understand and Prevent HIV Transmission: Vaccines and Sexual Transmission

Ending HIV infection requires a better understanding of HIV transmission at the cellular, clinical, and social levels with a comprehensive and innovative approach. Here, outcomes and ongoing research results, spanning from understanding the physiology of the target cell and the initial processes of infection in mucosal tissues in order to develop blocking antibodies and vaccine antigens to the use of biodegradable nanoparticles in HIV vaccine development and the effect of male circumcision in South Africa on HIV infection of women at population scale, will be presented. The current state of the art in biomedical prevention tools such as PrEP, vaccines, and antibodies as well as evidence-based public policies will be discussed.

These multidisciplinary research projects in HIV transmission were funded by the Pierre Bergé endowment fund in collaboration with Sidaction.

Chairs:
Jean-Daniel Lelievre (INSERM/VRI, France)
Bonnie Mathieson (Office of AIDS Research, United States)
From Basic to Population Sciences: How to Understand and Prevent HIV Transmission: Vaccines and Sexual Transmission

Roger Le Grand (Commissariat à l’Énergie Atomique (CEA), France)
Christiane Moog (INSERM U1109, FMTS, Université de Strasbourg, France)
Bertran Auvert (INSERM U1018, France)
Philippe Van De Perre (INSERM, France)

Satellites
09:00 - 11:00
Erie

SA08, Replicating HIV Prevention Impact Evaluations

Three decades of work on HIV prevention have yielded a series of effective biomedical, behavioral, social, and structural interventions among specific population groups in small-scale settings and/or in controlled trials. Although most interventions show clear potential for a major impact in reducing HIV and the associated human and economic costs, the importance of the effort to prevent HIV and the magnitude of effort required to scale up any evidence-based intervention require the study results to be carefully reviewed, understood, and confirmed before scaling up interventions. Replications are the most established method of research validation in science. Replications funded by 3ie are internal replications—those that use data from the original study, and possibly existing secondary datasets from the same location, in order to check the validity and robustness of the findings and recommendations in order to inform scaling up interventions. Panelists will present five replications of impact evaluations involving HIV prevention from a Thematic Replication Window that will be published in the International Initiative for Impact Evaluations (3ie) Replication Paper Series. In addition, Ben Wood will present the benefits of replication for impact evaluations around HIV prevention interventions as well as previous replications from 3ie.

Chairs:
Ben Wood (International Initiative for Impact Evaluation)

Replicating HIV Prevention Impact Evaluations
Baojiang Chen (University of Texas Health Science Center)
Eric Djimeu (International Initiative for Impact Evaluation)
Fang Yu (University of Nebraska Medical Center)
Jiangtao Luo (University of Nebraska Medical Center)
Lynette Smith (University of Nebraska Medical Center)

Conference Event
11:00 - 16:00
Columbus B

Speaker Check-In
Non-human primates (NHPs) have been indispensable for modeling HIV susceptibility, infection, and pathogenesis, as well as for the development of prophylactic and therapeutic interventions. Macaque models are used to evaluate safety and determine pharmacokinetics (PK)/pharmacodynamics (PD) relationships of prevention products. Several SIV and chimeric SIV/HIV (SHIV) models in macaques are utilized for testing efficacy of HIV prevention strategies. These models encompass both stringent high viral dose challenge, often with progesterone pre-treatment to thin the vaginal epithelium, and the more physiologically relevant repeated low-dose challenge. Importantly, studies carefully mimicking the designs of vaccine (Step) and PreP (iPrEx) clinical trials suggest that NHP models can recapitulate the results of studies in humans. Recently, new in vivo (HSV-2, T. vaginalis and C. trachomatis) and ex vivo (HSV-2) STI models (single or coinfection with SHIV) were established, providing an opportunity to test prevention strategies in high-risk HIV transmission settings. Session objectives include: 1. Show how macaques are a valuable tool to test preclinical safety and efficacy of microbicides, PrEP, and vaccines targeting HIV and/or other STIs, 2. Discuss selection of models for prevention studies in macaques, 3. Discuss future strategies for prevention studies in macaques.

Chairs:
Elena Martinelli (Population Council, United States)
Walid Heneine (CDC, United States)
Nina Derby (Population Council)
Dorothy Patton (University of Washington, United States)
Natalia Teleshova (Population Council, United States)
Jeffrey Lifson (National Institutes of Health, United States)
Dan Barouch (Beth Israel Deaconess Medical Center, United States)
Despite the success of many vaccines in the young age groups, our understanding of vaccine-elicited immune responses in infants, and how they differ from those of adults remains limited. Important factors that distinguish the infant immune system from that of adults include differences in effector cell subsets, immune-regulatory mechanisms of fetal development, passive acquisition of maternal antibodies, and limited pre-exposure to environmental immune stimuli. These immunologic differences may result in distinct immune responses following infant and adult vaccination. An understanding of the infant immune landscape is therefore critical for the design and selection of vaccines and vaccine adjuvants that will elicit optimal immune responses and target long-term immunity in infants. The workshop goal is to achieve a better understanding of the complex interplay between the maturing immune system and distinct immune responses to HIV and non-HIV vaccines in infants, that will not only inform upon prevention strategies to develop efficacious HIV vaccine candidates, but may also lead to the identification of correlates of susceptibility to HIV infection and improved animal models to test HIV prevention modalities. The workshop presentations and panel discussions aim to foster collaborative opportunities among experts targeting HIV and non-HIV prevention strategies, and to further inform and prioritize vaccine design and immunization approaches for guiding effective and comprehensive HIV prevention efforts in infants.

OBJECTIVES
• To probe the relationship between infant immune landscape and distinct immune responses to HIV and non-HIV vaccines in pediatric populations from that of adults.
• To address the research gaps to understand establishment of adaptive immunity during infancy that results in distinct immune responses in infants following HIV vaccination.
• To determine optimal animal model system(s) to test proof of concept by immune responsiveness of the HIV vaccine candidates in infants.
• To identify avenues to facilitate HIV vaccine design, development, testing and effectiveness in infants.

Chairs:
Sallie Permar (Duke University Medical Center)
Anjali Singh (Division of AIDS, NIAID, NIH)

Vaccine Elicited Immunity in the Pediatric Immune System
Sallie Permar (Duke University Medical Center)
Anjali Singh (Division of AIDS, NIAID, NIH)
Rebecca Adkins (University of Miami, United States)
Hayley Gans (Stanford University, United States)
Ann J. Hessell (Oregon Health & Science University, Oregon National Primate Research Center, United States)
Tobias Kollmann (University of British Columbia, Canada)
Ofer Levy (Boston Children’s Hospital, United States)
Joseph Mccune (University of California San Francisco, United States)
Elizabeth McFarland (Children’s Hospital Colorado, United States)
Julie Overbaugh (Fred Hutchinson Cancer Research Center, United States)
Octavio Ramilo (The Ohio State University, United States)
Stuart Shapiro (DAIDS/NIAID/NIH, United States)
Georgia Tomaras (Duke University, United States)
SA09, Engaging High-risk Fishing Communities in HIV Prevention Research

Studies in Lake Victoria fishing communities have documented high HIV incidence and limited access to healthcare and HIV services. In fishing communities in Uganda, the overall HIV incidence is about 5-fold greater than the surrounding agrarian population. Incidence is equally high in Kenya and under investigation in Tanzania. The fishing communities are home to over a million people, and heterogeneous in structure. HIV risks vary with occupation, mobility, age, and alcohol use. The Lake Victoria Health Research Consortium (LVHRC), composed of research organizations in Uganda, Kenya, and Tanzania, with IAVI, is conducting research activities among the fishing communities and has demonstrated that the populations can be meaningfully engaged in health research and that this population could be important for large-scale HIV prevention trials. This session will provide brief descriptions and characteristics of the cohorts and key research questions addressed with an emphasis on HIV epidemiology and risk factors, HIV prevention/care interventions. The session will in addition review the access to care, engagement in research, and care. Discussion will focus on additional research questions, ethical concerns, and the potential for Lake Victoria fishing communities to participate in future large-scale HIV prevention studies and treatment scale-up.

Chairs:
Anatoli Kamali (International AIDS Vaccine Initiative, Kenya, Kenya)
Saidi Kapiga (London School of Hygiene and Tropical Medicine, Mwanza Intervention Trials Unit, Tanzania, United Republic of)

Engaging High-risk Fishing Communities in HIV Prevention Research

SA13, Long-acting Drug Release Systems for PrEP and Treatment

There is currently great interest in increasing antiretroviral adherence by using long-acting drug delivery systems that do not require daily dosing by HAART and PrEP users. These systems will increase adherence to control or prevent HIV infection. Drs. Patrick Kiser and Thomas Hope, co-Pis on the SLAP-HIV UM1, host this workshop to bring together experts in the field to discuss various approaches to sustained release of antiretrovirals including lymphatic delivery, controlled release refillable implant systems, degradable implants, controlled release implants, long-acting intravaginal rings, and injectable nanoformulations. This meeting will have broad appeal to HIVR4P attendees interested in sustained-release PrEP approaches that increase adherence and subsequent protection from HIV acquisition. The workshop’s cross-disciplinary and translational focus will drive innovation, stimulate interactions, and facilitate the exchange of ideas to catalyze the development of sustained release PrEP. In this satellite, six speakers will give 20-minute presentations followed by 5 minutes of discussion.

Chairs:
Craig Hendrix (Johns Hopkins School of Medicine, United States)
Peter Anton (University of California, Los Angeles, United States)

Long-acting Drug Release Systems for PrEP and Treatment

Rodney Ho (University of Washington, United States)
Alessandro Grattoni (Houston Methodist Research Institute, United States)
William Lykins (University of California, San Francisco, United States)
Meredith R. Clark (CONRAD, Eastern Virginia Medical School, United States)
Patrick Kiser (Northwestern University, United States)
Bill Spreen (GSK/ViiV)
SA12, Germline Targeting Immunogens: Taking the First Steps toward bNAb Development

It is becoming more and more evident that unique approaches may be necessary to elicit broadly neutralizing antibodies (bNAb) against HIV through vaccination. Looking back to understand the germline versions of the antibodies that have been isolated from patients has given the field potential clues as to the way forward. The emerging vaccine strategy of immunizing people with a series of different engineered HIV proteins as immunogens in order to teach the immune system to produce HIV bNAb from these germline beginnings, has generated a great deal of interest and momentum. To this end, it was recently reported that HIV-1 bNAb precursor B cells for one particular class of bNAb are present in most people, and that an HIV vaccine germline-targeting immunogen can be designed that is capable of binding those B cells. The recent development of knock-in mouse models with germline bNAb precursor B cells has also opened the door to immunization testing of germline-targeting immunogens and follow-on boosting regimens. With different bNAb targets on the Env protein being investigated by several groups, the field is set for researchers to assess whether other new vaccine proteins can bind and activate their intended precursor B cells, and whether boosting protocols can be devised to mature the response toward bNAb activity. These types of experiments provide the ability to vet germline-targeting and boosting immunogens before testing them in large, time-consuming and costly clinical trials.

Chairs:
William Schief (The Scripps Research Institute and IAVI, United States)
Barton Haynes (Duke University, United States)
Andrew McGuire (Stamatatos Lab, FHCRC)
John Mascola (National Institute of Allergy and Infectious Diseases, NIH, United States)
Amelia Escolano (Nussenzweig Lab, Rockefeller)
Dennis Burton (The Scripps Research Institute, United States)
Peter Kwong (Vaccine Research Center, United States)

SA14, Target Product Profile for HIV Vaccines

Registration is required for attendance. Space is limited. Please click the link below to register.

https://app.smartsheet.com/b/form?EQBCT=c28196bb7f1240c3bef9bbed47a63dd9

Target Product Profile (TPP) is a strategic document that lists key attributes of a candidate vaccine as well as studies required to support the claims. First developed by FDA to facilitate discussions with drug developers, TPP is now widely used in industry to ensure that all team members are working toward common goals and targets. Funders of HIV vaccine R&D are increasingly asking researchers to create TPPs for their vaccine candidates. In this hands-on workshop, product development experts will guide small groups of attendees through creation of TPP for a fictional preventive HIV vaccine candidate. Participants will learn about key elements of TPP, what choices have to be made in prioritizing attributes, and how set targets define the path for product development. Space is limited, advance registration is required for attendance.

Chairs:
Yegor Voronin (Global HIV Vaccine Enterprise, United States)
Target Product Profile for HIV Vaccines
Sanjay Phogat (Sanofi Pasteur)
James Ackland (International AIDS Vaccine Initiative)
Charla Andrews (NIAID)
Jane Halpern (National Institute of Allergy and Infectious Diseases)
Dagna Laufer (International AIDS Vaccine Initiative)

Satellites
13:30 - 15:30
Chicago Ballroom IX

SA15, Designing Prevention Clinical Trials in the Era of Highly Effective Combination Prevention

We are at a pivotal moment in HIV prevention where highly effective HIV prevention, particularly PrEP, has been developed but is not yet accessible to the majority of the population in need. Further advance in prevention requires the development of vaccines, alternative oral regimens, and long-acting or coitally dependent dosing strategies. Clinical trials in HIV prevention lack a surrogate, and any efficacy study is a resource-intensive undertaking. The issues of populations in which new agents should be tested, the comparator arms, and the standard package of prevention services present statistical and ethical challenges. This session aims to gather perspectives from clinical investigators, statisticians, ethicists, and community stakeholders on designing efficient and ethical trials for the pipeline of prevention agents.

Chairs:
Mitchell Warren (AVAC, United States)
Susan Buchbinder (San Francisco Department of Public Health, United States)
Deborah Donnell (Fred Hutchinson Cancer Research Center, United States)
David Glidden (University of California, San Francisco, United States)
Jeremy Sugarman (John Hopkins, United States)
Timonthy Horn (Treatment Action Group)

Opening Plenary
16:00 - 18:00
Sheraton Chicago Ballroom IV-VII

PL01, Get It and Forget It: Long-acting HIV Prevention

Chairs:
Jeanne Marrazzo (University of Alabama at Birmingham School of Medicine, United States)
Nelly Mugo (Kenya Medical Research Institute (KEMRI), Kenya)
Lynn Morris (National Institute for Communicable Diseases of the NHLS, South Africa)
Thomas Hope (Northwestern University, United States)

Welcome to HIVR4P 2016 16:00 - 16:10
Thomas Hope (Northwestern University, United States)

Ruxandra Draghia-Akli (European Commission, Belgium)

Update on the Global HIV Vaccine Enterprise 16:30 - 16:37
William Snow (Global HIV Vaccine Enterprise, United States)
Scientific Program (PDF)

Congratulations to the 2016 Scholars 16:37 - 16:45
Maureen Goodenow (NIH Associate Director for AIDS Research and Director, Office of AIDS Research, United States)

ART Prevents HIV Transmission: What Happens Next? 16:45 - 17:10
Myron Cohen (University of North Carolina, United States)

Overview of Humoral and Cellular Immune Responses to HIV Vaccination 17:10 - 17:35
Georgia Tomaras (Duke University, United States)

HIV Prevention and Persistence: A Novel Approach Involving α4β7 Integrin 17:35 - 18:00
Anthony Fauci (National Institute of Allergy and Infectious Diseases, NIH, United States)

Conference Event
18:00 - 20:00  Sheraton/Chicago Promenade

Welcome Reception
Tuesday, 18 October 2016

Plenary
08:30 - 10:00
Sheraton Chicago Ballroom IV-VII

PL02, Unraveling the Mysteries of HIV Transmission

Chairs:
Carl Dieffenbach (NIAID, National Institutes of Health, United States)
Elizabeth Bukusi (KEMRI, Kenya)

HIV Transmission Dynamics
Deenan Pillay (Africa Centre for Population Studies, South Africa) 08:30 - 09:00

Mechanisms of HIV Transmission: Implications for Prevention
Julie Overbaugh (Fred Hutchinson Cancer Research Center, United States) 09:00 - 09:30

Providing Prevention Where It Matters Most: Data-informed Targeting of HIV Prevention and Care
Patrick Sullivan (Emory University Rollins School of Public Health, United States) 09:30 - 10:00

Oral
10:30 - 12:00
Sheraton Ballroom II-III

OA01, Antibody Epitopes: Connecting the Dots

Chairs:
James Bradac (National Institute of Allergy and Infectious Diseases, United States)
Pascal Poignard (Université de Grenoble-Alpes, France)

A Prominent Site of Antibody Vulnerability on HIV Env Incorporates the CCR5 Coreceptor Site and Its Camouflaging Glycans
Devin Sok (International AIDS Vaccine Initiative (IAVI), United States) 10:30 - 10:45

HIV-1 MPER-directed Broadly Neutralizing Antibodies from an Acute-infection Cohort RV217 Subject
Nicole A. Doria-Rose (Vaccine Research Center, NIAID, NIH, United States) 10:45 - 11:00

Persistence of an HIV Broadly Neutralizing Antibody Lineage Despite Complete Neutralization Escape
Jinal N Bhiman (National Institute for Communicable Diseases of the National Health Laboratory Services, South Africa) 11:00 - 11:15

Viral Escape from HIV Broadly Neutralizing Antibodies Is Slower and More Complex than for Early Strain-specific Neutralizing Antibodies
Colin Anthony (University of Cape Town, South Africa) 11:15 - 11:30
The Anti-gp120 mAb CH58 Recognizes a Not-fully-processed Form of Surface-expressed Env  
Jason Yolitz (NIAID, NIH, United States)

Fusion Peptide of HIV-1 as a Site of Vulnerability to Neutralizing Antibody  
Rui Kong (Vaccine Research Center, NIAID, NIH, United States)

OA02, Crossing the Border: Mechanisms of Mucosal Transmission

Chairs:
Jean Patterson (NIH, United States)  
Roger Le Grand (Commissariat à l’Énergie Atomique (CEA), France)

Defining HIV/SIV Infection after Rectal Challenge in Rhesus Macaque Model Using Dual Reporter System  
Danijela Maric (Northwestern University, United States)

Broadly Neutralizing Antibodies Can Prevent HIV Infection in Foreskin Ex-vivo Explant Infection Models  
Maria Lemos (Fred Hutchinson Cancer Research Center, United States)

In Vivo Analysis of Fluorescently Tagged HIV-specific and Non-specific Antibodies in Non-human Primates  
Ann M. Carias (Northwestern University, United States)

HIV Susceptibility in CD4+ T Cells Derived from the Inner Versus Outer Foreskin  
Ronald Galiwango (University of Toronto, Canada)

Intestinal Dendritic Cells and Macrophages Differentially Affect HIV-1 Transmission Across the Intestinal Mucosa  
Mariangela Cavarelli (CEA, France)

Levels of Immune Activation in Cervical Cells, Rectal Cells and PBMCs Isolated from a Kenyan Women Cohort at Low-risk of HIV Acquisition  
Catia Perciani (University of Toronto, Canada)

OA03, PrEP Problems: Real and Imagined

Chairs:
Peter Cherutich (Ministry of Health, Kenya)  
Wanjiru Mukoma (LVCT Health, Kenya)

The Effect of Oral Pre-exposure Prophylaxis on the Progression of HIV-1 Seroconversion  
Deborah Donnell (Fred Hutchinson Cancer Research Center, United States)
Scientific Program (PDF)

Infant Exposure to Tenofovir and Emtricitabine through Breast Milk when Used as Pre-exposure Prophylaxis by HIV-uninfected Lactating Women 10:45 - 11:00
Kenneth Mugwanya (University of Washington, United States)

HIV-1 Resistance Outcomes in Seroconverters from the MTN-020/ASPIRE Dapivirine Vaginal Ring Study 11:00 - 11:15
Urvi M. Parikh (University of Pittsburgh, United States)

Evaluation of Resistance to Cabotegravir Long-acting (CAB LA) in SIVmac251-infected Macaques 11:15 - 11:30
Chasity Andrews (Aaron Diamond AIDS Research Center, United States)

The Potential for Condom Ideology to Cloud Clinical Judgment around Prescribing HIV Pre-exposure Prophylaxis (PrEP) 11:30 - 11:45
Sarah K. Calabrese (Yale School of Public Health, Yale University, United States)

Newly Acquired HIV-1 Infection with Multi-Drug Resistant (MDR) HIV-1 in a Patient on TDF/FTC-based PrEP 11:45 - 12:00
Howard Grossman (Cleveland Clinic, United States)

Oral
10:30 - 12:00
Chicago Ballroom VIII-X

OA04, It Takes Two to Tango: Host, Hormones and Drug Levels in the Mucosa

Chairs:
Melanie Nicol (University of Minnesota, United States)
Lisa Rohan (University of Pittsburgh, United States)

Pharmacokinetic Analysis of Tenofovir Gel Use in Pre Versus Postmenopausal Women 10:30 - 10:45
Andrea Ries Thurman (CONRAD Eastern Virginia Medical School, United States)

Modulation of Tenofovir (TFV) Pharmacokinetics (PK) and Antiviral Activity by Vaginal Microbiota: Implications for Topical Preexposure Prophylaxis 10:45 - 11:00
Ekaterina Taneva (Albert Einstein College of Medicine, United States)

Hypo-osmolar Formulation of TFV Enemas Promotes Uptake and Transformation of TFV to TFV-DP in Tissues and Prevents SHIV/SIV Infection 11:00 - 11:15
Francois Villinger (University of Louisiana at Lafayette, United States)

Use of Injectable Depot Medroxyprogesterone Acetate (DMPA) Downregulates Cervicovaginal Epithelial Barrier Genes - Similarly to Mucosal Inflammation 11:15 - 11:30
Irina A Zalenskaya (CONRAD, Eastern Virginia Medical School, United States)

Microbiome Composition and Function Drives Wound-healing Impairment in the Female Genital Tract 11:30 - 11:45
Irene Xie (Public Health Agency of Canada, Canada)

MPA Has Minimal Impact on HIV-1 Replication in Ectocervical Tissue Ex Vivo 11:45 - 12:00
Charlene Dezzutti (University of Pittsburgh, United States)
Scientific Program (PDF)

Networking Lunch
12:00 - 13:00 Superior

NL01, Networking Lunch - Superior Hosts

Chairs:
Sharon Hillier (University of Pittsburgh, United States)
Martina Kovarova (University of North Carolina at Chapel Hill, United States)
Kenneth H. Mayer (Fenway Health, United States)
Jean Patterson (NIH, United States)
Jeanna M. Piper (National Institute of Allergy and Infectious Diseases / NIH, United States)
Nina Russell (Bill & Melinda Gates Foundation, United States)
Barbara Shacklett (University of California, United States)
Robin Shattock (Imperial College, United Kingdom)
Jim Turpin (Division of AIDS, NIAID, NIH, United States)
Morenike Ukpong (Institute of Public Health, Obafemi Awolowo University; New HIV Vaccine and Microbicide Advocacy Society, Nigeria)
Janneke van de Wijgert (University of Liverpool, United Kingdom)

Networking Lunch
12:00 - 13:00 Michigan

NL01, Networking Lunch - Michigan Hosts

Chairs:
Sharon L. Achilles (University of Pittsburgh, United States)
Galit Alter (Ragon Institute of MGH, MIT and Harvard, United States)
Peter Anderson (University of Colorado, Denver, United States)
Adam Burgener (Public Health Agency of Canada, Canada)
Elizabeth Bukusi (KEMRI, Kenya)
Claudia Cicala (National Institute of Allergy and Infectious Diseases, NIH, United States)
Myron Cohen (University of North Carolina, United States)
Donna Farber (Columbia University Medical Center, United States)
Julie Fox (United Kingdom)
Geoffrey Garnett (Bill & Melinda Gates Foundation, United States)
Barton Haynes (Duke University, United States)

Oral
13:00 - 14:30 Sheraton Ballroom II-III

OA05, Risky Business

Chairs:
Frances Priddy (International AIDS Vaccine Initiative, United States)
Judith Auerbach (University of California, San Francisco, United States)

Behavioral and Biological Risk Factors among MSM in Kigali, Rwanda 13:00 - 13:15
Julien Nyombayire (Project San Francisco, Rwanda Zambia HIV Research Group, Rwanda)

Jocelyn Elmes (Imperial College London, United Kingdom)
A Validated Risk Score to Predict HIV Acquisition in African Women: Assessing Risk Score Performance among Women who Participated in the ASPIRE Trial
Jennifer Balkus (Fred Hutchinson Cancer Research Center, United States)

Wipas Wimonsate (Thailand MOPH - U.S. CDC Collaboration, Thailand)

Bacterial Vaginosis Associated Microbes Induce Altered Innate Immune Profiles
Ryan Cheu (University of Washington, United States)

HIV Treatment Cascade among Transgender Women: Population-estimates from Rio de Janeiro, Brazil
Beatriz Grinsztejn

OA06, Of Mice and (Wo)men: Pharmacokinetics/Pharmacodynamics of Novel Products

Vaginal Transmission of WT or Resistant HIV-1 Was Not Inhibited by Long Acting Rilpivirine at High Plasma and Genital Concentrations in BLT Mice
Zandrea Ambrose (University of Pittsburgh School of Medicine, United States)

Pharmacokinetics and Safety of Pod-intravaginal Rings Delivering VRC01-N for HIV Prophylaxis in a Macaque Model
John Moss (Oak Crest Institute of Science, United States)

Pharmacokinetic Profile of Lamivudine (3TC) in Macaques and Relative Drug Exposure in Rectal and Vaginal Tissues
Ivana Massud (Centers for Disease Control and Prevention, United States)

Comparison of Safety and Pharmacokinetics of Vaginal Rings Releasing Tenofovir Disoproxil Fumarate Alone and with Emtricitabine in Sheep and Humans
Kathleen Vincent (University of Texas Medical Branch, United States)

Clinical Performance, Acceptability, and Optimization of Fast-dissolve Vaginal Inserts Designed for HIV-prevention: Results from Two Clinical Studies
Andrea Ries Thurman (CONRAD Eastern Virginia Medical School, United States)

Assessment of the Potential for Pharmacodynamic Interaction Between Dapivirine and Levonorgestrel When Co-administered in an MPT Vaginal Ring
Jonathon Holt (International Partnership for Microbicides, United States)
OA07, Through the Looking Glass: New Insights into Mucosal Biology

Chairs:
Alexandra Schuetz (USAMD-AFRIMS, Thailand)
Lyle McKinnon (Centre for the AIDS Programme of Research in South Africa, South Africa)

The Role of Gut Homing Receptor α4β7 in HIV Pathogenesis and Transmission - a Prospective Cohort Study
Aida Sivro (Center for AIDS Programme of Research in South Africa, South Africa) 13:00 - 13:15

Immuno-PET/CT Imaging Reveals Differences in Virus and CD4+ Cell Localization in SIV infected Rhesus Macaques Treated with an Anti-α4β7 mAb
James Arthos (NIAID, NIH, United States) 13:15 - 13:30

Multivalent Immunoglobulin Muc5AC Complexes Enhance Antibody Potency Against HIV-1
Arangassery Rosemary Bastian (Northwestern University, United States) 13:30 - 13:45

Semen Demons: Immunosuppressive Factors Within Semen Modulate Anti-HIV-1 Cellular Immune Responses
Kevin John Selva (University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Australia) 13:45 - 14:00

Antiretroviral Therapy Contributes to Intestinal Immune Dysfunction in Healthy Macaques
Alexandra Ortiz (LPD, NIAID, NIH, United States) 14:00 - 14:15

Initiation of c-ART During HIV Primary Infection Maintains HIV-specific Memory B Cells and Tfh Cells in the Gut Mucosa
Cyril Planchais (INSERM U955, Team 16, Vaccine Research Institute (VRI), France) 14:15 - 14:30

OA08, A Sugar Coated Pill: Immunogenicity of Envelope

Chairs:
Ann J. Hessell (Oregon Health & Science University, Oregon National Primate Research Center, United States)
Michael Zwick (TSRI, United States)

Potent HIV Neutralizing Antibodies Elicited by BG505 SOSIP Trimer Immunization in Rhesus Macaques as a Starting Point for Iterative Vaccine Design
Marit van Gils (Academic Medical Center, University of Amsterdam, Netherlands) 13:00 - 13:15

Priming a VRC01-like Antibody Response in Human Immunoglobulin Locus Transgenic Mice
Devin Sok (International AIDS Vaccine Initiative (IAVI), United States) 13:15 - 13:30

Induction of Cross-clade Reactive, Functional Antibodies with Immunogens Targeting the V2 Region of HIV
Susan Zolla-Pazner (Icahn School of Medicine at Mount Sinai, United States) 13:30 - 13:45
Rationally Designed Immunogens Induce Antibody Responses Targeting Polymorphic Forms of gp120 V1V2
Xunqing Jiang (New York University School of Medicine, United States)

An Adenovirus 26 Vaccine Expressing Clade A Env (Ad26.EnvA) Does Not Elicit Diversionary gp41-specific Antibodies in Humans
Helen D’Couto (Beth Israel Deaconess Medical Center, United States)

MVA-expressed gp140 Boosts More Durable V1/V2 and gp120 Antibody Responses than gp120 Protein in Alum
Xiaoying Shen (Duke Human Vaccine Institute, United States)

Meet the Experts
14:45 - 15:15
Chicago Ballroom VIII-X

ME01, Meet the Experts

Chairs:
Carl Dieffenbach (NIAID, National Institutes of Health, United States)
Elizabeth Bukusi (KEMRI, Kenya)

Plenary Session 1 Speakers
Myron Cohen (University of North Carolina, United States)
Georgia Tomaras (Duke University, United States)

Plenary Session 2 Speakers
Julie Overbaugh (Fred Hutchinson Cancer Research Center, United States)
Deenan Pillay (Africa Centre for Population Studies, South Africa)
Patrick Sullivan (Emory University Rollins School of Public Health, United States)

Symposium
15:30 - 17:00
Sheraton Ballroom II-III

SY04, Adolescents: Bodies, Brains and Behaviors

Chairs:
Sybil Hosek (Stroger Hospital of Cook County, United States)
Jintanat Ananworanich (U.S. Military HIV Vaccine Research Program, United States)

Research Gaps in Understanding Sex Steroid Hormones and Biological and Immunological Features that May Impact Susceptibility to HIV
Sharon L. Achilles (University of Pittsburgh, United States)

Promoting Resilience: Understanding Implications of Psychological Development and Decision-making
Susan Rosenthal (Columbia University Medical Center, United States)

How to Talk to Me about Sex
Two Youth from Chicago (United States)

What Interventions Are Suitable for Adolescents?
Chewe Luo (UNICEF, United States)
SY02, The Role of Mucosal Barriers and Targets in HIV Acquisition

**Chairs:**
Barbara Shacklett (University of California, United States)
Julie McElrath (Fred Hutchinson Cancer Research Center, United States)

15:30 - 15:52
*A Central Role for α4β7+ CD4+ T Cells in HIV Transmission and Pathogenesis*
Claudia Cicala (National Institute of Allergy and Infectious Diseases, NIH, United States)

15:52 - 16:14
*Effects of Sex Hormones and Vaginal Microbiota on the Cervicovaginal Mucosal Barrier*
Janneke van de Wijgert (University of Liverpool, United Kingdom)

16:14 - 16:36
*Tissue Compartmentalization of Human Immune Responses*
Donna Farber (Columbia University Medical Center, United States)

16:36 - 16:58
*Vaginal Bacteria modulate HIV Pre-exposure Prophylaxis Efficacy in Women*
Adam Burgener (Public Health Agency of Canada, Canada)

SY01, Vaccine-Induced Humoral Immunity

**Chairs:**
Bonnie Mathieson (Office of AIDS Research, United States)
Etienne Karita (Project San Francisco, Rwanda)

15:30 - 15:52
*Initiation of Neutralizing Antibody B Cell Lineages by HIV Vaccine Candidates*
Barton Haynes (Duke University, United States)

15:52 - 16:14
*Protection from Rectal SHIV Infection Induced by Mucosal Vaccination with a Replication-competent VSV-HIV Chimera Delivering Env Trimers*
Christopher Parks (The International AIDS Vaccine Initiative, United States)

16:14 - 16:36
*Towards a Global HIV Vaccine: (Pre)-Clinical Evaluation of Prime-Boost Regimens Using Ad26 and MVA with Mosaic Antigens and Soluble Gp140 Proteins*
Hanneke Schuitemaker (Janssen Vaccine and Prevention, Netherlands)

16:36 - 16:58
*Defining Correlates of Protective Humoral Immunity against HIV*
Galit Alter (Ragon Institute of MGH, MIT and Harvard, United States)
Scientific Program (PDF)

Symposium
15:30 - 17:00

Chicago Ballroom VIII-X

SY03, Choosing ARVs for Prevention: Ensuring and Measuring Effective Tissue Delivery

Chairs:
Craig Hendrix (Johns Hopkins School of Medicine, United States)
Carolina Herrera (Imperial College London, United Kingdom)

Location, Location, Location: Pharmacology and Tissue Delivery of ARVs 15:30 - 15:52
Angela Kashuba (University of North Carolina, United States)

Issues with Administration Route as It Relates to Participant Preference, Dosing Strategies, and Coverage Around Times at Risk 15:52 - 16:14
Julie Fox (United Kingdom)

Pharmacologic Approaches to Assess Adherence 16:14 - 16:36
Peter Anderson (University of Colorado, Denver, United States)

Linking PK and PD: Choosing Drugs and Predicting Clinical Outcomes Using Data from Explant Models, Animal Models 16:36 - 16:58
Jim Turpin (Division of AIDS, NIAID, NIH, United States)

Poster Discussion
17:15 - 18:00

Sheraton Ballroom II-III

PDO2, Alternative Antibody Functions

Chairs:
George Lewis (Institute of Human Virology, University of Maryland School of Medicine, United States)
Guido Ferrari (Duke University Medical Center, United States)

Antibodies Targeting the V1V2 Domain of gp120 Display Strong ADCC and Inhibitory Activities 17:15 - 17:24
Luzia Mayr (INSERM U1109, FMTS, Université de Strasbourg, France)

Uncovering the Co-receptor Binding Site of HIV-1 Envelope for Antibody-dependent Cell-mediated Cytotoxicity 17:24 - 17:33
William Tolbert (Institute of Human Virology, University of Maryland, School of Medicine, United States)

Anti-HIV-1 Antibodies within Blood and Seminal Plasma Trigger NK Cell Production of CCR5 Ligands 17:33 - 17:42
Matthew Parsons (University of Melbourne, Australia)

Mucin-binding IgG: Characterizing a Novel Antibody Effector Function and Discovery of a New Fc Receptor 17:42 - 17:51
Jeffrey Schneider (Northwestern University, United States)

Enhanced Effector Functionality of a V2 Broadly Neutralizing Antibody with a Novel IgG3 Fc Allotype 17:51 - 17:56
Simone Irene Richardson (Centre for HIV & STIs, National Institute for Communicable Diseases, South Africa)
PD01, Evaluation of Vaccine Concepts

Chairs:
Anatoli Kamali (International AIDS Vaccine Initiative, Kenya, Kenya)
Merlin Robb (US Military HIV Research Program, United States)

Recombinant Sendai Vaccine Delivered Mucosally Induces Gag-specific Functional T-cells or Antibody Responses in Prime-boost Regimens in Humans
Julien Nyombayire (Project San Francisco, Rwanda Zambia HIV Research Group, Rwanda)

Development of the Full Length Single Chain gp120-CD4 (FLSC), a Novel Vaccine for HIV Prevention
Timothy Fouts (Profectus BioSciences, United States)

Intradermal Electroporation of HIV-DNA Vaccine Followed by HIV-MVA Boost with or Without Addition of GLA Adjuvanted gp140
Edna Omar Viegas (Instituto Nacional de Saúde, Mozambique)

Frequent and Durable VIV2 Antibody Responses Induced by HIV-1 DNA Priming Followed by HIV-MVA Boosting in Healthy Tanzanian Volunteers
Agricola Joachim (Muhimbili University of Health and allied Sciences, Tanzania, United Republic of)

EV06 Trial: Modulation of the Immunogenicity of the DNA-HIV-PT123 and AIDSVAX®B/E combination HIV vaccine in adult Ugandans by S. mansoni Infection
Pietro Pala (MRC/UVRI Uganda Research Unit on AIDS, Uganda)

PD03, Innovation in Topical Delivery

Chairs:
Sharon Hillier (University of Pittsburgh, United States)
David Katz (Duke University, United States)

3D Printing of Microbicide Vaginal Rings: A Proof-of-Concept Study
Nicole Welsh (Queen's University Belfast, United Kingdom)

Optimizing Enema Vehicle Osmolality for Improved Colorectal Microbicide Delivery
Abhijit Date (The Center for Nanomedicine, Johns Hopkins University School of Medicine, United States)

Vaginal Safety Evaluation of a Triple Antiretroviral Drug-loaded Electrospun Fiber Microbicide in Nonhuman Primates
Yonghou Jiang (University of Washington, United States)

Pharmacokinetics of a Multipurpose Prevention Technology Pod-intravaginal Ring for HIV-1, HSV, and Contraception
James M Smith (Centers for Disease Control and Prevention, United States)
IQP-0528: The Pharmacokinetics of an Anti-HIV NNRTI in Non-human Primates from Various Dosage Forms 17:51 - 18:00
Anthony Ham (ImQuest BioSciences, United States)

Poster Discussion
17:15 - 18:00
Chicago Ballroom VIII-X

PD04, Prepping for PrEP

Chairs:
Patrick Kiser (Northwestern University, United States)
Marla Keller (Albert Einstein College of Medicine/Montefiore Medical Center, United States)

Pharmacokinetics of Dapivirine and Levonorgestrel in Sheep When Administered Vaginally in a Silicone Matrix Ring 17:15 - 17:24
Jonathon Holt (International Partnership for Microbicides, United States)

Treatment And Prevention for female Sex Workers in South Africa: First-year Results for the TAPS Demonstration Project 17:24 - 17:33
Robyn Eakle (Wits Reproductive Health and HIV Institute (Wits RHI), South Africa)

The Incremental Cost of Delivering PrEP as a Bridge to ART to HIV Serodiscordant Couples in Public HIV Care Clinics in Kenya 17:33 - 17:42
Elizabeth Irungu (Partners in Health, Research and Development, Kenya)

“PrEP in the Wild” - Preliminary Results from a Global Survey on “Informal” PrEP Use in Settings where it is Approved and where it Is Not 17:42 - 17:51
Jerome Galea (Socios En Salud Sucursal Peru, Peru)

HIV RNA Set Point Level after Infection While on PrEP: A Placebo-controlled Comparison 17:51 - 18:00
Katherine Thomas (University of Washington, United States)

Poster Session 01

Odd-numbered abstracts will be presented in Poster Session 01 on Tuesday, 18 October. Even-numbered abstracts will be presented in Poster Session 02 on Wednesday, 19 October.

Poster
18:00 - 19:30
River Exhibit AB

P01, Antibody functions (neutralizing and non-neutralizing)

Isolation of HIV Specific Monoclonal Antibodies Using a Combined Antigen-specific and B Cell Culture Supernatant Method 17:51 - 18:00
Anna Lee (U.S. Military HIV Research Program, Walter Reed Army Institute of Research, United States)
**Conformational Dynamics upon Immune Complex (IC) Formation in Human Anti-HIV-1 Env Adcc-mediating Antibodies Improve the Binding to FcgRs**
Chiara Orlandi (University of Maryland, United States)

**Genetic Determinants of Broad and Potent Neutralization in the CAP256-VRC26 HIV-1 V1V2 Specific bNAb Lineage**
David Sacks (National Institute for Communicable Diseases, National Health Laboratory Service, South Africa)

**A Broadly Neutralizing HIV-1 Antibody with a Non-projecting CDRH3 Loop Engages the V1V2 Apex of Native Envelope Glycoprotein Trimers**
Evan Cale (Vaccine Research Center, NIAID, NIH, United States)

**Combining Env Trimer Engagement with Germline V1V2- and CD4bs-directed Antibodies**
Jason Gorman (Vaccine Research Center, NIAID, NIH, United States)

**HIV-1 Evades Antibody-dependent Cell-mediated Phagocytosis in Monocytes**
Johannes S. Gach (University of California Irvine, United States)

**Testing Human Anti-HIV Monoclonal Antibodies Produced in Nicotiana for Activity Against Cell-associated HIV**
Kadryn Kadasia (Boston University School of Medicine, United States)

**Post-attachment Neutralization of a Wide Range of HIV-1 Strains by Anti-CD4i Single Chain Variable Fragment (scFv)**
Kazuki Tanaka (Matsushita Project Laboratory, Center for AIDS Research, Kumamoto University, Japan)

**Maternal V3 Loop Specific α4β7 Blocking Antibodies in a Mother to Child Transmission Cohort Are Significantly Increased in Non-transmitting Mothers**
Kristina Peachman (U.S. Military HIV Research Program, Henry M. Jackson Foundation for the Advancement of Military Medicine, United States)

**Structural Basis of Antigen Recognition by gp41 Specific Antibody F240**
Neelakshi Gohain (Institute of Human Virology, University of Maryland, School of Medicine, United States)

**Induction of Fc-dependent, Functional Antibody by Immunization with Scaffolded V1V2**
Rebecca Powell (Icahn School of Medicine at Mount Sinai, United States)

**Characterization of Neutralization Antibody Responses in HIV-1 Subtype G Infected Patients in Cameroon**
René Ghislain Essomba (Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Cameroon)

**Structural and Epitope Polymorphism of gp120 V1V2**
Ruimin Pan (New York University School of Medicine, United States)

**A Highly-conserved gp120 Inner Domain Residue Modulates Env Conformation and Trimer Stability**
Andres Finzi (CRCHUM / Université de Montréal, Canada)

**Association of V3/C3 Mutations with Enhanced Sensitivity of Autologous HIV-1 Clade C Envelope to Contemporaneous Broadly Cross Neutralizing Plasma**
Jayanta Bhattacharya (Translational Health Science and Technology Institute, India)

**HIV-1 Env Compactness as the Mechanism of Neutralisation Resistance of CFR02_AG Virus 253-11**
Thandeka Moyo (International Centre for Genetic Engineering and Biotechnology, South Africa)
Scientific Program (PDF)

Tier 1 Strains of HIV-1: Time to Break an Old Habit?
David Montefiori (Duke University Medical Center, United States)

Comparative Assessment of the Potency and Breath of Activity of Griffithsin and Broad Neutralizing Antibodies Against HIV
José A. Fernández-Romero (Population Council, United States)

Poster
18:00 - 19:30
River Exhibit AB

P02, Behavioral and social science research

Vaginal Probiotics for Treatment of Women with Bacterial Vaginosis (BV) in a Region with High HIV and BV Prevalence Rates
Anna-Ursula Happel (University of Cape Town, South Africa)

Alcohol Use Disorders in Fishing Communities along Lake Victoria, Uganda
Barbarah Kawoozo (UVRI-IAVI HIV Vaccine Program, Uganda)

Provider Perspectives on Clients’ Needs for Multipurpose Prevention Technologies
Laura Dellplain (Initiative for Multipurpose Prevention Technologies (IMPT), United States)

How to Recruit Healthy Volunteers? Becoming Participant in an HIV Preventive Vaccine Trial in France in 2014
Caroline Ollivier-Yaniv (University Paris-Est, France)

Relative Perceptions of HIV/AIDS among People Living in Fishing Communities along Lake Victoria, Uganda
Gertrude Nanyonjo (UVRI-IAVI HIV Vaccine Program, Uganda)

A Mobile Health Application Feasibility Study to Collect Sexual Risk Information among Young Women from Soweto, South Africa
Janan Dietrich (Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, South Africa)

Understanding Adolescents a Strategy to Engage Them in HIV Prevention Research: Health Improvements for Teen Ugandans (HI-4-TU) Study Kampala-Uganda
Juliane Etima (MU-JHU Research Collaboration, Uganda)

Prevalence and Correlates of Outside Sexual Partnerships in HIV-1 Serodiscordant Couples Enrolled in a Clinical Trial in Thika Kenya
Lawrence Mwihaki (Partners in Health Research and Development, Kenya)

How Could Effective HIV Prevention Products Change Risk Incentives in Sex Work? The Stated Preferences of Female Sex Workers in South Africa
Matthew Quaife (London School of Hygiene & Tropical Medicine, United Kingdom)

“I Would Like It, but I Know It Will Never Happen”: Acceptability and Feasibility of Male Partners Coming to the Clinic for Microbicide Information
Kristine Torjesen (FHI 360, United States)

Determinants of Sero-status Disclosure to Sexual Partners and Family Members among HIV-infected Peri-partum Women in Eastern Cape, South Africa
Oladele Vincent Adeniyi (Walter Sisulu University, South Africa)
Sex Work, Risk and Incentives: An Exploration of Risk Perceptions and Relationship Dynamics among Female Sex Workers in Ekurhuleni, South Africa
Robyn Eakle (Wits Reproductive Health and HIV Institute (Wits RHI), South Africa)

Complexities, Considerations and Challenges of Educating Men about Vaginal Microbicides in Kisumu, Kenya
Serah Gitome (Kenya Medical Research Institute, Kenya)

Patterns of Gender-based Violence and Associations with Sexual Risk Behavior among Female Sex Workers in Mombasa Kenya: A Latent Class Analysis
Sarah Roberts (University of Washington, United States)

Relationships Dynamics, Agency, and Trust in the Context of Microbicide Use: Formative Research Results from the CHARISMA Study in Johannesburg
Liz Montgomery (RTI International)

P03, Cellular immunity

Defining the Fitness Landscape of HIV-1 Escape from CD8+ Cytotoxic T-lymphocytes
Aleksandr Gorin (David Geffen School of Medicine at The University of California Los Angeles, United States)

The Impact of Myeloid Derived Suppressor Cells on Vaccine Immunogenicity in South African HIV-infected and Uninfected Mothers and Their Infants
Elvis Kidzeru (University of Cape Town, South Africa)

Gene Expression Profiling Revealed Low Level of Inflammation in HIV-1 Controllers
Hakim Hocini (INSERM U955, team 16, Vaccine Research Institute, UPEC, France)

Defective Dendritic Cells Status Correlates with Alterations in B Cell Subsets in HIV-1 Infected Children at Different Stages of Disease
Heena Aggarwal (All India Institute of Medical Sciences, India)

CD4 T-cell Counts More Closely Associate with the Cytokine Profiles Observed in Acutely Infected Volunteers than Viral Load or Replicative Capacity
Jonathan Hare (International AIDS Vaccine Initiative (IAVI), United Kingdom)

In Vitro Priming of HIV-1-specific CD8+ T Cells from Naïve T Cells
Nozomi Kuse (Kumamoto University, Japan)

Novel pDNA Prime-boost Vaccine Regimen to Augment Magnitude, Breadth, and Cytotoxicity of Cellular Immunity to Subdominant Gag Epitope of HIV and SIV
Xintao Hu (National Cancer Institute at Frederick, United States)

ALVAC-HIV Prime Enhanced T Cell and Antibody Responses in an RV144 Preclinical Trial in Rhesus Macaques
Sampa Santra (Beth Israel Deaconess Medical Center, Harvard Medical School, United States)
**P04, Community engagement in prevention research**

**Nigerian Sex Workers Don’t Know about PrEP - But When They Find Out, They Want it!**
Amaka Enemo (Nigeria Sex Workers Association, Nigeria)

**Inspiring Demand: Leveraging Human Centered Design to Improve Microbicide Uptake and Adherence**
Andrea Ries Thurman (CONRAD Eastern Virginia Medical School, United States)

**Recruitment for the First Phase I HIV Vaccine Trial in Fishing Communities of Lake Victoria, Uganda**
Annet Nanvubya (UVRI-IAVI HIV Vaccine Program, Uganda)

**Investing in Community Own Resource Persons for Efficient and Sustainable HIV/AIDS Services in Resource Limited Settings: TASO Uganda Experience**
Collins Agaba (The AIDS Support Organisation (TASO), Uganda)

**The Impact of Secrecy, Empowerment and Protection on Pre-exposure Prophylaxis (PrEP) Adherence: Lessons from KwaZulu-Natal, South Africa**
Eliza.M Govender (The Centre for the Aids Programme of Research in South Africa (CAPRISA), South Africa)

**Recruiting Women at High Risk of HIV Acquisition into a Microbicide Trial in South Western Uganda**
Faith Naddunga (MRC/UVRI, Uganda Research Unit on AIDS, Uganda)

**Barriers to Microbicide Trials among Women Artisans in Lagos, Nigeria**
Gbemisola Oyeneyin (Initiative For Better Public Health, Nigeria)

**Participation of Fisher Folks in HIV Vaccine Trials and Social-behavioral Studies**
Gertrude Nanyonjo (UVRI-IAVI HIV Vaccine Program, Uganda)

**Achievements of Building Community Partnerships, “Cross -CAB Network in Uganda”**
Jauhara Nanyondo (Makerere University Walter Reed University project, Uganda)

**A Case Study of Four African-led Civil Society Organizations Promoting Biomedical HIV Prevention Research for Africa**
Lillian Naigaga Mutengu (International AIDS Vaccine Initiative (IAVI), Kenya)

**Strategic Partnerships for HIV Prevention Research in Uganda**
Mathias Wambuzi (UVRI-IAVI HIV Vaccine Program, Uganda)

**Relating HIV Prevention Technologies with Access to Lubricant**
Obiajulu Augustina Amuamuziam (New HIV Vaccine and Microbicide Advocacy Society (NHVMAS), Nigeria)

**We Cannot Do without Them: Getting Men Involved in the Vaginal Ring Study, Southwestern Uganda**
Sylvia Kusemererwa (MRC/UVRI Uganda Research Unit on AIDS, Uganda)

**A Community-led Education Intervention for Human Papillomavirus Vaccination as a Model for Future HIV Vaccination Campaigns**
Eliza Squibb (GAIA Vaccine Foundation, United States)
Implications of PrEP Approval on HIV Prevention Research in Kenya: Outcomes of a National Consultative Meeting
Lillian Naigaga Mutengu (International AIDS Vaccine Initiative (IAVI), Kenya)

Poster
18:00 - 19:30
River Exhibit AB

P05, Contraception, pregnancy and HIV prevention

Knowledge and Willingness of Young Adults to Participate in Early HIV Vaccine Trials and Contraceptive Practices in Southwestern, Nigeria
Adeolu Oluremi (Ladoke Akintola University of Technology, Nigeria)

The Relationship between Condom Errors and Number of Sex Partners in a High HIV Burden Region in Western Kenya, 2012-2014
Kennedy Mutai (Kenya Medical Research Institute Center for Global Health Research, Kenya)

Community-based HIV Testing Services in Tanzania Double the Uptake of Family Planning among Adolescent Girls/Young Women and Female Sex Workers
Caterina Casalini (Jhpiego, Tanzania, United Republic of)

Lessons Learned from a Decade of Mother to Child Transmission Prevention in a Community Health Center in Bamako, Mali
Eliza Squibb (GAIA Vaccine Foundation, United States)

Uptake of Long Acting Reversible Contraception (LARC) among Cohabiting Couples with Known HIV Status in Kigali, Rwanda
Jeannine Mukamuyango (Project San Francisco, Rwanda)

Early Terminations During the MTN-020/ASPIRE Study at the CAPRISA eThekwini Clinical Research Site (CRS): A Review of Screening and Termination Data
Kalendri Naidoo (CAPRISA, South Africa)

Determinants of Contraceptive Use among Kenyan Women
Laura Lunani (KAVI-Institute of Clinical research, University of Nairobi, Kenya)

Traditional Birth Attendants and HIV Prevention of Mother-to-Child Transmission in Ibadan, Nigeria
Oladipupo Olaleye (Department of Health Promotion and Education, College of Medicine, University of Ibadan, Nigeria)

Implementation of Option B+ in Selected Parts of Northern Zambia: Early Lessons Learnt
Prisca Kasonde (FHI 360 Zambia, Zambia)

Correlation between Co-therapy of Efavirenz-based ART and Pregnancy among HIV-positive Women Using Hormonal Contraceptive Implants in Tororo, Uganda
Stephen Okoboi (The AIDS Support Organisation (TASO), Uganda)

High Incidence of Intended Pregnancy among Partners of Men Living with HIV in Rural Uganda: Implications for Safer Conception Services
Angela Kaida (Simon Fraser University, Canada)
Scientific Program (PDF)

Poster
18:00 - 19:30

**P06, Correlates of protection and exposure**

**Best Practices for Use of the Rabbit Rectal Irritation (RRI) Model for Assessing the Safety and Systemic Exposure of Rectal Gel Microbicides**
Anabel Lowry (Division of AIDS, NIAID, NIH, United States)

**High Adherence to Daily Vaginal Swabs and Reliable Sexual Behavior Reporting via Mobile Phone App for Assessing HIV Virion Exposure (HVTN 915)**
Maria Lemos (Fred Hutchinson Cancer Research Center, United States)

**Daily Uptake of Low Dose Acetylsalicylic Acid Reduces HIV Target at the Female Genital**
Julie Lajoie (University of Manitoba, Canada)

**Utility of the Sheep Model for Testing the 28-day MK-2048A Intravaginal Ring and Determining the Correlates of Exposure for Vicriviroc and MK-2048**
Leslie J. Marshall (Division of AIDS, NIAID, NIH, United States)

**Peptide Targeted by Human Antibodies Associated with HIV Vaccine-associated Protection Assumes a Dynamic Alpha-Helical Structure**
Timothy Cardozo (New York University School of Medicine, United States)

**Long-term Non-progressors and HIV Controllers among Women Infected with Non-subtype B HIV-1 in Mombasa, Kenya**
Vernon Mochache (National AIDS Control Council, Kenya)

**Use of a “Lead-in” Pharmacokinetic (PK) Study to Predict the Tissue Concentration of Cabotegravir that Protects Macaques against SIV Infection**
James Cummins (Division of AIDS, NIAID, NIH, United States)

**KIR3DL1 Alleles and Their Epistatic Interactions with HLA Class I in Resistance and Susceptibility to HIV Infection in the Pumwani Sex Worker Cohort**
Ma Luo (NML/PHAC, Canada)

**Characterizing Viral Evolution and bNAb Specificities in Two Subjects Infected with Closely Related Founder Strains of HIV**
Ruchi M. Newman (Ragon Institute of MGH, MIT and Harvard, United States)

**Protein Correlates of HIV Prevention in the Male Genital Tract**
Nyaradzo Chigorimbo-Tsikiwa (Desmond Tutu HIV Centre, University of Cape Town, South Africa)

Poster
18:00 - 19:30

**P07, Delivery technologies: novel approaches, formulation and multi-purpose**

**Use of Fingerprinting Technology in HIV Prevention Studies. Experience from Fishing Communities in South-western Uganda**
Andrew Abaasa (MRC/UVRI, Uganda Research Unit on AIDS, Uganda)

**Designing Microbicide Suppositories for Rectal or Vaginal Administration**
Anthony Ham (ImQuest BioSciences, United States)
Vaginal Microbicide Gel of CCR-5 Receptor Antagonist Nifviroc for the Prevention of HIV Sexual Transmission
Bisheng Dong (Nanjing University, China)

Pharmacokinetic Evaluation of Rectal Tenofovir Suppositories in Macaques
Charles Dobard (Centers for Disease Control and Prevention/Division of HIV/AIDS Prevention/Laboratory Branch, United States)

Do Microbicide Gel Volume and Properties Matter? Effects on Deployment, PK and User Sensory Perceptions and Experiences
David Katz (Duke University, United States)

Manufacture, Release Testing and Content Assay of Dapivirine and Dapivirine+Levonorgestrel Vaginal Rings for Testing of Pharmacokinetics in Sheep
Diarmaid Murphy (School of Pharmacy, Queen's University Belfast, United Kingdom)

Impact of Vaginal Ring Geometry and Drug Loading on Pharmacokinetics of Dapivirine and Darunavir in Macaques
Diarmaid Murphy (School of Pharmacy, Queen's University Belfast, United Kingdom)

Safety and Efficacy Assessment of VRCO1-N and MB66 Microbicide Film in an in Vitro Vaginal Environment
Gabriela Baldeon Vaca (Boston University School of Medicine, United States)

Pharmacodynamics of Griffithsin after Vaginal Application of a Gel or Intravaginal Ring in Macaques
Natalia Teleshova (Population Council, United States)

GRFT/Carrageenan Gel Inhibits HIV and HSV-2 in Human Cervical Mucosa
Natalia Teleshova (Population Council, United States)

Adaptable Griffithsin Delivery from Polymer Blend Nanoparticles and Electrospun Fibers
Jill M. Steinbach-Rankins (University of Louisville, United States)

Osmotically Activated Release of 5P12-RANTES from Silicone Elastomer Matrices
John McBride (Queen's University Belfast, United Kingdom)

Pharmacokinetics and Safety of Vaginal Tenofovir/Efavirenz-loaded Nanoparticles-in-Film in Mice
José das Neves (i3S – Instituto de Investigação e Inovação em Saúde & INEB – Instituto de Engenharia Biomédica, Universidade do Porto, Portugal)

Synthetic Biocompatible Polymers Are an Effective Delivery Platform That Elicits Potent Antibody Responses Against HIV-1 Glycopeptide Immunogens
Joseph Francica (National Institutes of Health, United States)

In Vivo PK/PD with Single Round Reporter Viruses: Drug Distribution and Infection Sites in Nonhuman Primates in the Presence of an Intravaginal Ring
Katrina Kotnik Halavaty (Northwestern University, United States)

A Phase I Crossover Trial of Intravaginal Rings Delivering Antiretroviral Agents
Marc M Baum (Oak Crest Institute of Science, United States)

Development of a Suppository Dosage Form for the Integrase Inhibitor, MK-2048
Kunal Jhunjhunwala (University of Pittsburgh School of Pharmacy, United States)
Silk Fibroin Provides Both Temperature Stabilization and Sustained Release of Protein-based HIV Inhibitors
Patricia LiWang (University of California Merced, United States)

The pH Dependence of in Vitro and in Vivo Delivery of Tenofovir Disoproxil Fumarate from Pod-IVRs
John Moss (Oak Crest Institute of Science, United States)

Formulation Development of DS003 Ethylene Vinyl Acetate Vaginal Rings
Peter Boyd (Queen's University Belfast, United Kingdom)

Development of Long-acting Nanoparticle-based Formulations for Prolonged Intravaginal Delivery of Elvitegravir
Wei Zhang (CONRAD, Eastern Virginia Medical School, United States)

Extended Release of a Combination Dapivirine/MK-2048 Film for HIV Prevention
Sheila Grab (University of Pittsburgh School of Pharmacy, United States)

Successive Site Translocating Inoculation Potentiates DNA/Recombinant Vaccinia Vaccination
Yanqin Ren (Fudan University, China)

Development and Evaluation of Release Profile of Innovative Two-Polymer (SR-2P) Bioadhesive Vaginal Microbicide Gels to Prevent HIV
Gita Shankar (SRI International, United States)

**Poster**
18:00 - 19:30
River Exhibit AB

**P08, Discovery and Evaluation of Biomedical Agents**

**Time of Addition Studies of Elvitegravir/TFV Prodrug Combinations Demonstrate Extended Window of Prophylactic Activity in Cell and Tissue Models**
Abenan Louise Ouattara (CONRAD, Eastern Virginia Medical School, United States)

**Preclinical Evaluation of a Reverse Transcriptase and Protease Inhibitory Combination as a Candidate Microbicide**
Carolina Herrera (Imperial College London, United Kingdom)

**5P12-RANTES Evaluation as a Dual Compartment Topical Microbicide**
Dana Tirabassi (Magee-Womens Research Institute, United States)

**Improving Structural Accuracy of HIV-1 env Trimeric Structure by Crystal Lattice Engineering and the Potential Application in Drug Discovery**
Yen-Ting Lai (Vaccine Research Center, NIAID, NIH, United States)

**Determination of Glycosylation Sites Necessary for Griffithsin Potency Against HIV Infection**
Kathryn Fischer (University of California Merced, United States)

**Antigenic Characterization of HIV-1 Trimers Using Meso Scale Discovery ECLIA**
Michael J. Chambers (Vaccine Research Center, NIAID, NIH, United States)

**THS, a Potential Candidate for Prevention Strategies, Reduces HIV and SIV Infection via CD4 Receptor Modulation**
Paola Silveira (Federal University of Rio de Janeiro, Brazil)
Hemoglobin Derived Anti-HIV Peptide, HbAHP-25, Restrains HIV-1 Associated Barrier Dysfunction: Potential for Therapeutic Application
Tahir Bashir Dar (National Institute for Research in Reproductive Health, India)

Preclinical Evaluation of a Griffithsin/Carrageenan Formulation to Prevent HIV Infection
José A. Fernández-Romero (Population Council, United States)

Poster
18:00 - 19:30
River Exhibit AB

P09, Epidemiology of HIV Prevention

Relationship Between Living Arrangements and HIV Risk among Key and Vulnerable Populations and the General Population in Tanzania
Amon Exavery (Jhpiego/Tanzania, Tanzania, United Republic of)

Condom Use Related Knowledge, Use and Access Amongst Young Men in Rural Kwazulu-Natal
Ayesha Kharsany (Centre For The AIDS Programme of Research In South Africa (CAPRISA), South Africa)

High Baseline STI Prevalence Identified During Recruitment for Three Phase II and a Phase III HIV Microbicide Study in the Madibeng Sub-district
Cheryl Louw (Madibeng Centre for Research, South Africa)

Factors Associated with HIV Prevalence in a High-risk Cohort in Thailand
Rob O’Connell (Armed Forces Research Institute of Medical Services, Thailand)

HIV Prevention Cascades: Identifying Gaps in the Delivery of HIV Prevention Interventions
Geoffrey Garnett (Bill & Melinda Gates Foundation, United States)

HIV Testing and Linkage to Prevention Services in Northern Manhattan: The First Step to Ending the Epidemic
Jason Zucker (Columbia University Medical Center, United States)

Incorporation of Rapid Test at a University Hospital STD Clinic Increased HIV and Syphilis Detection. Effect on Linkage to Care
Lucia Gallo Vaulet (Cátedra de Microbiologia Clinica, Facultad de Farmacia y Bioquimica, Universidad de Buenos Aires, Argentina)

Matthew Levy (George Washington University Milken Institute School of Public Health, United States)

HIV Risk Behaviours and HIV Incidence among High-risk Adult Men: Findings from a HIV Vaccine Preparedness Study Conducted in South Africa
Pholo Maenetje (The Aurum Institute, South Africa)

Evaluating Areas of Poor Outcomes for HIV/AIDS in the District of Columbia
Suparna Das (HIV/AIDS, Hepatitis, STD and TB Administration (HAHSTA), United States)

Male Circumcision and Incidence, Clearance and Prevalence of Human Papilloma Virus (HPV) Infection in Men and Women: An Updated Systematic Review
Tim Farley (Sigma3 Services SARL, Switzerland)
Exploring Female Condom Use for Anal Sex among the Receptive Men Who Have Sex with Men (MSM) in Benue State, Nigeria
Toyese Akinade (Population Council Nigeria, Nigeria)

Keith Rawlings (Gilead Sciences, United States)

HIV Incidence Among High Risk Population Groups Living in a Peri-urban Area of Maputo City, Mozambique: A Cohort Study
Ivalda Macicame (Instituto Nacional de Saúde, Ministério da Saúde, Mozambique)

Poster
18:00 - 19:30
River Exhibit AB

P10, Ethics in HIV Prevention Research

Ethical Issues in Design of Prevention Trials: Grappling with Changing Standards of Prevention
Liza Dawson (Division of AIDS, NIAID, NIH, United States)

Post-trial Access to Truvada® among HIV-1 Discordant Couples Enrolled in the PrEP Study in Kisumu, Kenya
Stella Njuguna (Kenya Medical Research Institute Center for Microbiology Research, Kenya)

Poster
18:00 - 19:30
River Exhibit AB

P11, HIV Drug Resistance in Prevention

Acute HIV-1 Transmission in Zambian Couples in the Post-HAART Era: Treatment Failure or Lack of Adherence?
Evonne Woodson (Emory Vaccine Center, Emory University, United States)

Mutations Associated with Tenofovir Resistance in Subtype C Isolates
Ntombikhona Maphumulo (University of Kwa-Zulu Natal, South Africa)

Poster
18:00 - 19:30
River Exhibit AB

P12, HIV Transmission and Viral Diversity

Phylogenetic Evidence for the Persistence of Contemporary Pre-endemic HIV-1M Viruses in Cameroon
Aime Marcel Tongo Passo (Division of Computational Biology and Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, South Africa)

Sieve Pressure toward the CD4 Binding Site of Env in HVTN 505 Breakthrough Infections
Allan C. deCamp (Fred Hutchinson Cancer Research Center, United States)
Dendritic Cells Are the Preferential HIV Target Cells at the Mucosal Sites
Camille Ducloy (INSERM U1109, FMTS, Université de Strasbourg, France)

Slow Disease Progression of Women Infected with HIV-1 Subtype C Versus Subtype A and D: Implications for the Epidemic
Colin Venner (University of Western Ontario, Canada)

Initial Host Responses to HIV and SIV Infection in Human and Macaque Female Reproductive Tract
Daniel Stieh (Northwestern University, United States)

HIV Surveillance Combining an Assay for Identification of Very Recent Infections and Phylogenetic Analyses on Dried Serum Spots, France 2012-2014
Francis Barin (Français-Rabelais University, France)

Near Full Length Genome Amplification and Sequencing of Acute HIV-1 Infections in Virologically-linked Heterosexual Transmissions in a Rwandan Cohort
Erick M O Muok (Project San Francisco, Rwanda Zambia HIV Research Group, Rwanda)

Early Occurred Compartmentalization of SIV Variants Suggests Multiple Virus Entries Following a High-dose Anorectal SIVmac251 Challenge
Jian Chen (Shanghai Public Health Clinical Center, Fudan University, China)

Getting to Zero New Infections: Determinants of HIV Positive Results among Infants Born to HIV Infected Mothers in TASO (U): A Retrospective Review
Lameck Bukenya Lumu (The AIDS Support Organisation (TASO), Uganda)

HIV Entry into Blood CD4+ T Cells Does Not Predict the Risk of HIV Acquisition in the Female Genital Tract
Vineet Joag (University of Toronto, Canada)

HIV 1 Acute Infection Detection in Seronegative Partners of Serodiscordant Couples Identified in Government Clinics in Lusak and Ndola, Zambia
Towela Nyapangula Mfune (Zambia Emory HIV Research Project (ZEHRP), Zambia)

Potential Effects of TILRR (FREM1 Isoform 2) on HIV-1 Vaginal Infection Through Regulating CXCL8 and TNFα
Md Kashem (University of Manitoba, Canada)

HIV-1 Subtype C Transmitted/Founder Variants Do Not Downregulate HLA-I, CD4 or CD62L Differently Than Non-transmitted Donor Variants
Zachary Ende (Emory Vaccine Center, Emory University, United States)

Poster
18:00 - 19:30
River Exhibit AB

P13, Immunogenetics (Host Immunity and Restriction Factors)

HLA-associated Polymorphisms of Gag Protein in HIV-1 B’ Infected Chinese
Kunxue Hong (National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, China)

IgG1 Allotypic Variants G1m17 and G1m3 Influence the Vaccine-Antigen Specific IgG1:IgG2 Ratio in HIV Vaccine Recipients
Sven Kratochvil (IAVI, United Kingdom)
A Preliminary Analysis of HIV-1 EAscape Mutations in Subtype A1 Virus and Impact on Disease Progression Rates  
Elnaz Shadabi (University of Manitoba, Canada)

Genetic Variants in DPH5, PRSS37 and TAS2R4 Increase Risk of HIV-1 Acquisition among HIV-1 Exposed Uninfected Africans  
Jairam Lingappa (University of Washington, United States)

P14, Impact of STI and the Human Microbiome on Susceptibility, Immunity & Prevention

Antibiotic Treatment Affects Gastrointestinal Luminal and Mucosal Microbial Communities in SIV-infected Macaques  
Alexander Zevin (University of Washington, United States)

Prevalence and Correlates of Sexually Transmitted Infections (STIs) among HIV-1 Sero-discordant Couples in Western, Kenya  
Godfrey Kutwa (Partners in Prevention, Moi University, Kenya)

Sexual HIV Transmission Risk and Genital Abnormalities in Both Partners of Serodiscordant Couples, Lusaka, Zambia  
Kristin Wall (Emory University, United States)

Do HIV-infected and Uninfected Women Have Different Human Papilloma Virus Genotypes Distribution: A Cross Sectional Study Carried out in Zimbabwe  
Racheal S. Dube Mandishora (University of Zimbabwe College of Health Sciences, Zimbabwe)

Dysbiosis in Vaginal Microbiota Alters Cervicovaginal Mucus Barrier Properties to HIV  
Laura Ensign (Johns Hopkins University, United States)

Prevotella bivia Induces TRAIL Expression and Cell Death Following Cervical Epithelial Cell Infection with C. trachomatis  
Melanie Gasper (Seattle Children's Research Institute, United States)

P15, Implementation Science, including Structural Interventions, PrEP and VMMC

Use of an Electronic Health Record (EHR) Best Practice Alert (BPA) in an Urban Emergency Department (ED) Diagnosed Acute and Chronic HIV Infection  
Beverly Sha (Rush University Medical Center, United States)

Correlates of Medication Adherence and Retention among PrEP Users in an HIV Prevention Program in Houston, TX  
Charlene Flash (Baylor College of Medicine, United States)

Role of Financial Incentives along the ART Adherence Continuum: A Qualitative Analysis from the HPTN 065 Study  
Elizabeth (Betsy) Tolley (FHI 360, United States)
Scientific Program (PDF)

Jordan Kyongo (LVCT Health, Kenya)

**Perceptions and Sexual Satisfaction among Recently Circumcised Men and their Female Partners from a Non-circumcising Community in Western Kenya**
Kennedy Mutai (Kenya Medical Research Institute Center for Global Health Research, Kenya)

Livingstone Ssali (The AIDS Support Organisation (TASO), Uganda)

**Evaluation of Patient Engagement and Health Promotion in a Community Health PrEP Program**
Megan Coleman (Whitman-Walker Health, United States)

**Determinants of AE among +400,000 VMMC Clients in Mozambique: Age, HIV Status, and Seasonality**
Fausto Vilanculos (Jhpiego, Mozambique)

**“We Are Ready to Embrace It”: Health Care Provider Perspectives on PrEP Rollout in Uganda**
Monique A Wyatt (Harvard Medical School, United States)

**Factors Associated with Uptake of Early Infant Male Circumcision by Mothers and Fathers in Western Kenya: Mtoto Msafi Mbili Study**
Robert C Bailey (University of Illinois at Chicago, United States)

**Pre-exposure Prophylaxis (PrEP) in Clinical Settings: Are Medical Providers PrEPared?**
Terri Wilder (Mount Sinai Health System, United States)

**PrEP and Early Antiretroviral Therapy Demonstration Project: Challenges to Ensure Follow-up and Adherence Among Female Sex Workers in Cotonou, Benin**
Luc Béhanzin (Dispensaire IST, Centre de Santé Communal de Cotonou 1, Benin)

---

**Poster**

18:00 - 19:30
River Exhibit AB

**P16, Innate Immunity**

**The Differential Effects of Polyvinyl Alcohol Based (PVA) Films and Gels on Vaginal Glycomic Signatures**
Bernard J Moncla (University of Pittsburgh School of Medicine, United States)

**Local Cytokine Elevation Is Associated with HIV Acquisition among African Women**
Jennifer Deese (FHI 360, United States)

**Impact of Chronic Sexual Abuse and HIV on Systemic Immune Biomarkers in Women**
Mimi Ghosh (George Washington University, United States)

---

**Poster**

18:00 - 19:30
River Exhibit AB

**P17, Mathematical Modeling: Impact and Effectiveness**
Scientific Program (PDF)

Population-level Impact of an ALVAC/AIDSVAX Vaccine Augmented with Additional Booster through Targeted Campaigns in South Africa
Christian Selinger (Institute for Disease Modeling, United States)

Projected Effectiveness of a TasP Strategy That Includes Detection of Acute HIV Infections among MSM in Peru
Dobromir Dimitrov (Fred Hutchinson Cancer Research Center, United States)

Modeling the HIV Epidemic in Côte d’Ivoire: Impact of Past Interventions
Mathieu Maheu-Giroux (Imperial College London, United Kingdom)

The Contribution of Heterosexual Anal Intercourse (AI) to HIV Transmission in Western Cape and KwaZulu-Natal Provinces in South Africa
Romain Silhol (Imperial College London, United Kingdom)

The Potential Impact of a Preventive Vaccine on HIV/AIDS Program Costs in Low- and Middle-income Countries
Arne Näveke (International AIDS Vaccine Initiative, United States)

Deterministic Compartment PK Model for Rectal Tenofovir (TFV) Delivery by an Enema
David Katz (Duke University, United States)

HIV Neutralizing Antibody Sensitivity/Resistance Signatures and Applications
Bette Korber (Los Alamos National Laboratory and Santa Fe Institute, United States)

Repeated Rectal Application of a Hyperosmolar Lubricant Increases HIV Susceptibility Markers but Does Not Reduce Antiretroviral Drug Concentrations
Alison Swaims-Kohlmeier (CDC, United States)

The Effect of Sampling Strategy on Phenotypic Characteristics of HIV Target Cells in the Female Genital Tract
Anandi N. Sheth (Emory University School of Medicine, United States)

Analysis of the Distribution of CD103 on CD8 T Cells in Blood and Genital Mucosa of HIV-infected Female Sex Workers
Anna Gibbs (Karolinska Institutet, Sweden)

Feasibility of Mucosal Sampling in Low-risk Women in HIV/AIDS Vaccine Clinical Trials
Borna Nyaoke (KAVI-Institute of Clinical research, University of Nairobi, Kenya)

Impact of Medroxyprogesterone Acetate and Sex Hormones on Wound Healing of Epithelial Cells and Fibroblasts from the Human Female Reproductive Tract
Charles Wira (Geisel School of Medicine at Dartmouth, United States)

Infection of Immune Cells by HIV in the Human Ovarian Tissue
Zheng Shen (Geisel School of Medicine at Dartmouth, United States)

Do Method and Site of Sampling Influence Measurement of Cytokines in Secretions from the Female Genital Tract?
Hoyam Gamieldien (Institute of Infectious Disease and Molecular Medicine, University of Cape Town, South Africa)
Surfactant Protein D Inhibits HIV-1 Transfer through Vaginal Explants and Safety Studies Exhibit Broad Therapeutic Index
Taruna Madan (National Institute for Research in Reproductive Health, India)

Human Papillomavirus and Discharge-associated Sexually Transmitted Infections Increase HIV Risk through CCR5+ T Cell Recruitment
Janine Jewanraj (Centre For The AIDS Programme of Research In South Africa (CAPRISA), South Africa)

Cyclical Changes in the Immunological Signature of the Female Genital Tract: Implications for the Design and Assessment of HIV Prevention Strategies
Julia Ekeruche-Makinde (Imperial College London, United Kingdom)

HIV Infection Impairs CD8+ Resident Memory T Cell Localization in Cervical Mucosa
Jennifer Lund (Fred Hutchinson Cancer Research Center, United States)

The Intestinal Microenvironment Restricts HIV-1 Replication in Human Dendritic Cells Through p21 Cip1/WAF1 Induction
Mariangela Cavarelli (CEA, France)

Regulation of Anti-HIV microRNA Expression in CD4+T Cells from the Human Endometrium and Cervix
Mickey Patel (Geisel School of Medicine at Dartmouth, United States)

Epithelial Barrier Alteration and Increased HIV Target Cells Coexist in Inflamed Human Cervices: A Biological Pathway to Enhanced HIV Susceptibility?
Neelima Chandra (CONRAD/Eastern Virginia Medical School, United States)

MISS-1 Study: Specific CD8+ T Cells and IgG Are Induced in the Female Reproductive Tract After Systemic MVA-HIV Vaccination
Romain Marlin (Immunology of viral infections and autoimmune diseases/IDMIT Infrastructure/CEA/DRF/IMETI/Division of Immuno-Virology, Université Paris Sud, Inserm U 1184, France)

HIV-susceptible Target Cells in Foreskins from Adolescents Following Medical Male Circumcision in South Africa: Markers of HIV Risk?
Rushil Harryparsad (Institute of Infectious Disease and Molecular Medicine, University of Cape Town, South Africa)

Antibody Characterization in Neovaginal and Rectal Secretions of Transgender Women
Siriwat Akapirat (Armed Forces Research Institute of Medical Sciences, Thailand)

Poster
18:00 - 19:30
River Exhibit AB

P19, Novel Vaccine and Prevention Concepts

Boosting MVA-B (HIV-modified Vaccinia Virus Ankara Expressing HIV-1 Antigens Clade B) Dose in Healthy Volunteers 4 Years after a First Immunization
Alberto C Guardo (Hospital Clinic de Barcelona, Spain)

Novel Conserved-region T-cell Mosaic Vaccine with High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection
Tomas Hanke (University of Oxford, United Kingdom)

Multivalent HIV-1 Env-based Pseudovirus Vaccines Elicit Broad Humoral Immune Response in Human CD4 B Cell Transgenic Mouse Model
Yong Gao (University of Western Ontario, United States)
Development of Virus-like Particles Resembling Mature Virions as Immunogens for HIV-1 Envelope Glycoprotein
Christopher Gonelli (University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Australia)

Dynamics of the HIV-1 Glycan Shield
Thomas Lemmin (University of California San Francisco, United States)

Immunogen Design to Target Carbohydrate-occluded Epitopes on the Surface of the HIV Env Protein
Elena Dukhovlinova (Lineberger Comprehensive Cancer Center, University of North Carolina, United States)

Development of a Combination HIV-heroin Vaccine
Gary R. Matyas (U.S. Military HIV Research Program, Walter Reed Army Institute of Research, United States)

Identification of Dispersed Glycans on HIV-1 Env Trimer and Design of Related Immunogens
Guillaume B. E. Stewart-Jones (Vaccine Research Center, NIAID, NIH, United States)

Targeting HIV Env to Clec9A+ Dendritic Cells to Enhance Antibody Affinity and Vaccine Efficacy
Hannah King (Centre for Biomedical Research, Burnet Institute, Australia)

Yeast Cell Surface Display of HIV Envelope Protein for Vaccine Development
Hong Zhu (University of Rochester Medical Center, United States)

Full Length Single Chain, a Novel gp120-CD4 Fusion HIV Subunit Vaccine, Does Not Cause an Autoimmune CD4 Response in Cynomolgus Macaques
Jennifer Schwartz (Profectus Biosciences, Inc., United States)

Characterization of an Oxidation Resistant Griffithsin for Use as an HIV Microbicide
Joshua Fuqua (University of Louisville School of Medicine, United States)

Can We Prevent HIV Infection by Focusing on the HIV Target Cell rather than the Virus?
Keith R Fowke (University of Manitoba, Canada)

Safety Evaluation of Live Biotherapeutics for Prevention of BV and HIV-1
Laurel Lagenaur (Osé Inc., United States)

Optimisation of Ex Vivo Memory B Cell Expansion/Differentiation for Interrogation of Rare Subsets in Response to Effective vs ineffective Vaccination
Luke Muir (Imperial College London, United Kingdom)

Comparison of Alhydrogel® and Addavax™ Adjuvants on Neutralizing Antibody Responses to HIV-1 Subtype C Trimeric Envelope Glycoproteins
M:T: van Diepen (University of Cape Town, South Africa)

Antigenicity of a HIV-1 B/C Recombinant Trimeric Envelope Protein that Retains its Near Native Conformation in CD4-bound State
Rajesh Kumar (Translational Health Science and Technology Institute, India)

Improving the Immune-complex Vaccine Strategy to Elicit Broader and More Potent Neutralizing Antibodies Against HIV
Rajnish Kumar (Icahn School of Medicine at Mount Sinai, United States)

Stabilization of Soluble Indian Clade C Env, 4.2-J41 in a Native Trimeric Form
Shubbir Ahmed (Translational Health Science and Technology Institute, India)
The Conserved Hydrophilic Domain in Cytoplasmic Tail of Indian Clade C HIV-1 Env Plays a Critical Role in Stabilization of Native-like Conformation
Sweety Samal (Translational Health Science and Technology Institute, India)

Novel Approach for Stabilizing Soluble Native Trimeric HIV-1 Clade C Env Harboring MPER by Linking Partial Cytoplasmic Domain
Tripti Shrivastava (Translational Health Science and Technology Institute, India)

Chromosomal Integrative Expression of Human CD4 on the Cell Surface of Lactobacillus Helveticus R0052 to Block HIV-1 Virus Infection
Shi-Hua Xiang (University of Nebraska-Lincoln, United States)

HIV-1 Conserved Mosaics Delivered by Regimens with Integration-deficient, DC-targeting Lentivirus Induce Robust T Cells
Tomas Hanke (University of Oxford, United Kingdom)

gp120-CD4i Antibody Complex as Immunogen
Andrey Galkin (Institute for Bioscience and Biotechnology Research, United States)

Immunogenicity of Oligomannose Env gp120 Vaccines
Godwin Nchinda (CIRCB, Cameroon)

Effects of gp140 Protein Booster Immunizations to DNA/MVA SHIV Vaccine on Immunogenicity and Protection against Intravaginal Tier-2 SHIV Challenges
Pradeep B. J. Reddy (Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, United States)

The Antiviral Lectin Q-GRFT is Safe and Effective in a Murine Model of HSV-2 Transmission
Amanda Lasnik (University of Louisville, United States)

Study of Vaccine-Elicited HIV-1 Fusion Peptide-Targeting Antibody
Kevin Liu (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States)

Poster
18:00 - 19:30
River Exhibit AB

P20, Passive Immunotherapy, including Neonates

Antibodies for Prevention of Subtype A, C & D HIV-1 Infection
Kshitij Wagh (Los Alamos National Laboratory, United States)

Poster
18:00 - 19:30
River Exhibit AB

P21, Pharmacology/Pharmacokinetics

Rapid and Sustained Release Combination Drug-eluting Fibers for Vaginal HIV Prevention Result in High, Lasting ARV Concentrations in Pigtail Macaques
Anna Blakney (University of Washington, United States)

Evaluation of Candidate Microbicides in the ICCA as a Means to Predicting Dosing Concentrations
Caitlin A. Buchholz (ImQuest BioSciences, United States)
**Scientific Program (PDF)**

**Transporters for Antiretroviral Drugs in Colorectal CD4+ T Cells and Circulating α4β7 Integrin CD4+ T Cells: Implications for HIV Microbicides**
Karolin Hijazi (University of Aberdeen, United Kingdom)

**Degradation, Transport, and Uptake of Tenofovir Disoproxil Fumarate in the Female Reproductive Tract**
Jonathan T. Su (Northwestern University, United States)

**ARV Drug Disposition in Ex Vivo, Sheep, and Human Tissues**
Michelle Reyzer (Vanderbilt University, United States)

**Biodistribution of Antiretroviral Therapies within the Ovaries and Testes of Rhesus Macaques**
Elias Rosen (Eshelman School of Pharmacy, University of North Carolina, United States)

**Poster**
18:00 - 19:30  River Exhibit AB

**P22, Policy and Advocacy**

**Tracking Resources Supporting Multipurpose Prevention Technologies: Investments to Meet the Sexual and Reproductive Health Needs of Women Worldwide**
Kathryn Stewart (Initiative for Multipurpose Prevention Technologies (IMPT), United States)

**Affordable HIV Prevention in Africa Begins with Testing and Counseling Couples Together**
Kristin Wall (Emory University, United States)

**HIVST a Catalyst for PrEP? Delivery of HIVST for PrEP Users: From Evidence to Practice**
Margaret Zulu (Southern African AIDS Trust (SAT), South Africa)

**Regulatory and Ethics Approval Timelines for HIV Vaccine Studies: An Analysis of IAVI Sponsored Studies in East and Southern Africa**
Prince Bahati Ngongo (International AIDS Vaccine Initiative (IAVI), Kenya)

**Negative Social Attitudes and Legal Prohibitions on Homosexuality in Nigeria Is a Barrier in Achieving the UNAIDS 90-90-90**
Uchenna Clifford Ononaku (Institute of Human Virology Nigeria (IHVN)/International Center for Advocacy on Rights to Health (ICARH), Nigeria)

**Poster**
18:00 - 19:30  River Exhibit AB

**P23, Populations-specific Prevention Science (Pediatric, Adolescents, Discordant Couples, MSM, IDU, Pregnant Women)**

**Prevalence of HIV Sero-discordance among Pregnant Women and Their Partners in Rivers State, Nigeria**
Abiola Olaleye (Achieving Health Nigeria Initiative, Nigeria)

**PrEP Adoption among Young Black and Latino Gay Men: A Qualitative Study of Social Network Differences Between Adopters and Non-adopters**
Viraj V. Patel (Montefiore Medical Center/Albert Einstein College of Medicine, United States)
The Use of Drop-in-Centres in Improving the Uptake of HIV/STI Treatment and Services for Key Populations in Nigeria  
Chiedu Ifekandu (University of Roehampton, United Kingdom)

Unmet Need for PrEP among HBV-infected/HIV-uninfected Partners in HIV Serodiscordant Partnerships  
Elizabeth Irungu (Partners in Health, Research and Development, Kenya)

Genetically Linked Transmission and ART Use in Discordant Couples in Rwanda  
Gisele Umviligihozo (Project San Francisco, RZHRG-Emory University, Rwanda)

Impact of Text Messaging and Peer Counseling on Initiation and Adherence of HIV Antiretroviral Therapy among Newly-diagnosed MSM  
Sten H. Vermund (Vanderbilt Institute for Global Health, Vanderbilt University Medical Center, United States)

Prevention of HIV/STI Acquisition from Concurrent Partners in a Cluster Randomised Controlled Trial of Concordant Negative Zambian Couples  
Kalonde Malama (Zambia Emory HIV Research Project (ZEHRP), Zambia)

Adolescent / Young Adults - A Priority Population that Needs PrEP and PEP Knowledge to Prevent HIV  
Maureen Akolo (Kenya AIDS Control Program, Kenya)

STIs and BV in Young South Africans at Risk of HIV  
Shaun Barnabas (University of Cape Town, South Africa)

HIV and STI Risk among Single Mothers in Ndola and Lusaka, Zambia: Is HIV Incidence High Enough for Enrollment in a Vaccine Efficacy Trial?  
Teresa Filipowicz (Zambia Emory HIV Research Project (ZEHRP), Zambia)

High Burden of Asymptomatic Genital Tract Infections among Sexually Active South African Youth: Considerations for HIV Prevention Programs  
Angela Kaida (Simon Fraser University, Canada)

High Rates of HIV/STIs with Low PrEP Uptake: Baseline Data from the POSSE Project for Black Young MSM in the Chicago House/Ball Community  
Sybil Nosek (Stroger Hospital of Cook County, United States)

Associations of HIV Status and Sex Work with Depression and Alcohol Abuse among Kenyan MSM  
Makobu Kimani (Kenya Medical Research Institute, Kenya)

Poster  
18:00 - 19:30

P24, Product Acceptability and Adherence

Residual Synthetic Estrogen and Progestin Levels in Used Intravaginal Rings of Women Participating in a Clinical Trial of Acceptability  
Richard Haaland (US Centers for Disease Control and Prevention, United States)

Are Ring Worries Affecting Use? Findings from the MTN-020/ASPIRE Phase III Dapivirine Ring Trial  
Ariane van der Straten (Women's Global Health Imperative, RTI International, United States)
**Reasons for Participant Non-return of Vaginal Rings in MTN-020/ASPIRE: Potential Counselling Implications for Open Label Extension Studies**
Clare Dott (Wits Reproductive Health and HIV Institute, South Africa)

**Vaginal Gel Surface & Coating Thickness Distribution Using Novel Optical Imaging and Correlation with User Sensory Perception/experience (USPE) Scales**
David Katz (Duke University, United States)

**PrEP for Transwomen in Rio De Janeiro, Brazil: Low Awareness but High Willingness and Candidacy to Take PrEP**
Beatriz Grinsztejn

**Converging Self-reports, Product Returns, and Pharmacokinetic Results to Improve Adherence Measurement in MTN-017 – a Phase 2 Rectal Microbicide Study**
Iván Balán (New York State Psychiatric Institute and Columbia University, United States)

**Attitudes and Perceptions about Counseling Fidelity among Clinical Trialists: Results from a Global Stakeholder Survey**
Kathleen MacQueen (FHI 360, United States)

**To Switch or Not to Switch: Anticipating Choices in Biomedical HIV Prevention**
Kathrine Meyers (Aaron Diamond AIDS Research Center, United States)

**If We Build It, Will They Come? Developing a Strategic Evaluation Framework (SEF) for Multipurpose Prevention Technologies (MPTs)**
Laura Dellplain (Initiative for Multipurpose Prevention Technologies (IMPT), United States)

**Optimizing Adherence Efforts During the Conduct of a Pivotal Phase 3 Dapivirine Vaginal Ring Trial (IPM 027 / the Ring Study)**
Michelle Isaacs (International Partnership for Microbicides, South Africa)

**Objective Adherence Measurements for the Dapivirine Vaginal Ring**
Patrick Spence (International Partnership for Microbicides, United States)

**Biomarkers and Biometric Measures of Adherence to Use of ARV-based Vaginal Rings**
Randy Stalter (FHI 360, United States)

**Correlation of Residual Microbicide Levels with Objective Biomarker Analysis to Determine Adherence in a Large Phase III HIV Prevention Trial**
Terry Jacot (CONRAD, Eastern Virginia Medical School, United States)

**Adherence in a Blinded RCT Versus Open Label Study: Motivations and Product Use in CAPRISA Tenofovir Gel Studies**
Kathleen MacQueen (FHI 360, United States)

---

**Poster 18:00 - 19:30 River Exhibit AB**

**P25, Results of Clinical Trials**

**Tenofovir/Emtricitabine plus Lopinavir/Ritonavir or Elvitegravir/cobicistat as a Single Tablet Regimen (STR) for PEP: A Randomized Clinical Trial**
Alexy Inciarte (Hospital Clinic/IDIBAPS/University of Barcelona, Spain)
Scientific Program (PDF)

Estimating the Protective Effect of Longitudinal Drug Concentration in Pre-exposure Prophylaxis for HIV
Claire Ruberman (Johns Hopkins University, United States)

Safety and Tolerability of pSG2.HIVconsv DNA MVA.HIVconsv and Ad35-GRIN Prime-boost Combinations Administered to Healthy HIV-uninfected Kenyan Adults
Gaudensia Mutua (KAVI-Institute of Clinical research, University of Nairobi, Kenya)

Characterization of Factors Associated with Mucosal Secretion Collections and Biopsies in RV306 Study
Punnee Pitisuttithum (Faculty of Tropical Medicine, Mahidol University, Thailand)

Experience in Setting up Sites for a Simulated Vaccine Efficacy Trial (SIVET) in Fishing Communities along Lake Victoria, Uganda
Juliet Mpendo (UVRI-IAVI HIV Vaccine Program, Uganda)

Safety, Immunogenicity, and Mucosal Shedding of a Live, Oral HIV-1 Vaccine (rcAd26.MOS1.HIV-Env) in a Phase 1, First-in-Human Clinical Trial (R001)
Kathryn E. Stephenson (Beth Israel Deaconess Medical Center, United States)

Growth and Development of Infants Born to Women Enrolled in a Clinical Trial of Tenofovir-based Pre-exposure Prophylaxis for HIV Prevention
Rachel Scheckter (FHI 360, United States)

Recruiting Participants for a Simulated Vaccine Efficacy Trial in Fishing Communities along Lake Victoria, Uganda
Sulaiman Matovu (UVRI-IAVI HIV Vaccine Program, Uganda)

The Ring plus Project: Safety and Acceptability of Vaginal Rings That Protect Women from Pregnancy
Tania Crucitti (Institute of Tropical Medicine, Belgium)

The Safety of Multiple Flexible Sigmoidoscopies in Clinical Trial Participants
Ian McGowan (University of Pittsburgh, United States)

Variation in Effectiveness of HIV Assisted Partner Services by Region, Rural Location and Gender in Kenya: A Cluster Randomized Clinical Trial
Sarah Masyuko (Ministry of Health - Kenya, Kenya)

Poster
18:00 - 19:30
River Exhibit AB

P26, Systems Biology and Novel Molecular Technologies

Use of the HIV-1 Human Interaction Database to Identify Virus-host Interactions That May Impact Vaccine- and Drug-based Infection Prevention Efficacy
Susan M Schader (Southern Research Institute, United States)

Whole Transcriptome Analysis of Longitudinally Sampled Acutely Infected HIV Patients by RNA Sequencing
Rasmi Thomas (US Military HIV Research Program (MHRP), Walter Reed Army Institute of Research, United States)
Poster
18:00 - 19:30

**P27, Therapeutic Vaccine, Viral Latency and Cure**

**Preclinical Evaluation of HTI-TriMix mRNA Vaccine Candidate**
Alberto C Guardo (Hospital Clinic de Barcelona, Spain)

**Effects of a Milk-derived Gp120-directed Non-broad Neutralizing Antibody on Oral SHIV Acquisition and Tissue-associated Virus in Infant Rhesus Monkeys**
Jonathon Himes (Duke University, United States)

**Loading Dendritic Cells with Gold Nanoparticles (GNPs) Bearing HIV-peptides and Mannosides Enhance HIV-specific T Cell Responses**
Núria Climent (Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)-AIDS Research Group and HIV Vaccine Development in Catalonia (HIVACAT), Hospital Clínic de Barcelona, Faculty of Medicine, University of Barcelona, Spain)

**Administration of IL-2 in Combination with Therapeutic Vaccination Affects Differentially T-regulatory Cell Subsets and Enhances Anti-HIV Responses**
Nabila Seddiki (Inserm, U955, Equipe 16, France)

**Preliminary Safety Results from the VRI02 ANRS 149 Light (Lipopeptide and DNA GTU HIV Therapeutic Trial)**
Jean-Daniel Lelievre (INSERM/VRI, France)

---

**P28, Treatment as Prevention**

**Factors Associated with Retention in Care among Newly Diagnosed HIV Cases in Washington, DC**
Jenevieve Opoku (DC Department of Health, United States)

**Evolution of Access to and Referral for Antiretrovirals (ARV) among Seroconvertors in Lusaka and Ndola, Zambia from 2004 to the Present**
Shabir Lakhi (Zambia Emory HIV Research Project (ZEHRP), Zambia)

**Semi-Quantitative Detection of HIV-1 RNA in Plasma Using an In-house RT-PCR Technique for Monitoring Self-reported Antiretroviral Treatment Adherence**
Clive Michelo (Zambia Emory HIV Research Project, Zambia)
Wednesday, 19 October 2016

Conference Event
07:30 - 17:00

Columbus B

Speaker Check-In

Plenary
08:30 - 10:00

Sheraton Chicago Ballroom IV-VII

PL03, Which Way Is Forward: Emerging Challenges and Opportunities

Chairs:
Zeda Rosenberg (IPM, United States)
Pontiano Kaleebu (UVRI, Uganda)

Progress in Neutralizing Antibody-based HIV Vaccine Design
08:30 - 09:00
Dennis Burton (The Scripps Research Institute, United States)

A View from the Ground
09:00 - 09:30
Noel Gordon (Human Rights Campaign, United States)

Rings and Things
09:30 - 10:00
Sharon Hillier (University of Pittsburgh, United States)

Oral
10:30 - 12:00

Sheraton Ballroom II-III

OA09, HIV Antibodies: The Good, the Bad and the Ugly

Chairs:
Elise Landais (International AIDS Vaccine Initiative (IAVI), United States)
Victoria Polonis (MHRP, United States)

Characterization of the Early Antibody Landscape in HIV-1 Infected Individuals Who Develop Poor to Elite Levels of Neutralization Breadth
10:30 - 10:45
S. Abigail Smith (Emory University, United States)

HIV-1 Superinfection Can Lead to Potent Neutralization of the Superinfecting Virus but Is Not Sufficient to Elicit Broadly Neutralizing Antibodies
10:45 - 11:00
Daniel J Sheward (University of Cape Town, South Africa)

Characterization of Broadly Neutralizing Antibody Responses in HIV-1 Subtype C Infected Children
11:00 - 11:15
Zanele Ditse (National Institute for Communicable Diseases of the National Health Laboratory Service, South Africa)

The Intrinsic Mutability of Antibody Variable Gene Is Critical for Reproducing Similar Mutation Signatures
11:15 - 11:30
Zizhang Sheng (Columbia University Medical Center, United States)
Structure of a CH58-like V2 Antibody from Natural Infection Reveals Convergent Heavy Chain Maturation and a Novel K169 Binding Light Chain Motif
Constantinos Kurt Wibmer (National Institute for Communicable Diseases (NHLS), South Africa)

Structure of a Natively-glycosylated HIV-1 Env Reveals a New Mode for VH1-2 Antibody Recognition of the CD4 Binding Site Relevant to Vaccine Design
Harry Gristick (Caltech, United States)

Oral
10:30 - 12:00
Sheraton Ballroom IV-V
OA10, Back to the Future: Optimizing the Cascade

Chairs:
Johnstone Kumwenda (University of Malawi, Malawi)
Geoffrey Garnett (Bill & Melinda Gates Foundation, United States)

Looking at the Whole Picture: The HIV Testing and Care Continuum among Community-recruited MSM, IDU, and Heterosexuals in Washington, DC, 2007-2015
Rudy Patrick (George Washington University Milken Institute School of Public Health, United States)

High Uptake of Antiretroviral Treatment among Female Sex Workers in Kigali, Rwanda
Etienne Karita (Project San Francisco, Rwanda)

Acceptability of a New Smartphone-based HIV and Syphilis Test to Screen Sexual Partners among High Risk MSM and Transgender Women
Iván Balán (New York State Psychiatric Institute and Columbia University, United States)

Potential Impact on HIV Incidence of Increasing Viral Suppression among HIV-positive MSM in Baltimore: Mathematical Modelling for HPTN 078
Kate M. Mitchell (Imperial College London, United Kingdom)

Detectable Viral Loads among Those Who Self-report Being Undetectable in the RADAR Cohort of Young MSM - Implications for Treatment as Prevention
Brian Mustanski (Northwestern University, United States)

Using Peer Educators to Scale-up HIV Oral Self-testing among Female Sex Workers: An Implementation Science Approach from Kenya
Kipruto Chesang (U.S. Centers for Disease Control and Prevention, Kenya, Kenya)
OA11, Testing Vaccine Concepts: Where the Rubber Hits the Road

Chairs:
Sandhya Vasan (Military HIV Research Program, Henry M. Jackson Foundation, Thailand)
Fatima Laher (Perinatal HIV Research Unit)

First-in-human Clinical Trial Evaluating Mosaic HIV-1 Immunogens 10:30 - 10:45
Lindsey R Baden (Brigham and Women's Hospital/Harvard medical School, United States)

Optimization of a Pediatric Vaccine to Prevent Breast Milk Transmission of HIV-1 10:45 - 11:00
Bonnie Phillips (University of North Carolina at Chapel Hill, United States)

DNA and Protein Co-delivery Vaccines Using TLR-4-based Adjuvants Induce Potent Immune Responses Able to Delay Heterologous SIV Acquisition 11:00 - 11:15
Barbara K. Felber (National Cancer Institute at Frederick, United States)

DNA and Protein Co-administration Elicits Higher HIV-specific nAb and Comparable CD4+ T-cell Responses as Traditional Prime/Boost Regimens (HVTN 105) 11:15 - 11:30
Nadine Rouphael (Emory University, United States)

Protective Efficacy of Candidate Clinical HIV-1 Vaccine Regimens Against SHIV-SF162P3 Challenges in Rhesus Monkeys 11:30 - 11:45
Frank Wegmann (Crucell Holland B.V., a Janssen pharmaceutical company of Johnson & Johnson, Netherlands)

Comparing Different Priming Strategies to Optimize HIV Vaccine Antibody Responses: Results from HVTN 096/EV04 (NCT01799954) 11:45 - 12:00
Giuseppe Pantaleo (Swiss Vaccine Research Institute, Switzerland)

OA12, Pipelines and Platforms for Prevention

Chairs:
Annalene Nel (International Partnership for Microbicides, South Africa)
Karl Malcolm (Queen's University Belfast, United Kingdom)

Ranpirnase Exhibits Dose-dependent Inhibition of Rectal Explant Infection with HIV-1 10:30 - 10:45
Ian McGowan (University of Pittsburgh, United States)

Development and Proof-of-Concept Clinical Evaluation of a Freeze-dried Topical Microbicide Insert for On-demand HIV Prevention 10:45 - 11:00
Wei Zhang (CONRAD, Eastern Virginia Medical School, United States)

Foamed Silicone Intravaginal Rings for Delivery of Macromolecular Therapeutics 11:00 - 11:15
Matthew A. Petersen (ProMed Pharma, United States)
A Single-reservoir Microbicide Intravaginal Ring for Dual Delivery of Tenofovir and Elvitegravir 11:15 - 11:30
Alexander Evanoff (Northwestern University, United States)

Evaluation of MK-2048 and Vicriviroc, Formulated as Single or Combination (MK-2048A) Intravaginal Rings, for Development as a Vaginal Microbicide 11:30 - 11:45
Charlene Dezzutti (University of Pittsburgh, United States)

ECLAIR Study of Cabotegravir LA Injections: Characterization of Safety and PK During the “PK Tail” Phase 11:45 - 12:00
Susan Ford (PAREXEL International, United States)

Networking Lunch
12:00 - 13:00
Superior

NL02, Networking Lunch - Superior Hosts

Chairs:
Stephen Kent (University of Melbourne, Australia)
Gustavo Kijak (U.S. Military HIV Research Program, Walter Reed Army Institute of Research, United States)
Nduku Kilonzo (National AIDS Control Council, Kenya)
Raphael Landovitz (UCLA Center for Clinical AIDS Research & Education, United States)
Gita Ramjee (South African Medical Research Council, South Africa)
Yiming Shao (Chinese Center for Disease Control and Prevention, China)
Steve Smiley (NIH/NIAID/DAIDS, United States)
Mitchell Warren (AVAC, United States)
Ntando Yola (Desmond Tutu Foundation, South Africa)

Networking Lunch
12:00 - 13:00
Michigan

NL02, Networking Lunch - Michigan Hosts

Chairs:
Jintanat Ananworanich (U.S. Military HIV Vaccine Research Program, United States)
Dan Barouch (Beth Israel Deaconess Medical Center, United States)
Kundai Chinyenze (International AIDS Vaccine Initiative, Kenya)
David Cooper (Kirby Institute, UNSW Australia, Australia)
Larry Corey (Fred Hutchinson Cancer Research Center, United States)
Demetre Daskalakis (New York City Department of Health and Mental Hygiene, United States)
Carl Dieffenbach (NIAID, National Institutes of Health, United States)
Barney Graham (NIH/Vaccine Research Center, United States)
Andrew Grulich (Kirby Institute, UNSW Australia, Australia)
Angela Kashuba (University of North Carolina, United States)
Scientific Program (PDF)

Oral
13:00 - 14:30 Sheraton Ballroom II-III

**OA13, Do Right to Do Well: Creating a Framework for Success**

**Chairs:**
Peter Godfrey-Faussett (UNAIDS, Switzerland)
Nomita Chandhiok (Indian Council of Medical Research, India)

- **Harmonization of Regulatory Framework for Control of Clinical Trials in East Africa: Progress, Challenges and Lessons Learnt**
  13:00 - 13:15
  Jane Humphrey Mashingia (East African Community Secretariat, Tanzania, United Republic of)

- **Ethics Research to Inform Sexual and Gender Minority Adolescent Participation in HIV Prevention Research**
  13:15 - 13:30
  Kathryn Macapagal (Northwestern University, United States)

- **The Journey to GPP Implementation for KAVI Institute of Clinical Research**
  13:30 - 13:45
  Jane Ng'ang'a (KAVI-Institute of Clinical research, University of Nairobi, Kenya)

- **Improving the Efficiency of African Research Ethics Committees and Standardizing Ethics Review Processes - Through an Automated Review Platform**
  13:45 - 14:00
  Boitumelo Mokgatla (International AIDS Vaccine Initiative (IAVI), Botswana)

- **Toward Innovation in HIV Prevention: Sustaining Funding in a Post-2015 Landscape**
  14:00 - 14:15
  Laura Marie Lazar (AVAC: Global Advocacy for HIV Prevention, United States)

- **From Research to Policy to Implementation: A National Plan for Couples' Voluntary HIV Counseling and Testing (CVCT) in Zambia**
  14:15 - 14:30
  Susan Allen (Rwanda Zambia HIV Research Group-Emory University, United States)

Oral
13:00 - 14:30 Sheraton Ballroom IV-V

**OA14, Teaching the Immune System New Tricks: Vaccine-Induced Immune Responses**

**Chairs:**
Patricia Fast (International AIDS Vaccine Initiative, United States)
William Kilembe (Zambia Emory HIV Research Project (ZEHRP), Zambia)

- **Ex Vivo Evaluation of Mucosal Cytokine Responses to in Vivo Vaccination with ALVAC-HIV/AIDSVAX® B/E of Non-human Primates (NHPs) and Humans**
  13:00 - 13:15
  Carolina Herrera (Imperial College London, United Kingdom)

- **Vaccine-induced Antibody that Captures but Does Not Neutralize SIVmac251 Increases the Rate of Infection after Low-dose, Repeated Rectal Challenge**
  13:15 - 13:30
  Johannes S. Gach (University of California Irvine, United States)
### Oral

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 - 14:30</td>
<td><strong>OA15, Unique and Essential: Mucosal Environment of the Female Reproductive Tract</strong></td>
<td></td>
<td>Chicago Ballroom VI-VII</td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong></td>
<td>Kristina Broliden (Karolinska Institutet, Sweden)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Elisabeth Menu (INSERM U1184, France)</td>
<td></td>
</tr>
<tr>
<td>13:00 - 13:15</td>
<td>Differences in Genital Tract Immune Cell Populations and Innate Cervicovaginal Fluid Anti-HIV Activity among Women from Zimbabwe and the United States</td>
<td>Sharon L. Achilles (University of Pittsburgh, United States)</td>
<td></td>
</tr>
<tr>
<td>13:15 - 13:30</td>
<td>Very Early Mucosal Responses to Vaginal Infection of SIV</td>
<td>Liang Shang (University of Minnesota, United States)</td>
<td></td>
</tr>
<tr>
<td>13:30 - 13:45</td>
<td>Characterization of Dendritic Cells with Rapid HIV Capture Potential from the Human Female Reproductive Tract</td>
<td>Marta Rodriguez-Garcia (Geisel School of Medicine at Dartmouth, United States)</td>
<td></td>
</tr>
<tr>
<td>13:45 - 14:00</td>
<td>Influence of Sex Hormones and Hormonal Contraceptives on Markers of HIV Risk in the Adolescent Female Genital Tract</td>
<td>Smrittee Dabee (University of Cape Town, South Africa)</td>
<td></td>
</tr>
<tr>
<td>14:00 - 14:15</td>
<td>Longitudinal Combined Immunomodulatory Effects of Hormonal Contraceptives and Cervicovaginal Infections in Women Who Did or Did Not HIV Seroconvert</td>
<td>Raina N. Fichorova (Brigham and Women's Hospital and Harvard Medical School, United States)</td>
<td></td>
</tr>
<tr>
<td>14:15 - 14:30</td>
<td>Inflammatory Cytokine Responses in the Lower Female Reproductive Tract in Response to Semen</td>
<td>Sinaye Ngcapu (Centre for the AIDS Programme of Research in South Africa (CAPRISA), South Africa)</td>
<td></td>
</tr>
</tbody>
</table>
OA16, PrEP and the Real World

Chairs:
Gus Cairns (Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, United States)
John Brooks (Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, United States)

PrEP Initiation and Early Adherence among Young MSM and Transgender Women in Chicago in the Enhancing PrEP in Community (EPIC) Study
Albert Liu (San Francisco Department of Public Health, United States)
13:00 - 13:15

PrEP Adherence among East African Women with HIV-infected Partners Participating in an Open-label Study
Maria Pyra (University of Washington, United States)
13:15 - 13:30

PrEP Implementation by Local Health Departments in US Cities and Counties: Findings from a 2015 Assessment of Local Health Departments
Dawn Smith (Centers for Disease Control and Prevention, United States)
13:30 - 13:45

Women’s Knowledge of, Interest in, and Eligibility for HIV Pre-exposure Prophylaxis at Family Planning Clinics in Northern California
Dominika Seidman (University of California San Francisco, United States)
13:45 - 14:00

Feasibility and Uptake of HIV Self-testing among Adults Visiting Community Pharmacies in Kenya
Peter Mugo (Kemri-Wellcome Trust Research Programme, Kenya)
14:00 - 14:15

Unplanned Discontinuations of HIV Pre-exposure Prophylaxis During Clinical Care
Douglas Krakower (Beth Israel Deaconess Medical Center, United States)
14:15 - 14:30

ME02, Meet the Experts

Chairs:
Pontiano Kaleebu (UVRI, Uganda)
Zeda Rosenberg (IPM, United States)

Plenary Session 3 Speakers
Dennis Burton (The Scripps Research Institute, United States)
Noel Gordon (Human Rights Campaign, United States)
Sharon Hillier (University of Pittsburgh, United States)

Plenary Session 4 Speakers
Deborah Birx (Office of the U.S. Global AIDS Coordinator, United States)
Emilio Emini (Bill & Melinda Gates Foundation, United States)
SYMPOSIUM 15:30 - 17:00

SY06, Effective Cellular Immune Responses

Chairs:
Jill Gilmour (International AIDS Vaccine Initiative, United Kingdom)
Nabila Seddiki (Inserm, U955, Equipe 16, France)

- **Role of T Cells in Controlling HIV Infection** 15:30 - 15:52
  Andrew McMichael (University of Oxford, United Kingdom)

- **Risk of HIV Acquisition Correlates Inversely with T Cell Polyfunctionality in Vaccine Efficacy Trials** 15:52 - 16:14
  Nicole Frahm (Fred Hutchinson Cancer Research Center, United States)

- **Development of a Cytomegalovirus-based HIV Vaccine** 16:14 - 16:36
  Louis Picker (Oregon Health & Science University, United States)

- **ADCC Immunity against HIV** 16:36 - 16:58
  Stephen Kent (University of Melbourne, Australia)

SY05, Using ARVs and Antibodies for Long-Acting Prevention

Chairs:
Magdalena E Sobieszczyk (College of Physicians and Surgeons, Columbia University, United States)
Glenda Gray (South African Medical Research Council, South Africa)

- **One Person’s Challenge Is Another Person’s Opportunity: Antibody Mediated Prevention Is a Milestone Opportunity** 15:30 - 15:52
  Larry Corey (Fred Hutchinson Cancer Research Center, United States)

- **Pipeline for Long-Acting Passive Prophylaxis: How and When Will We Choose?** 15:52 - 16:14
  Nina Russell (Bill & Melinda Gates Foundation, United States)

- **AAV and Other Novel Antibody Delivery Platforms** 16:14 - 16:36
  Frances Priddy (International AIDS Vaccine Initiative, United States)

- **Engineering HIV Antibodies for Potency, Breadth and Half-life** 16:36 - 16:58
  John Mascola (National Institute of Allergy and Infectious Diseases, NIH, United States)

Rountable 15:30 - 17:00

RT01, What Is Sterilizing Immunity?

Chairs:
Eric Hunter (Emory University, United States)
Peggy Johnston (Bill & Melinda Gates Foundation, United States)
**Factors that Impact on the Genotypic and Phenotypic Features of Heterosexually Transmitted Clade C Founder Viruses**
Carolyn Williamson (University of Cape Town & NHLS, South Africa)

**Early Events in HIV-1 Infection: New Insight from the RV217 Early Capture Acute Infection Cohort**
Gustavo Kijak (U.S. Military HIV Research Program, Walter Reed Army Institute of Research, United States)

**Breakthrough Occult HIV Infections Despite Sustained Plasma Levels of Antiretroviral Drugs Delivered in Long-acting Formulations**
Martina Kovarova (University of North Carolina at Chapel Hill, United States)

**Gp120 Signatures Determining HIV Infectivity Are Universal across Primate Lentiviruses**
Mileidy Gonzalez (NCBI, NIH, United States)

**Neutralizing Antibody-mediated Protection against Mucosal SHIV Challenge Includes Systemic Clearance of Distal Virus**
Dan Barouch (Beth Israel Deaconess Medical Center, United States)

**Moderated Discussion**

---

**RT02, The PrEP Prevention Package: From Efficacy Studies to the Real World**

**Chairs:**
Jim Pickett (AIDS Foundation of Chicago, United States)
Sheena McCormack (MRC Clinical Trials Unit at UCL, United Kingdom)

Andrew Grulich (Kirby Institute, UNSW Australia, Australia)

**Pre-Exposure Prophylaxis (PrEP): NYC Implementation Strategy**
Demetre Daskalakis (New York City Department of Health and Mental Hygiene, United States)

**Structural Interventions to Enhance PrEP Availability and Delivery**
Nduku Kilonzo (National AIDS Control Council, Kenya)

**Key Populations and Young People Views and Experiences on PrEP. Messages for Advocacy**
Matteo Cassolato (International HIV/AIDS Alliance)

**Moderated Discussion**
Poster Discussion
17:15 - 18:00
Sheraton Ballroom II-III

PD07, Reproductive Health and Prevention

Chairs:
Lisa Noguchi (JHPIEGO/JHU, United States)
Nelly Mugo (Kenya Medical Research Institute (KEMRI), Kenya)

The Ring plus Project: High Acceptability and Adherence of a Contraceptive Vaginal Ring in Kigali, Rwanda
Tania Crucitti (Institute of Tropical Medicine, Belgium)

Effectiveness of PMTCT Programs Despite Detectable Viral Loads in Nigerian HIV Positive Mothers
Sophia Osawe (Institute of Human Virology, Nigeria)

Sex Work Alters the Vaginal Microbiome: A Comparison Between Sex Workers and Lower Risk Women from the Same Community in Nairobi, Kenya
Jocelyn Wessels (McMaster University, Canada)

Does a History of Intimate Partner Violence Modify the Effectiveness and Safety of HIV Assisted Partner Services in Kenya?
Marielle Goyette (University of Washington, United States)

Cervicovaginal Bacterial Composition Impacts HIV Acquisition in Young African Women
Christina Gosmann (Ragon Institute of MGH, MIT and Harvard, United States)

Poster Discussion
17:15 - 18:00
Sheraton Ballroom IV-V

PD05, Pushing the Envelope

Chairs:
Cynthia Derdeyn (Emory University, United States)
Guillaume B. E. Stewart-Jones (Vaccine Research Center, NIAID, NIH, United States)

Common Env Escape Drives the Maturation of V2-apex Targeting bnAbs in HIV-1 Infected Individuals
Elise Landais (International AIDS Vaccine Initiative (IAVI), United States)

Direct Access to the Co-receptor Binding Site in Virus Is Dependent on Mass of the Inhibitory Molecule and the Length of Variable Loops, V1/V2 of Env
Bimal K Chakrabarti (THSTI, India)

High-throughput Paired Heavy: Light Antibody Sequencing Enables Genetic Analyses of Broadly Neutralizing Antibody Lineage Development
Brandon DeKosky (Vaccine Research Center, NIAID, NIH, United States)

N-linked Glycan Taxonomy and the HIV-1 Glycan Shield
Chen-Hsiang Shen (Vaccine Research Center, NIAID, NIH, United States)

Tier 1 Strains of HIV-1: Time to Break an Old Habit?
17:51 - 18:00
Poster Discussion  
17:15 - 18:00  
Chicago Ballroom VI-VII

PD06, Germinating Germline Antibodies

Chairs:  
Yiming Shao (Chinese Center for Disease Control and Prevention, China)  
Dan Kulp (Scripps, United States)

**Construction and Characterization of Chimeric SHIVs Displaying V1V2 Epitopes that Bind Germline Precursors of Broadly Neutralizing Human Antibodies**  
Mangaiarkarasi Asokan (VRC/NIAID/NIH, United States)  
17:15 - 17:24

**Interactions of Germline VRC01-Class Antibodies with HIV-1 Env: The Role of CDRH3**  
Christina Yacoob (Fred Hutchinson Cancer Research Center, United States)  
17:24 - 17:33

**Selective Activation of VRC01-class Germline Antibodies in Knock-in Mice with Diverse Precursor Repertoires**  
Hongying Duan (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States)  
17:33 - 17:42

**The Role of the CDRH3 of Germline VRC01-class Antibodies in HIV-1 Env Interactions**  
Marie Pancera (Fred Hutchinson Cancer Research Center, United States)  
17:42 - 17:51

Poster Discussion  
17:15 - 18:00  
Chicago Ballroom VIII-X

PD08, Enter New Inhibitors

Chairs:  
Walid Heneine (CDC, United States)  
Deborah Anderson (Boston University School of Medicine, United States)

**Pre-exposure Prophylaxis with EFdA Offers Strong Protection against High Dose Mucosal HIV Challenges**  
Martina Kovarova (University of North Carolina at Chapel Hill, United States)  
17:15 - 17:24

**Increased Activity of the Entry Inhibitor DS003, a BMS-378806 Analogue, through Binding to the CD4-induced Epitope in HIV-1 gp120**  
Carolina Herrera (Imperial College London, United Kingdom)  
17:24 - 17:33

**Prevention of Vaginal Transmission of Simian-human Immunodeficiency Virus (SHIV) in Rhesus Monkeys by Small-molecule CD4-mimetic Compounds**  
Navid Madani (Dana-Farber Cancer Institute, United States)  
17:33 - 17:42

**Preclinical Characterization of a Potent D-peptide Inhibitor of HIV Entry: Cholesterol-conjugated PIE12-trimer**  
Michael Kay (University of Utah, United States)  
17:42 - 17:51

**Next Generation SIV Broadly Neutralizing Antibodies Mediate Complete Neutralization of SIVmac239**  
Rosemarie Mason (Vaccine Research Center, NIAID, NIH, United States)  
17:51 - 18:00
Poster Session 02

Odd-numbered abstracts will be presented in Poster Session 01 on Tuesday, 18 October. Even-numbered abstracts will be presented in Poster Session 02 on Wednesday, 19 October.

P28, Treatment as Prevention

Option B Plus Is Working in Nairobi, Kenya; Case Study of Baba Dogo Health Centre
John Ng’ang’a (University of Manitoba / University of Nairobi, Kenya)

Predictors of Lost to Follow Up among HIV Adults Initiated on ART with More than 500 CD4 cells/in a Rural Clinic in Uganda
Sulaiman Kawooya (AHF/Uganda Cares, Masaka Healthcare Centre, Masaka Regional Referral Hospital, Uganda)

P27, Therapeutic Vaccine, Viral Latency and Cure

Development of a Latency Reversing Activator Vaccine (ACT-VEC) Platform as a Curative Approach for SIV
Jamie Mann (University of Western Ontario, Canada)

Memory CD4+CD45RO+SAMHD1low Cells Exhibit the Highest Level of HIV DNA and May Contribute to HIV-1 Persistence
Lylia Hani (INSERM, U955, Equipe 16, France)

Dissecting Responses to Dendritic-cell Vaccination in the DALIA Trial by Gene Expression Analysis after PBMC Stimulation
Rodolphe Thiebaut (INSERM U1219, ISPED, Bordeaux Population Health; Vaccine Research Institute - VRI, France)

Anti-HIV-1 ADCC Antibodies Following Latency Reversal and Treatment Interruption
Wen Shi Lee (University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Australia)

HIV-Tat Fused to the Oligomerisation Domain of the C4-binding Protein Is Highly Immunogenic and Controls EcoHIV Challenge in Mice
Tomusange Khamis (University of Adelaide, Australia)

P26, Systems Biology and Novel Molecular Technologies
Throughput Screening of HIV-1 Broad Neutralizing Antibodies and Env Immunogens
Yongping Yang (NIH, United States)

P25, Results of Clinical Trials

Pharmacokinetics/Pharmacodynamics of Tenofovir and Tenofovir Plus Levonorgestrel Vaginal Rings in Women
Andrea Ries Thurman (CONRAD Eastern Virginia Medical School, United States)

The Results of Phase II Clinical Trial of Therapeutic HIV DNA Vaccine: The Possible Reach of Viral Reservoirs
Ekaterina Akulova (State Research Institute of Highly Pure Biopreparations, Russian Federation)

CUTHIVAC 001: Results from a Phase I Clinical Trial of a Prophylactic Clade B HIV-1 DNA Vaccine Comparing Multiple Routes of Administration
Goli Haidari (Imperial College London, United Kingdom)

Env-specific IgG Responses Induced by Identical and None-identical Immunogen Prime-boost Vaccination Strategies Target Different Antigenic Regions
Christof Geldmacher (Medical center of the Ludwig-Maximilians University of Munich, Germany)

Late Boost Strategies of ALVAC-HIV/AIDSVAX B/E® Prime-boost Regimen (RV306) Increased Functional B Cell Responses and Frequency of Plasmablasts
Alexandra Schuetz (USAMD-AFRIMS, Thailand)

Vaccine Induced HIV Seropositivity/reactivity (VISP/R) among Recipients of Adenovirus Vectored HIV-1 Vaccine Prime/boost Regimens
Paul Kitandwe (UVRI-IAVI HIV Vaccine Program, Uganda)

The Clinical Impact of Intravaginal Ring Placement and Sustained TDF and FTC Delivery over 7 Days on Vaginal Microbiomes
Richard Pyles (University of Texas Medical Branch, United States)

Dissecting the Kinetic and Functional Immunoprofile of Antigen-specific B Cells in the Peripheral Blood and Mucosal Samples of HIV Vaccine Recipients
Sven Kratochvil (IAVI, United Kingdom)

Vaccine Induced Seroreactivity Induced by ALVAC-HIV and AIDSVAXB/E Prime-boost Vaccinations with Varying Late Boosts (RV306)
Tanyaporn Wansom (Armed Forces Research Institute of Medical Sciences, Thailand)

Randomized Controlled Trial of Daily Text Messages for Adherence to Pre-exposure Prophylaxis (PrEP) in Men who Have Sex with Men and Transgender Women
Sheldon Morris (University of California at San Diego, United States)
Impact of Implementing Innovative Adherence Measures during the Conduct of a Pivotal Phase 3 Trial (IPM 027 / The Ring Study)
Annelene Nel (International Partnership for Microbicides, South Africa)

Acceptability of New HIV Prevention Technologies among Transgender Women in Jamaica
Carmen Logie (University of Toronto, Canada)

The Association between Sexual Behavior and Acceptability of Oral PrEP and a Rectal Microbicide Gel to Prevent HIV Transmission
Curtis Dolezal (New York State Psychiatric Institute and Columbia University, United States)

Development and Validation of Measures to Screen for Potential Adherence and Support Adherence Prospectively
Elizabith (Betsy) Tolley (FHI 360, United States)

Disclosure of Vaginal Ring Use to Male Partners in an HIV Prevention Study: Impact on Adherence
Gonasagrie Nair (CAPRISA, South Africa)

Initial Feasibility, Acceptability and User Experience of a Multi-drug Pod-IVR: A Mixed Methods Study
Kate Morrow Guthrie (Brown Medical School, United States)

Attitudes and Perceptions about Adherence Counseling Barriers and Facilitators among Clinical Trialists: Results from a Global Stakeholder Survey
Kathleen MacQueen (FHI 360, United States)

Acceptability of and Preference for Injectable PrEP among Young U.S. Men, Transgender Women and Transgender Men who Have Sex with Men
Katie Biello (Brown University School of Public Health, United States)

Willingness to Use Long-acting Injectable PrEP among Men Who Have Sex with Men in Washington, DC
Matthew Levy (George Washington University Milken Institute School of Public Health, United States)

Acceptability of HIV Pre-exposure Prophylaxis (PEP) among Young Women Aged 18-29 Years in Kenya
Michael Kiragu (LVCT Health, Kenya)

Attitudes and Perceptions Towards Novel Objective Measures of ARV-based Vaginal Ring Use: Results from a Global Stakeholder Survey
Randy Stalter (FHI 360, United States)

Feasibility and Acceptability of an International SMS Text Message-based Adherence and Survey System in a Biomedical HIV Prevention Study (MTN-017)
William Brown III (Columbia University, United States)

“I Didn't Want to Be the First”: Reasons HIV-uninfected Partners in Serodiscordant Couples Decline PrEP in Uganda
Timothy R Muwonge (Makerere University, Uganda)

US Women in the HPTN069/ACTG 5305 Phase 2 PrEP Study: A Substudy Evaluating Acceptability and Experiences
Adaora Adimora (UNC School of Medicine, United States)
Scientific Program (PDF)

Poster
18:00 - 19:30
River Exhibit AB

P23, Populations-specific Prevention Science (Pediatric, Adolescents, Discordant Couples, MSM, IDU, Pregnant Women)

HIV and Injecting Drug Use among Out of School Youths: Experience from Nigeria
Adedayo Adeyemi (Healthmatch International, United Kingdom)

Correlates of STI Testing among Transgender Women in Jamaica
Carmen Logie (University of Toronto, Canada)

Depressive Symptoms, Alcohol and Drug Use, and Physical and Sexual Abuse among Men who Have Sex with Men in the Anza Mapema Study in Kisumu, Kenya
Colin Kunzweiler (University of Illinois at Chicago, United States)

High HIV Prevalence among Young People Aged 13-24 Years Living in Fishing Communities along Lake Victoria, Uganda
Gertrude Nanyonjo (UVRI-IAVI HIV Vaccine Program, Uganda)

Factors Associated with HIV Prevalence among Sex Workers and Truckers in the Border Towns of Busia and Malaba, Uganda
Stephen Okoboi (The AIDS Support Organisation (TASO), Uganda)

Impact of Community-based HIV Campaign on Prevention of Mother-to-Child Transmission of HIV in Nigeria
Isaac Adejo (Achieving Health Nigeria Initiative, Nigeria)

PrEP Knowledge, Uptake, and Comparative Interest in New Prevention Modalities in an Online Sample of American Men who Have Sex with Men (MSM)
Kenneth H. Mayer (Fenway Health, United States)

Lack of PrEP Awareness Amongst Chicago's Injection Drug Users and Missed Opportunities for PrEP Engagement
Ramona Bhatia (CDPH, United States)

A Qualitative Examination of Attitudes and Perceptions of HIV Clinical Research among Historically Black College and University Faculty and Students
Stephaun Wallace (Fred Hutchinson Cancer Research Center, United States)

HIV Vaccine Preparedness Study in a Mobile Fishing Population in Uganda: Assessing; Feasibility, Retention and Estimating HIV Incidence
Ubaldo Bahemuka (MRC/UVRI Uganda Research Unit on AIDS, Uganda)

The Incremental Cost of Delivering PrEP as a Bridge to ART to HIV Serodiscordant Couples in Public HIV Care Clinics in Kenya
Elizabeth Irungu (Partners in Health, Research and Development, Kenya)

Tapping into the Unheard Voices of End-users to Deliver on Pre-exposure Prophylaxis (PrEP) for Adolescent Girls and Young Women
Megan S. Dunbar (Pangaea Global AIDS, United States)

Poster
18:00 - 19:30
River Exhibit AB

P22, Policy and Advocacy
Scientific Program (PDF)

Promoting Access to Condom-compatible Lubricants as Key HIV Prevention Commodity Among GMTs and Other Key Populations in Kisumu County, Kenya
Kennedy Olango (Men Against AIDS Youth Group, Kenya)

Using the Evolution of PrEP Profiles on Cruising Apps as an Informal Time Sequence Analysis: The Case of Canadian PrEP Users on BBRT
Marc-André LeBlanc (HIV Prevention Advocate, Canada)

Health Policy Maker's Perspectives on PrEP Implementation and Scale-up in Kenya
Michael Kiragu (LVCT Health, Kenya)

Regina Ombam (National AIDS Control Council, Kenya)

P21, Pharmacology/Pharmacokinetics

Differential Drug Transporter Expression in the Female Genital Tract of Animal Models for HIV Prevention
Ashlyn Norris (University of North Carolina at Chapel Hill, United States)

A Comparative Pre-phase I Study of the Impact of Gel Vehicle Volume on Distal Colon Distribution and Acceptability
Ethel Weld (Johns Hopkins University, United States)

In Vivo Drug-drug Interactions Between Tenofovir Gel and Three Commonly Used Vaginal Products
Jill Schwartz (CONRAD Eastern Virginia Medical School, United States)

Role of Menopause in Tenofovir and Emtricitabine Disposition and Efficacy in Cervicovaginal Explants with Ex Vivo HIV Challenge
Melanie Nicol (University of Minnesota, United States)

Tenofovir Diffusion and Partitioning Vs Structure of Vaginal and Rectal Tissue Using Noninvasive Raman Spectroscopy and Optical Coherence Tomography
Oranat Chuchuen (Duke University, United States)

A PK/PD Model to Predict Effective HIV PrEP Dosing Strategies for IV Drug Users
Julie B. Dumond (UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, United States)

P19, Novel Vaccine and Prevention Concepts

HIV Virus-like Particles Displaying a High Density of Antigenically Correct Envelope Spikes
Armando Stano (The Scripps Research Institute, United States)
Characterisation of mAb from Cows Yielding Broad HIV-1 Neutralizing Antibody in Colostrum after Vaccination with Env-gp140 Trimer Vaccine  
Damian Purcell (Doherty Institute, University of Melbourne, Australia)

Exploiting Natural Cross-reactivity between HIV-1 p17 Protein and 2F5 Antibody to Induce Neutralizing Responses In Vivo  
Capucine Phelip (CNRS LBTI UMR5305, France)

Partial Protection from Intravenous Challenge by an Integration-defective SIV Vaccine  
Chu Wang (National Engineering Laboratory for AIDS Vaccine, China)

Development of a Plant-based Expression System for the Production of Soluble HIV-1 Subtype C Envelope Antigens  
Emmanuel Margolin (Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, South Africa)

Chronic Helminthiasis Suppresses Both T Cell and Antibody Responses to DNA-MVA and MVA-Protein HIV Vaccine Regimens Despite Anti-helminthic Treatment  
Godfrey Dzhivhuho (University of Cape Town, South Africa)

Increased Thermostability and Reduced CD4 Affinity of Structure-based Stabilized Prefusion Closed HIV-1 Env Trimer  
Hui Geng (Vaccine Research Center, NIAID, NIH, United States)

Preclinical Considerations on Advancing DNA/MVA or MVA-only Vaccines into Human Efficacy Trials  
Harriet L. Robinson (GeoVax Inc., United States)

Enhancing Sensitivity of HIV-1 to Antibody Neutralization by Modulating the Energy Landscape of the Envelope Glycoproteins  
Jacklyn Johnson (University of Iowa, United States)

Immunogenicity Study of a Designed Polypeptide HIV Vaccine in Mice  
Jiayi Shu (Institut Pasteur of Shanghai, China)

HIV-1 gp140 Protein Boost Augments Vector Primed Antibody Responses Against Env Variable Regions in Rhesus Monkeys  
Kathryn E. Stephenson (Beth Israel Deaconess Medical Center, United States)

Quality Studies to Support the Biopharmaceutical Development of the Rectal Microbicide Candidate Griffithsin  
Krystal Hamorsky (University of Louisville School of Medicine, United States)

Proteoliposomal Formulations of an HIV-1 gp41-based Miniprotein Elicit a Lipid-dependent Immunodominant Response Overlapping the 2F5 Binding Motif  
Luis M Molinos-Albert (AIDS Research Institute IrsiCaixa-HIVACAT, Spain)

Designed HIV-1 Env Molecules from Multiple Clades That Display Structural and Antigenic Characteristics of the Mature Prefusion HIV-1 Env  
M. Gordon Joyce (Vaccine Research Center, NIAID, NIH, United States)

Potent and Broadly Neutralizing Antibodies of Multiple Specificities in HIV-1 Infected Individuals from India  
Narayanaiah Cheedarla (National Institute for Research in Tuberculosis, India)

Reducing V3 Antigenicity on Soluble, Native-like SOSIP.664 Trimers  
Rajesh P Ringe (Weill Cornell Medical College, United States)
Chronic Helminthiasis Prevents Optimal Boosting of T Cell and Antibody Responses by an MVA-Env Protein HIV Vaccine Regimen in a Mouse Model
Samantha Humby (University of Cape Town, South Africa)

V2 and C2 Domain-dependent Antigenic Properties of Efficiently Cleaved HIV-1 Clade B Env, JRCSF that Can be Used as a Platform for Immunogen Design
Supratik Das (Translational Health Science and Technology Institute, India)

An Early Phase I/II HIV Vaccine Trial Experience: The Voice of the Young Volunteers in Dar Es Salaam, Tanzania: A Qualitative Study
Theodora Mbunda (Infectious Diseases Clinic, Tanzania, United Republic of)

Comparison of Safety and Immunogenicity of MVA-B (Modified Vaccinia Virus Ankara Expressing HIV-1 B) in HIV-uninfected and HIV-infected Volunteers
Alberto C Guardo (Hospital Clinic de Barcelona, Spain)

Bi-specific Immunoadhesin Fully Protects Humanized NSG Mice Challenged by HIV
Xilin Wu (AIDS Institute, Hong Kong)

Mucosal Vaccination with a Live Recombinant Rhinovirus Followed by Intradermal DNA Administration Elicits Protective HIV-specific Immune Responses
Tomusange Khamis (University of Adelaide, Australia)

The Stability of Tenofovir in Urine over Temperature and Time
Giffin Daughtridge (Perelman School of Medicine, United States)

Isolation of SIV Env-specific Tier 2 Neutralizing Antibody from iMac-ΔD Immunized Macaque
Hugh Welles (VRC / NIH, United States)

Membrane-anchored HIV-1 Envelope Immunogens with Native Trimer Antigenicity for DNA Vaccine
Timothy Wanninger (National Institute of Allergy and Infectious Disease (NIAID)/National Institute of Health (NIH), United States)

Cryo-EM Structure of the First Contact of CD4 Receptor with HIV-1 Env
Priyamvada Acharya (NIH, United States)

Poster
18:00 - 19:30
River Exhibit AB

**P18, Mucosal Immunology**

**Oral Maraviroc Reduces CD4 T Cells at the Genital Mucosal Surface of HIV-seronegative Women**
Anandi N. Sheth (Emory University School of Medicine, United States)

**Seminal Plasma Induces Inflammation and Enhances HIV-1 Infection in Human Ectocervical Explants**
Andrea Introini (Karolinska Institutet, Sweden)

**Mucins in the Cervicovaginal Fluid and Their Association with Bacterial Vaginosis**
Bernard J Moncla (University of Pittsburgh School of Medicine, United States)

**Probiotic Bacteria and Estrogen Can Enhance Genital Epithelial Barrier Function and Decrease Inflammation, Thereby Lowering HIV-1 Infection**
Sara Dizzell (McMaster University, Canada)
Scientific Program (PDF)

The Relationship of Condomless Receptive Anal Intercourse, Mucosal Injury, and the Rectal Microbiota in Men Who Have Sex with Men
Colleen Kelley (Emory University School of Medicine, United States)

Inhibition of α4β7 Activation May be Necessary to Reduce Susceptibility to SIV: Differential Effect of an Agonist and an Allosteric Inhibitor
Elena Martinelli (Population Council, United States)

Use of Vaginal Explants: HIV-1 Induced Transcriptome, Candidate Genes and a Simple Assay System to Screen Efficacy of Candidate Microbicides
Hrishikesh Pandit (National Institute for Research in Reproductive Health, India)

Seminal Macrophages: Viability, Phenotype, Function and Potential Role in HIV Sexual Transmission
Jai Marathe (Boston University, United States)

Dissemination of HIV-1 Following Intra-vaginal Infection in Humanized Mice
Jocelyn Wessels (McMaster University, Canada)

miRNA let-7f: The Key Modulator of Cervico Vaginal Immune Function in the Context of Developing a Safe Vaginal Anti-HIV Microbicide
Kanchana Ayyar (National Institute for Research in Reproductive Health, India)

Impact of HIV-ART on Th17 and Treg Subpopulations in Blood and Genital Mucosa
Maria Pia Holgado (Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), UBA-CINICET, Argentina)

Effecets of Symptomatic Bacterial Vaginosis Before and After Treatment on Genital Mucosal Immunity in Women in Bronx, New York and Thika, Kenya
Marla Keller (Albert Einstein College of Medicine/Montefiore Medical Center, United States)

Impact of Chronic Sexual Abuse and HIV on Genital Tract Biomarker Expression in Women
Jason Daniels (George Washington University, United States)

Female Sex Hormones Affect HIV-1 Infection Kinetics and Viral Dissemination in a Humanized Mouse Model
Philip Nguyen (McMaster Immunology Research Center, Canada)

MISS-1 Study: Enhancement of Specific Immunity After HIV-1+ Seminal Plasma Exposure in the Female Reproductive Tract of MVA-HIV Vaccinated Macaques
Romain Marlin (Immunology of viral infections and autoimmune diseases/IDMIT Infrastructure/CEA/DRF/iMETI/Division of Immuno-Virology, Université Paris Sud, Inserm U 1184, France)

The Role of Vitamin D on Genital Mucosal Immunity and Markers of HIV Susceptibility in Women
Sharon Anderson (CONRAD, Eastern Virginia Medical School, United States)

Characterization of Antibody Responses in Anogenital Secretions of ALVAC-HIV and AIDSVAXB/E Prime-boost Vaccinations with Varying Late Boosts (RV306)
Siriwat Akapirat (Armed Forces Research Institute of Medical Sciences, Thailand)

Poster
18:00 - 19:30
River Exhibit AB

P17, Mathematical Modeling: Impact and Effectiveness
**Predicted Effectiveness of Daily and Non-daily PrEP Based on Sex Coverage Data from HPTN 067 ADAPT Sites in South Africa, Thailand and US**  
Dobromir Dimitrov (Fred Hutchinson Cancer Research Center, United States)

**The Cost-effectiveness, Affordability and Impact of HIV Prevention: Concepts and Reviews**  
Geoffrey Garnett (Bill & Melinda Gates Foundation, United States)

**Modeling the Cost-effectiveness of Home-based HIV Testing and Education (HOPE) for Pregnant Women and Their Male Partners in Nyanza Province, Kenya**  
Monisha Sharma (University of Washington, United States)

**Assessing the Impact of the Vaccine Efficacy Profile and Regimen Adherence on Projected Effectiveness of the HVTN 702 Vaccine Regimen in South Africa**  
Simon de Montigny (CHU Sainte-Justine Research Center, Canada)

**Ending the AIDS Epidemic in Women and Girls in Sub-Saharan Africa: The Potential Role of a Preventive AIDS Vaccine**  
Arne Näveke (International AIDS Vaccine Initiative, United States)

**Deterministic Compartmental Pharmacokinetic Model for an Intravaginal Ring (IVR)**  
David Katz (Duke University, United States)

---

**Poster 18:00 - 19:30 River Exhibit AB**

**P16, Innate Immunity**

**Preclinical Evaluation of Serpins as Potential Colorectal Microbicides**  
Carolina Herrera (Imperial College London, United Kingdom)

**NMR Assignments and Dynamics of Ligand-free HIV-1 gp120 Outer Domain**  
Malika Sastry (Vaccine Research Center, NIAID, NIH, United States)

**TLR10 Plays an Important Role in Significantly Enhancing HIV-1 Infection, Integration and Innate Immune Responses**  
Kenneth Rosenthal (McMaster University, Canada)

---

**Poster 18:00 - 19:30 River Exhibit AB**

**P15, Implementation Science, including Structural Interventions, PrEP and VMMC**

**Applying Lean Thinking and Rapid Process Improvement to Multiple Global HIV Vaccine Trial Processes**  
Carissa Karg (Fred Hutchinson Cancer Research Center, United States)

**Introducing PrEP into HIV Combination Prevention Services in Kenya: Emerging Lessons for Scale Up**  
Wanjiru Mukoma (LVCT Health, Kenya)

**A Cost Evaluation of Integrating Non-communicable Disease Screening into Home-based HIV Testing and Counseling**  
Ilya Golovaty (University of Washington Department of Medicine, United States)
Willingness to Take or Allow a Partner to Take HIV Pre-exposure Prophylaxis (PrEP) among Residents of Siaya County, Western Kenya, 2012-2014
Joseph Mogunde (Jaramogi Oginga Odinga Teaching and Referral hospital, Kenya)

Cervical Abnormalities amongst Participants Screened for the MTN020/ASPIRE Trial in Hillbrow, Johannesburg
Krishnaveni Reddy (Wits Reproductive Health and HIV Institute, South Africa)

Factors Associated with Self-disclosure of Sexual Behavior to Healthcare Providers amongst Young Men Who have Sex with Men in Washington DC
Evan Tasios (George Washington University Milken Institute School of Public Health, United States)

Models of VMMC Service Delivery in Mozambique, What Works Best? An Analysis of Productivity and Safety
Fausto Vilanculos (Jhpiego, Mozambique)

Successful Recruitment in a Treatment as Prevention and Pre-exposure Prophylaxis Demonstration Study among Female Sex Workers in Benin
Michel Alary (CHU de Québec, Canada)

Social Harms and Social Benefits among Participants Taking Prep in the US PrEP Demo Project
Nikole Trainor (San Francisco Department of Public Health, United States)

Samuel Jenness (Emory University Rollins School of Public Health, United States)

Cedric Bien (Montefiore Medical Center/Albert Einstein College of Medicine, United States)

Pre-exposure Prophylaxis Knowledge and Beliefs in Chicago Department of Public Health Disease Intervention Specialists
Ramona Bhatia (CDPH, United States)

Poster
18:00 - 19:30
River Exhibit AB

P14, Impact of STI and the Human Microbiome on Susceptibility, Immunity & Prevention

Effects of a Vaginal Ring Containing Dapivirine Worn for 12 Weeks on the Vaginal Microbiota of Postmenopausal Women

Recent Semen Exposure and Higher Nugent Scores Are Associated with Reduced Antimicrobial Activity in Adolescent Female Genital Tract Secretions
Rebecca Pellett Madan (Albert Einstein College of Medicine, United States)

Female-to-male Transmitted/Founder HIV-1 are Less Susceptible to Inactivation by Vaginal Microbiota Acid Metabolites than Non-transmitted Strains
Gilda Tachedjian (Burnet Institute, Australia)

A Macaque Model of Rectal Lymphogranuloma Venereum (LGV) and non-LGV Chlamydia trachomatis: Impact on Susceptibility to Rectal SHIV Acquisition
Sundaram Ajay Vishwanathan (Centers for Disease Control and Prevention, United States)
Repertive Tract Infections Among Low Risk Women Attending KAVI-VZV 001 Study in Nairobi, Kenya
Catia Perciani (University of Toronto, Canada)

Profound Impact of Metronidazole Treatment on Genital Cytokine and Chemokine Levels in Women with Bacterial Vaginosis
Vineet Joag (University of Toronto, Canada)

P13, Immunogenetics (Host Immunity and Restriction Factors)

Immunogenetic Correlation of Vitamin D and Antiviral Molecules with Natural Resistance to HIV-1 Infection
Wildeman Zapata (Grupo Immunovirología, Facultad de Medicina, Universidad de Antioquia UdeA, Colombia)

Rare Variant Association Testing Finds AXL is Associated with Significantly Decreased Risk of Sexually-acquired HIV-1
Mary J Emond (University of Washington, United States)

Fc-gamma Receptor Affinity as a Host Factor for HIV Transmission
Sarah Connolly (Emory Vaccine Center and Yerkes National Primate Research Center, United States)

Random Forests Uncover an Interaction Between PAX5 and FAM189A2 Variants in Discovery of Genomic Variation Associated with HIV-1 Acquisition Risk
Duncan McArthur (University of Washington, United States)

P12, HIV Transmission and Viral Diversity

HIV Intravesicular Sequestration in Infant Tonsil Epithelial Cells
Sharof Tugizov (University of California San Francisco, United States)

Near Whole Genome Sequencing of Emerging URFs in Cameroon
Andrew N. Banin (NYULMC, United States)

Features of Recently Transmitted HIV-1 Clade C Viruses That Impact Antibody Recognition: Implications for Active and Passive Immunization
Cecilia Rademeyer (University of Cape Town, South Africa)

BLT Humanized Mice Recapitulate the Preferential Transmission of Env N362 Observed During Heterosexual HIV Infection
Damien C. Tully (Ragon Institute of MGH, MIT and Harvard, United States)

Persistence of Transmitted Antiretroviral Drug Resistance Mutations in the IAVI-early HIV Infection Cohort (Protocol C)
Dean Harris (University of the Witwatersrand, South Africa)
Investigating HIV-1 Envelope Evolution in Response to Early Neutralizing Antibody Pressure Using Next Generation Sequencing  
Dieter Mielke (University of Cape Town, South Africa)

The Transmission Bottleneck of HIV-1 in IDUs of China Xinjiang  
Fan Li (China CDC, China)

Innovative Semen Collection Strategy in an HIV Prevention Clinical Trial in Thika Kenya  
John Mwathi (Partners in Health Research and Development, Kenya)

Drift of the Envelope Glycoprotein of HIV-1 Clade B towards Higher Infectious Properties over the Course of the Epidemic  
Mélanie Bouvin-Pley (Inserm U966 MAVIVH, France)

Super-infection and Development of MPER-specific Neutralization Breadth in Subject 40512 from the Acute Infection Cohort RV217  
Christopher Owen (U.S. Military HIV Research Program, Henry M. Jackson Foundation for the Advancement of Military Medicine, United States)

Origin of AIDS Virus in Semen  
Nathalie Dejucq-Rainsford (INSERM U 1085-IRSET, France)

HIV-infected Macrophages Can Establish DAe Novo Infection after Vaginal Exposure  
Sean Patro (University of North Carolina (UNC), School of Medicine, United States)

Diversity of HIV-1 Proviral Sequences During Antiretroviral Treatment from Transmitted Variants  
Kelsie Brooks (Emory University, United States)

Poster  
18:00 - 19:30  
River Exhibit AB

**P11, HIV Drug Resistance in Prevention**

Utility of a Relatively Affordable Inhouse HIV-1 Genotyping Assay for Drug Resistance Testing among nonB HIV-1 Infected Drug Naïve Patients in Nigeria  
Joseph Anejo-Okopi (University of JOS, Nigeria)

Poster  
18:00 - 19:30  
River Exhibit AB

**P10, Ethics in HIV Prevention Research**

Privacy and Confidentiality for PLHIV Accessing Health Services in Kenya  
Lucy Ghati (KELIN, Kenya)

Poster  
18:00 - 19:30  
River Exhibit AB

**P09, Epidemiology of HIV Prevention**
Medical Male Circumcision and HIV Prevalence in Rural KwaZulu-Natal, South Africa  
Anneke Grobler (CAPRISA, South Africa)

Assays for Estimating HIV Incidence: Updated Global Market Assessment and Estimated Economic Value  
Charles Morrison (FHI 360, United States)

Encouraging Trends in HIV Diagnoses, Care and Viral Suppression in 5 US Cities, 2009-2013: Surveillance-based Data from HPTN 065 (TLC-plus)  
Deborah Donnell (Fred Hutchinson Cancer Research Center, United States)

Innovative Social Communication Facility to Promote Access to HIV Prevention and Treatment Services for Key Affected Populations in Lagos State  
Florita Durueke (New HIV Vaccine and Microbicide Advocacy Society (NHVMAS), Nigeria)

Assessing Training Needs of Clinical Officers to Target Acute HIV Infection Evaluation of Adult Patients Seeking Urgent Healthcare in Kenya  
Hannah Rafferty (Oxford University, United Kingdom)

Comparing Cisgender and Transgender Persons Diagnosed in Washington, DC: Has a Population Been Ignored?  
Jenevieve Opoku (DC Department of Health, United States)

High Prevalence of HIV p24 Antigen among HIV Antibody Negative Prospective Blood Donors in Ile-Ife, Nigeria  
Margaret Japhet (Obafemi Awolowo University, Nigeria)

ITAPS/IAVI: Mentorship and Training in Scientific Writing on HIV Prevention Research in Low- and Middle-income Countries  
Matthew Price (University of California San Francisco, United States)

Sex Work in the City: MSM and Transgender Women Who Receive Money or Goods for Sex, Bangkok, Thailand  
Sarika Pattanasin (Thailand MOPH-U.S.CDC Collaborations, Thailand)

Partners of Female Sex Workers Who Are Older and Unaware of Their HIV Status Are at Higher Risk of HIV Infection in Tanzania  
Caterina Casalini (Jhpiego, Tanzania, United Republic of)

Toyese Akinade (Population Council Nigeria, Nigeria)

HIV, Syphilis and Trichomonas Incidence in Female Sex Workers in Lusaka and Ndola, Zambia  
William Kilembe (Zambia Emory HIV Research Project (ZEHRP), Zambia)

Understanding Longitudinal HIV Care Trajectories to Improve Health and Reduce HIV Transmission in North Carolina  
Kimberly Powers (The University of North Carolina at Chapel Hill, United States)
Detection of HIV Env-mediated B Cell Receptor Aggregation on Engineered B Cells by Flow Cytometry
Brandon Gallaher (Fred Hutchinson Cancer Research Center, United States)

Increased Activity of the Entry Inhibitor DS003, a BMS-378806 Analogue, through Binding to the CD4-induced Epitope in HIV-1 gp120
Carolina Herrera (Imperial College London, United Kingdom)

Tenofovir / IQP-0528 Combination Gel Effectively Inhibits HIV and Is Not Affected by Semen
Cory Shetler (Magee-Womens Research Institute, United States)

Preclinical Evaluation of Prototype Rectal Griffithsin Gels for HIV Prevention
Charlene Dezzutti (University of Pittsburgh, United States)

Development of a Novel and Safe Microbicide Gel Formulation for the Prevention of HIV
Kudumula Venkata Rami Reddy (National Institute of Research in Reproductive Health, India)

A Lectibody Targeting Env Glycans Exhibits Broad Antiviral Activity against HIV Virions and Infected Cells
Nobuyuki Matoba (University of Louisville School of Medicine, United States)

Design, Synthesis, and Antiviral Activity of Novel Bifunctional CD4-mimetic Small Molecules Containing Mono-cyclohexyl Moieties, YIR-819 and YIR-821
Shigeyoshi Harada (National Institute of Infectious Diseases, Japan)

Effectiveness of Broadly Neutralizing Antibodies against Drug Resistant and Transmitter/Founder HIV Strains
Charlene Dezzutti (University of Pittsburgh, United States)

Toxicology Profile of a Topical Multipurpose Prevention Technology that Combines Griffithsin and Carrageenan
José A. Fernández-Romero (Population Council, United States)

Poster
18:00 - 19:30
River Exhibit AB

P07, Delivery technologies: novel approaches, formulation and multi-purpose

Preformulation Advances of Q-Griffithsin, a Novel Candidate for HIV Prevention
Andrew Pearlman (Magee-Womens Research Institute, United States)

Truncated HIV Envelope Expressed by Synthetic Recombinant Replication-competent (SRRC) Human Ad4 Recognized by Conformation-dependent Antibodies
Apisit A Patamawenu (National Institutes of Health, United States)

Silk-formulated Antiretrovirals as Candidate Microbicides
Carolina Herrera (Imperial College London, United Kingdom)

Production and Characterisation of Nanosuspensions as Long-acting Multi-purpose Prevention Technology (MPT) Injectable Formulations
Clement M. Haeck (Queen's University Belfast, United Kingdom)

Visualising Maraviroc Release from Silicone Elastomers Using Magnetic Resonance Imaging
Diarmaid Murphy (School of Pharmacy, Queen's University Belfast, United Kingdom)
Impact of Butyrate Prodrug on Extent of LNG Binding in Addition-cure Silicone Elastomer Vaginal Rings
Karl Malcolm (Queen's University Belfast, United Kingdom)

Sustained Delivery of Etravirine from Nanoparticle-releasing Nanofiber Composites after Vaginal Administration in Mice
Emily A. Krogstad (University of Washington, United States)

Novel Application of Hot Melt Extrusion for the Manufacture of Vaginal Microbicide Films
Galit Regev (University of Pittsburgh, United States)

Safety of GRFT-containing Vaginal Gels in Rhesus Macaques
Natalia Teleshova (Population Council, United States)

Adherence Measurements of Post-use Tenofovir Disoproxil Fumarate (TDF) and Tenofovir/Levonorgestrel (TFV/LNG) Intravaginal Rings
Jiang Qiu (Northwestern University, United States)

Sheep Pharmacokinetics of a Topical Aqueous Gel Containing the Anti-HIV CCR5 Receptor Inhibitor 5P12-RANTES
John McBride (Queen's University Belfast, United Kingdom)

Intravaginal Drug Delivery System with Dual Microbicide Delivery
John Moss (Oak Crest Institute of Science, United States)

Electrospinning Process Considerations to Formulate a Triple Drug Microbicide for Rapid and Asynchronous Release
Rick Edmark (University of Washington, United States)

Targeting Cellular Drug Transporters to Boost Antiretroviral Drug Activity at Mucosal Sites
Julia Ekeruche-Makinde (Imperial College London, United Kingdom)

Incorporation of Early End-user Feedback into the Iterative Design of Fiber-based Microbicides: Considering Adherence from Inception
Kate Morrow Guthrie (Brown Medical School, United States)

Electrospun Polymer Nanofibers for Long-term Protection against HIV and HSV-2
Kevin M. Tyo (University of Louisville, United States)

Preclinical Safety and Stability Assessment of a Dual Compartment Microbicide Gel Targeting Multiple Viral Sexually Transmitted Infections
José A. Fernández-Romero (Population Council, United States)

The Ring Plus Project: The Effect of a Contraceptive Vaginal Ring on the Vaginal Microbiota
Tania Crucitti (Institute of Tropical Medicine, Belgium)

Establishment of Assays for Culture and Manipulation of Haematopoietic Stem Cells for Use in HIV/AIDS Single-cell Therapy
Marianne Mureithi (University of Nairobi, Kenya)

Long-acting Intrauterine System Delivers Integrase Inhibitor Throughout the Reproductive Tract of Rabbits and Macaques
Meredith R. Clark (CONRAD, Eastern Virginia Medical School, United States)

HIV Prevention Efficacy Results Using Vaginal or Rectal TDF, FTC and TDF/FTC Combination in Humanized Mice
Philippe Gallay (The Scripps Research Institute, United States)
**A Biodegradable, Subcutaneous Implant for Delivery of Antiretroviral (ARV) Drugs**  
Stephanie Swarner (RTI International, United States)

**A Convenient, Self-administered Microbicide Fast-dissolving Insert as Pre-exposure Prophylaxis for HIV Prevention**  
Manjari Lal (PATH, United States)

**Poster**  
18:00 - 19:30  
River Exhibit AB

**P06, Correlates of protection and exposure**

Sex Differences in Cumulative Exposure to Tenofovir as Determined via Hair Levels in VOICE, iPrEx OLE, and PrEP Demo  
Catherine Koss (University of California San Francisco, United States)

HIV Replication in Cervical and Vaginal Tissue for the Ex Vivo Challenge Assay  
Charlene Dezzutti (University of Pittsburgh, United States)

Correlates of Unprotected Sex Among African HIV Serodiscordant Couples  
Kenneth Ngure (School of Public Health, Jomo Kenyatta University of Agriculture and Technology, Kenya)

PK, Ex-vivo Efficacy on HIV Infectivity and Effect on Immune System of Maraviroc, Raltegravir and Ritonavir-boosted Lopinavir in MSM on PEP  
Lorna Leal (Hospital Clinic de Barcelona, Spain)

The Prevalence and Associated Factors of Self-reported Penile and Rectal Coital Injuries among Men who Have Sex with Men (MSM) in Kisumu, Kenya  
Supriya Mehta (University of Illinois at Chicago, United States)

Active and Inactive Forms of Vitamin D Reduce the HIV-1 Infection in Vitro  
Wbeimar Aguilar-Jimenez (Grupo Inmunovirología, Facultad de Medicina, Universidad de Antioquia UdeA, Colombia)

Development of Human Follicular Dendritic Cells and B Cell Follicles in BLT Humanized Mice  
Todd Allen (Ragon Institute of MGH, MIT and Harvard, United States)

Characterizing Viral Evolution and bNAb Specificities in Two Subjects Infected with Closely Related Founder Strains of HIV  
Ruchi M. Newman (Ragon Institute of MGH, MIT and Harvard, United States)

**Poster**  
18:00 - 19:30  
River Exhibit AB

**P05, Contraception, pregnancy and HIV prevention**

Knowledge and Willingness of Young Adults to Participate in Early HIV Vaccine Trials and Contraceptive Practices in Southwestern, Nigeria  
Adeolu Oluremi (Ladoke Akintola University of Technology, Nigeria)

An Internet-based Study of Medical Providers’ Attitudes, Knowledge and Behavior about Pregnancy Planning for HIV-impacted Women  
Amy Johnson (AIDS Foundation of Chicago, United States)
The Relationship between Condom Errors and Number of Sex Partners in a High HIV Burden Region in Western Kenya, 2012-2014
Kennedy Mutai (Kenya Medical Research Institute Center for Global Health Research, Kenya)

Sexual Experiences and HIV Risk Perception among Pregnant Adolescents: Health Improvements for Teen Ugandans (HI-4-TU) Study
Carolyne Agwau Akello (Makerere University - Johns Hopkins University, Uganda)

Community-based HIV Testing Services in Tanzania Double the Uptake of Family Planning among Adolescent Girls/Young Women and Female Sex Workers
Caterina Casalini (Jhpiego, Tanzania, United Republic of)

Uptake of Non-hormonal Intrauterine Contraceptive Devices (IUDs) among Women Participating in MTN-020, a Clinical Trial for HIV Prevention in Africa
Felix Mhlanga (University of Zimbabwe College of Health Sciences, Zimbabwe)

Lessons Learned from a Decade of Mother to Child Transmission Prevention in a Community Health Center in Bamako, Mali
Eliza Squibb (GAIA Vaccine Foundation, United States)

Prevalent HIV Infection and Coitus Interruptus - Findings from a Peri-urban Community of South Africa
Heeran Makkan (Aurum Institute, South Africa)

Uptake of Long Acting Reversible Contraception (LARC) among Cohabitng Couples with Known HIV Status in Kigali, Rwanda
Jeannine Mukamuyango (Project San Francisco, Rwanda)

Factors Associated with Change of Contraceptive Methods among Women at Risk of HIV Participating in a Microbicide Trial in South Western Uganda
Sylvia Masawi (MRC/UVRI Uganda Research Unit on AIDS, Uganda)

Early Terminations During the MTN-020/ASPIRE Study at the CAPRISA eThekwini Clinical Research Site (CRS): A Review of Screening and Termination Data
Kalendri Naidoo (CAPRISA, South Africa)

Acceptability of Antiretroviral-based Safer Conception among HIV-infected Individuals Receiving Care at a Publicly Funded Clinic in Seattle, WA
Kerry Thomson (University of Washington, United States)

Determinants of Contraceptive Use among Kenyan Women
Laura Lunani (KAVI-Institute of Clinical research, University of Nairobi, Kenya)

The Progestin-only Injectable Contraceptive MPA, Unlike NET, Directly Increases R5 HIV-1 Replication in Ectocervical and Endocervical Tissue Explants
Michelle F Maritz (University of Cape Town, South Africa)

Traditional Birth Attendants and HIV Prevention of Mother-to-Child Transmission in Ibadan, Nigeria
Oladipupo Olaleye (Department of Health Promotion and Education, College of Medicine, University of Ibadan, Nigeria)

Saving Babies from Vertical Transmission of HIV: Evidence from a Retrospective Cohort Analysis of Mother-infant Pair in South Africa
Olusegun Solomon Akinsanya (University of Witwatersrand, South Africa)

Implementation of Option B+ in Selected Parts of Northern Zambia: Early Lessons Learnt
Prisca Kasonde (FHI 360 Zambia, Zambia)
**Scientific Program (PDF)**

**Long Acting Reversible Contraceptive (LARC) Uptake, Dual Method Use and Unplanned Pregnancies in Female Sex Workers Recruited in Kigali, Rwanda**
Rosine Ingabire (Project San Francisco, Rwanda)

**Correlation between Co-therapy of Efavirenz-based ART and Pregnancy among HIV-positive Women Using Hormonal Contraceptive Implants in Tororo, Uganda**
Stephen Okoboi (The AIDS Support Organisation (TASO), Uganda)

**Dapivirine and Tenofovir Disoproxil Fumarate Regulate Immunomodulatory Gene Expression in Cervical Cells Alone and in Combination with MPA**
Sigcinile Dlamini (University of Cape Town, South Africa)

**High Incidence of Intended Pregnancy among Partners of Men Living with HIV in Rural Uganda: Implications for Safer Conception Services**
Angela Kaida (Simon Fraser University, Canada)

**Poster**
18:00 - 19:30  
River Exhibit AB

**P04, Community engagement in prevention research**

**Pre-screening, Screening, and Enrollment of Female Sex Workers and Single Mothers into a Simulated HIV Vaccine Efficacy Trial in Zambia**
Amanda Tichacek (Rwanda Zambia HIV Research Group-Emory University, United States)

**Exploring a New Approach to Distance Learning of the Good Participatory Practice Guidelines**
Anne Schley (AVAC: Global Advocacy for HIV Prevention, United States)

**Utilizing Influence of Religious Leaders and Faith Organizations: An Effective Strategy in Promoting Biomedical HIV Prevention Research in Uganda**
Betty M. Nabirye (Uganda Catholic Medical Bureau, Uganda)

**A Study Conducted among Healthy Adults to Evaluate Relationship Between Willingness and Actual Participation in a HIV Vaccine Clinical Trial: Kenya**
Delvin Nyasani (KAVI-ICR, Kenya)

**Science or Media Cafés; Where Scientists Meet the Media**
Esther Nakkazi (Health Journalists Network in Uganda, Uganda)

**Assessing Impact of Traditional Circumcisers as Agents to Improve Access to Quality VMMC Services in NW Province, Zambia**
Chama Chanda (FHI 360/ZPCTIIB, Zambia)

**Ensuring Good Participatory Practices in a Simulated Vaccine Efficacy Trial (SiVET) with MSM and Sex Workers (SW) - Challenges and Lessons Learnt**
George Victor Owino (International AIDS Vaccine Initiative (IAVI), Kenya)

**Engaging Men for Mobilization for Oral Pre-exposure Prophylaxis among Adolescent Girls and Young Women in Kenya**
Jane Karong'e (LVCT Health, Kenya)

**Bridging the Gap 2: Role of LGBT Community in Ensuring Meaningful Engagement in Research**
Jonah Chinga (Gay and Lesbian Coalition of Kenya/G10, Kenya)
The Use of Mentor Mothers in Prevention of Mother to Child Transmission of HIV in Nigeria
Maryann Obidike (Actionaid Nigeria, Nigeria)

Utilizing a Community-Based Participatory Research Approach to Develop Animated Videos for Community Engagement for a Phase 2b HIV Prevention Trial
Gail Broder (Fred Hutchinson Cancer Research Center, United States)

Engaging Transgender Men in Biomedical HIV Prevention Research in New York City
Magdalena E Sobieszczyk (College of Physicians and Surgeons, Columbia University, United States)

Making PrEP Work for Women - Effective Engagement to Ensure Access
Teresia Otieno (ATHENA Network, United States)

Assessing Readiness for a PrEP Demonstration Project among Female Sex Workers in Southern India: Results from a Feasibility Study
Sushena Reza-Paul (University of Manitoba, Canada)

Community Mobilization in Generating Demand and Recruiting Participants for a PrEP Demonstration Project among Female Sex Workers in India
Sushena Reza-Paul (University of Manitoba, Canada)

Poster
18:00 - 19:30
River Exhibit AB

P03, Cellular immunity

Activation Profile of Mycobacterium tuberculosis-specific CD4+ T Cells Reflects Disease Activity, Irrespective of HIV Status
Catherine Riou (University of Cape Town, South Africa)

HIV-specific CD4+ T Cell Responses Targeting the Immunodominant Gag41 Peptide Are Associated with Reduced Viral Load in HIV-1 Clade C Infection
Faatima Laher (HIV Pathogenesis Programme, South Africa)

Impaired Effect of HLA-A*24:02-associated Mutation on HLA-B*35:01-associated HIV-1 Control
Hayato Murakoshi (Center for AIDS Research, Kumamoto University, Japan)

Differential Impact of Inhibitory Receptors and Inhibitory Receptor Blockade on Cytokine-producing CD4 T Cell Subsets
Jeffrey E. Teigler (Henry M. Jackson Foundation for the Advancement of Military Medicine, United States)

Mechanisms of Abrupt HIV Disease Progression in a Cohort of Previous Elite and Viremic HIV Controllers
Miriam Rosas (AIDS Research Institute IrsiCaixa-HIVACAT, Spain)

Macrophage Heterogeneity and Their Role in HIV Infection
Ousman Jobe (U.S. Military HIV Research Program, Henry M. Jackson Foundation for the Advancement of Military Medicine, Walter Reed Army Institute of Research, United States)

HIV-infected Macrophages Resist Perforin-mediated Killing and Promote Pro-inflammatory Cytokine Release by Cytotoxic T Lymphocytes
Kiera Clayton (Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, United States)
P01, Antibody functions (neutralizing and non-neutralizing)

Limited Evolution of a Strain-specific Antibody Lineage Targeting the C3 Region of the HIV-1 Envelope
Cathrine Scheepers (School of Pathology, University of the Witwatersrand, South Africa)

Envelope Immunogen Properties Direct Selective B Cell Expansion and Neutralizing Antibodies in HIV-1 Immunized Rhesus Macaques
Christina Yacoob (Fred Hutchinson Cancer Research Center, United States)

Induction of Broadly Neutralizing Antibodies against Conserved Epitopes in HIV-1 V3 Domain
Deyan Chen (Nanjing University, China)

A Unique Broadly Neutralizing Antibody Involving the CD4bs and N332 Glycan Supersite Affects Multiple Waves of Virus Quasispecies in a Slow Progressor
Hanna Ebner (University of Zurich, Switzerland)

Deciphering the Specificity of Antibody Profiles in Patients that Control HIV
Jéromine Klingler (UMR S_1109, France)

Role of Antibody-dependent Cell-mediated Cytotoxicity in HIV-1 Uninfected Bystander CD4+ T Cell Killing
Andres Finzi (CRCHUM / Université de Montréal, Canada)

A Combination of Broadly Neutralizing Antibodies Prevents in Vitro SHIV162P3 Cell-free Transmission More Efficiently than Cell-to-cell Transmission
Karunasinee Suphaphiphat (CEA, France)

Detection and Analysis of Broadly Neutralizing Antibodies in HIV-1 Subtype C Chronically Infected Individuals
Kim Robertson (University of KwaZulu Natal, South Africa)

Neutralizing Antibody Induced by the Vaccination of a Peptide Antigen with a gp120 V3 Epitope
Nan Zheng (Nanjing University, China)

Three Related HIV-1 Cross-superinfected Individuals Exchange Similar Viral Strains, but Evolve Different Immunological Responses
Ralf Duerr (New York University - School of Medicine, United States)

Potency and Breadth of Single Chain Variable Fragments (scFv) of Broadly Neutralizing HIV Antibodies
Rebecca van Dorsten (Center for HIV and STIs, National Institute for Communicable Diseases, South Africa)

HIV-1 Env Immunogen-elicted Cross-reactive Tier 2 Virus Neutralizing Antibody Response in Non-human Primates
Yimeng Wang (The Scripps Research Institute, United States)

Env-specific Rabbit Antibody Mediated ADCC Activities via Human Fc-receptor
Shan Lu (University of Massachusetts Medical School, United States)

V1 Loop Length Limits Neutralization of HIV-1 Clade C Primary Viruses by Broadly Neutralizing Antibodies Targeting the V3 Glycan
Suprit Deshpande (Translational Health Science and Technology Institute, India)
Development of Autologous Neutralizing Antibodies in HIV-1 CRF01_AE-infected Patients Spanning the First Three Years of Infection
Syna K Gift (U.S. Military HIV Research Program, United States)

Peripheral Immune Cells Improve the Inhibitory Activity of Non-neutralising HIV-1-specific Antibodies
Hannah M. Cheeseman (Imperial College London, United Kingdom)

Antibody Responses Elicited by Cleaved Soluble HIV-1 Envelope Trimers in Guinea Pigs Revealed by Single B Cell Sorting and Cloning
Lin Lei (Institute for Bioscience and Biotechnology Research, University of Maryland, United States)

Poster
18:00 - 19:30
River Exhibit AB

P02, Behavioral and social science research...

“Striving and Hoping” - Women's Motivations to Join an HIV Prevention Clinical Trial: Narratives from the VOICE-D Study
Ariana Katz (Women's Global Health Imperative, RTI International, United States)

Supply and Demand Strategies to Promote Uptake of Long Acting Reversible Contraception (LARC) to Prevent Unintended Pregnancy and Perinatal HIV
Bellington Vwalika (Zambia Emory HIV Research Project (ZEHRP), Zambia)

Social and Structural Landscapes Shaping HIV Prevention among Lesbian, Gay, Bisexual and Transgender Persons in Lesotho
Carmen Logie (University of Toronto, Canada)

Knowledge Associated with Interest in Using Pre-exposure Prophylaxis (PrEP) for HIV Prevention among Sexually Active Men Who Have Sex with Men
Erin Kahle (University of Michigan, United States)

Patient Satisfaction with Services for Prevention of Mother-to-Child Transmission of HIV in Dar es Salaam, Tanzania
Helga Naburi (Muhimbili University of Health and Allied Sciences, Tanzania, United Republic of)

Vaginal Practices in Microbicide Ring Trials in Southwestern Uganda
Josephine Bayigga (MRC/UVRI Uganda Research Unit on AIDS, Uganda)

Measuring Sensory Experiences Elicited by Product Properties During Receptive Anal Sex: Implications for Prevention Design and Marketing
Sara E Vargas (Brown Medical School, United States)

Embodying the New Orthodoxy: How Gay Service Providers Incorporate Emerging Biomedical HIV Knowledge into Their Professional and Personal Lives
Marc-André LeBlanc (HIV Prevention Advocate, Canada)

Divergent Stated Preferences for New Multipurpose Prevention Products Across Adults, Adolescents and Female Sex Workers in South Africa
Matthew Quaife (London School of Hygiene & Tropical Medicine, United Kingdom)

Knowledge of HIV Acquisition and Transmission as a Predictor of Sexual Behaviour among Young Women 18-24 Years Old in Kenya
Njambi Njuguna (Partners in Health, Research and Development, Kenya)
“Another Experiment from the Government”: Leveraging Facebook to Explore Black Women’s Perspectives on PrEP
Oni Blackstock (Montefiore Medical Center/Albert Einstein College of Medicine, United States)

“It’s Too Complicated for Them”: Service Providers as Information Gatekeepers for PrEP in African, Caribbean and Black Communities
San Patten (San Patten and Associates, Canada)

Increasing Access To/Demand for HIV Testing among Men Who Have Sex with Men (MSM) and Transgender Women (TW) Should Become a Priority in Peru
Carlos F. Caceres (Universidad Peruana Cayetano Heredia, Peru)

High Prevalence of HIV and Syphilis Amongst Female Sex Workers in Port Elizabeth, South Africa Point to Prevention Needs to Reduce Transmission Risks
Zamakayise Kose (Human Sciences Research Council, South Africa)

Potential Benefits and Risks of HIV Self-testing Access by Female Sex Workers: Views of Service Providers, Outreach Workers and Sex Workers in Kenya
Kawango Agot (Impact Research & Development Organization, Kenya)

Costs of Recruiting Men for Medical Male Circumcision in a Peri-urban Clinic in Johannesburg, South Africa: Results from the IMBiZO Study
Jonathan Grund (Centers for Disease Control and Prevention, United States)
Thursday, 20 October 2016

Conference Event
07:30 - 15:00
Columbus B

Sympoisum Check-In

Symposium
08:30 - 10:00
Sheraton Ballroom II-III

SY07, Entering the Dark Zone: Germinal Centers in Immune Response

Chairs:
Christiane Moog (INSERM U1109, FMTS, Université de Strasbourg, France)
Elias Haddad (Drexel University, United States)

Role of Adjuvants in Enhancing Durability of HIV Vaccine Responses by Inducing Potent Germinal Centers and Plasma Cell Responses
Sudhir Kasturi (Emory University, United States)
08:30 - 08:52

The Many Flavors of Vaccine-Induced CD4 T Cell Responses
Hendrik Streeck (Institute for HIV Research, Germany)
08:52 - 09:14

B Cell Follicle Sanctuary Permits Persistent Productive SIV Infection in Elite Controllers: Implications for HIV Cure
Afam Okoye (Oregon Health & Science University, United States)
09:14 - 09:36

Selection Dynamics in the Germinal Center during Antibody Affinity Maturation
Alexander Gitlin (Rockefeller University, United States)
09:36 - 09:58

Symposium
08:30 - 10:00
Sheraton Ballroom IV-V

SY08, Envelope Structure and Broadly Neutralizing Antibodies

Chairs:
Gabriella Scarlatti (Global HIV Vaccine Enterprise, United States)
David Montefiori (Duke University Medical Center, United States)

Structural Dynamics of HIV Env Glycoproteins: A Link between Structural, Functional, and Phenotypic Variation among Isolates
Kelly Lee (University of Washington, United States)
08:30 - 08:52

The HIV Glycan Shield as a Target for Broadly Neutralizing Antibodies
Katie Doores (King's College London, United Kingdom)
08:52 - 09:14

Immunogenicity of Multiple SOSIP Trimers in Different Animal Species
John Moore (Weill Medical College, United States)
09:14 - 09:36

Broadly Neutralizing Antibody Lineages and Precursors
Penny Moore (University of the Witwatersrand, South Africa)
09:36 - 09:58
RT03, Combinations and Keys: The Complexities and Successes of Reaching the People Who Need It

Chairs:
Manju Chatani (AVAC, United States)
Jason Reed (Jhpiego)

HIV and Sex Workers: Challenges and Lessons for Scaling up Programmes 08:30 - 08:40
Sinead Delany-Moretlwe (University of the Witwatersrand, South Africa)

Reaching Epidemic Control by 2030: Challenges and Opportunities for Adolescent Girls and Young Women in Kenya 08:40 - 08:50
Kawango Agot (Impact Research & Development Organization, Kenya)

Finding the Right Fit: Combination HIV Prevention for Men Who Have Sex with Men 08:50 - 09:00
Hyman Scott (San Francisco Department of Public Health, United States)

Understanding HIV Risk Among Transgender Women and Developing Interventions for this Vulnerable Population 09:00 - 09:10
Amy Johnson (Ann & Robert H. Lurie Childrens Hospital of Chicago, United States)

The Complexities and Successes of Reaching the People Who Inject Drugs 09:10 - 09:20
John Brooks (Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, United States)

Moderated Discussion 09:20 - 10:00
### Oral 
10:30 - 12:00

**OA17, Cellular Immunity Matters!**

**Chairs:**
Nicole Bernard (Research Institute of the McGill University Health Centre, Division of Clinical Immunology, Faculty of Medicine, McGill University, Canada)  
Tomas Hanke (University of Oxford, United Kingdom)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 10:45</td>
<td>Programming T and B Cell Homing to Mucosal Sites to Induce Protective and/or Therapeutic Vaccination Using Chemokine-adjuvanted DNA Plasmids</td>
<td>Yoann Aldon (Imperial College London, United Kingdom)</td>
<td>Sheraton Ballroom II-III</td>
</tr>
<tr>
<td>10:45 - 11:00</td>
<td>Mucosal Administration of Particulate Antigens Improves TFH Generation, HIV-specific High-quality and Long-lasting Immunity</td>
<td>Thomas Vazquez (I3 Laboratory - UPMC/INSERM UMR5959, France)</td>
<td>Sheraton Ballroom II-III</td>
</tr>
<tr>
<td>11:00 - 11:15</td>
<td>Vaccine-induced CD8+ T Cell Immunity Strongly Predicts Lower HIV Infection Risk in HVTN 505</td>
<td>Holly Janes (Fred Hutchinson Cancer Research Center, United States)</td>
<td>Sheraton Ballroom II-III</td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td>Induction of Unique Subset of Follicular Homing SIV-specific CD8 T Cells by Vaccination Is Associated with Enhanced Control of Pathogenic SIV</td>
<td>Rama Amara (Emory University, United States)</td>
<td>Sheraton Ballroom II-III</td>
</tr>
<tr>
<td>11:30 - 11:45</td>
<td>Restoration of Defective T Cell Priming and Polarization in BLT Humanized Mice through Systemic Administration of IL-12p70</td>
<td>Daniel Claiborne (Ragon Institute of MGH, MIT and Harvard, United States)</td>
<td>Sheraton Ballroom II-III</td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td>Antiviral CD8+ T Cells Restricted by HLA Class II DRB1 Exist in HIV Infection and Exhibit Clonal Expansion</td>
<td>Srinika Ranasinghe (Ragon Institute of MGH, MIT and Harvard, United States)</td>
<td>Sheraton Ballroom II-III</td>
</tr>
</tbody>
</table>

### Oral 
10:30 - 12:00

**OA18, The Great Escape: Host-Virus Transmission Dynamics**

**Chairs:**
Morgane Rolland (MHRP | HJF, United States)  
Jonathan Carlson (Microsoft Research, United States)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 10:45</td>
<td>Gender Differences in Transmission of HIV-1 Viral Variants and Their Impact on Early Immune Activation</td>
<td>Elina El-Badry (Emory University, United States)</td>
<td>Sheraton Ballroom IV-V</td>
</tr>
<tr>
<td>10:45 - 11:00</td>
<td>Infant Peripartum Transmitted-founder HIV-1 Variants are Resistant to Autologous Maternal Plasma Neutralization</td>
<td>Amit Kumar (Duke Human Vaccine Institute, United States)</td>
<td>Sheraton Ballroom IV-V</td>
</tr>
<tr>
<td>11:00 - 11:15</td>
<td>Transmission of Multiple HIV-1 Founder Viruses and High Frequency of Unique Recombinant Forms among MSM in Kenya</td>
<td>Gladys Macharia (IAVI Human immunology Lab, Imperial College London, United Kingdom)</td>
<td>Sheraton Ballroom IV-V</td>
</tr>
</tbody>
</table>
**Scientific Program (PDF)**

**11:15 - 11:30**

**Higher HIV-1 Envelope Sequence Diversity in the Vaginal Tract than in Blood at Early Stage of Infection**
Katja Klein (University of Western Ontario, Canada)

**11:30 - 11:45**

**CD8+ T Cell Dynamics in Untreated and Treated Hyperacute HIV Infection; Implications for HIV Vaccines and Cure Strategies**
Zaza Ndhlouvu (University of KwaZulu Natal, South Africa)

**11:45 - 12:00**

**Localization of the First Infected Cells after Oral Viral Exposure in Infant Macaques**
Michael McRaven (Northwestern University, United States)

### Oral
10:30 - 12:00  
Chicago Ballroom VI-VII

**OA19, Passive Immunization: Instant Protection**

**Chairs:**
Marina Caskey (The Rockefeller University, United States)  
Nyaradzo Mgodi (University of Zimbabwe Collaborative Research Program, Zimbabwe)

**10:30 - 10:45**

**Rational Design of Bispecific Antibodies Targeting HIV-1 Env to Achieve Enhanced Anti-viral Potency and Breadth**
James Steinhardt (Institute for Bioscience and Biotechnology Research, United States)

**10:45 - 11:00**

**Partial Efficacy of a Broadly Neutralizing Antibody against Cell-associated SHIV Infection**
Stephen Kent (University of Melbourne, Australia)

**11:00 - 11:15**

**Durable Marked Attenuation and Clearance of SHIV Infection in Infant Macaques with Human Neutralizing mAbs as Post-exposure Treatment Within 48 Hours**
Ann J. Hessell (Oregon Health & Science University, Oregon National Primate Research Center, United States)

**11:15 - 11:30**

**Virus Fitness after Infusion with Broadly Neutralizing Antibody VRC01**
Rebecca Lynch (The George Washington University, United States)

**11:30 - 11:45**

**Rectal and Vaginal Biopsies from Men and Women Infused Intravenously with VRC01 Show Protection in Ex Vivo HIV-1 Challenge**
Rena D. Astronomo (Fred Hutchinson Cancer Research Center, United States)

**11:45 - 12:00**

**Variable IgG Transplacental Transfer in the Setting of Maternal HIV Infection**
David R. Martinez (Duke Human Vaccine Institute, United States)
OA20, Trust But Verify: Understanding Adherence

Chairs:
Jessica Haberer (Massachusetts General Hospital/Harvard Medical School, United States)
Kenneth Ngure (School of Public Health, Jomo Kenyatta University of Agriculture and Technology, Kenya)

10:30 - 10:45
High Levels of Adherence to a Rectal Microbicide Gel and to Oral PrEP Achieved in MTN-017
Alex Carballo-Diéguez (HIV Center for Clinical and Behavioral Studies at New York State Psychiatric Institute and Columbia University, United States)

10:45 - 11:00
Vaginal Ring Use in a Phase 3 Microbicide Trial: A Comparison of an Objective Measure of Adherence in ASPIRE with Self-reports of Product Use
Barbara S. Mensch (Population Council, United States)

11:00 - 11:15
Frequency of Partner-related Social Harms and their Impact on Adherence to the Dapivirine Vaginal Ring during the MTN020/ASPIRE HIV Prevention Trial
Thesla Palanee-Phillips (Wits Reproductive Health and HIV Institute, South Africa)

11:15 - 11:30
Can Infrared Spectroscopy (IR) Coupled with Chemometrics Be Used for Objective Measure of Adherence to Microbicide Products?
Oluwatosin Adedipe (CONRAD, Eastern Virginia Medical School, United States)

11:30 - 11:45
Novel Implementation of a Real-time Adherence Monitoring Strategy within a Phase III, Blinded, Placebo-Controlled, HIV-1 Prevention Clinical Trial
Marla J. Husnik (Fred Hutchinson Cancer Research Center, United States)

11:45 - 12:00
Clinical Assessment of New Objective Measures of Adherence for Four Placebo Vaginal Dosage Platforms
Terry Jacot (CONRAD, Eastern Virginia Medical School, United States)

Networking Lunch
12:00 - 13:00

NL03, Networking Lunch - Superior Hosts

Chairs:
Lyle McKinnon (Centre for the AIDS Programme of Research in South Africa, South Africa)
Penny Moore (University of the Witwatersrand, South Africa)
Thumbi Ndung’u (University of KwaZulu-Natal, South Africa)
Afram Okoye (Oregon Health & Science University, United States)
Anne Philpott (Department for International Development, United Kingdom)
Jim Pickett (AIDS Foundation of Chicago, United States)
Dianne Rausch (Division of AIDS Research, NIMH, United States)
Helen Rees (Wits Reproductive Health and HIV Institute, South Africa)
Hyman Scott (San Francisco Department of Public Health, United States)
Michael Stirrat (NIMH Division of AIDS Research, United States)
Hendrik Streeck (Institute for HIV Research, Germany)
Carolyn Williamson (University of Cape Town & NHLS, South Africa)
Kim A. Woodrow (University of Washington, United States)
Networking Lunch
12:00 - 13:00

NL03, Networking Lunch - Michigan Hosts

Chairs:
Kawango Agot (Impact Research & Development Organization, Kenya)
Cesar Boggiano (NIH/NIAID/DAIDS, United States)
John Brooks (Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, United States)
James Cummins (Division of AIDS, NIAID, NIH, United States)
Katie Doores (King's College London, United Kingdom)
Alexander Gitlin (Rockefeller University, United States)
Karin Hatzold (Population Services International, Zimbabwe)
Eric Hunter (Emory University, United States)
Kelly Lee (University of Washington, United States)
Jean-Daniel Lelievre (INSERM/VRI, France)
Bonnie Mathieson (Office of AIDS Research, United States)
Stuart Shapiro (DAIDS/NIAID/NIH, United States)

Oral
13:00 - 14:30

OA21, Designer Envelopes for Fashionable Responses

Chairs:
Nathan Nicely (Duke University, United States)
Gilad A. Ofek (University of Maryland, United States)

Characterization of Transmitted/Founder CRF01 AE Virus Envelope Trimers from the RV217-early Capture HIV Cohort Study
Neeti Ananthaswamy (The Catholic University of America, United States)

Targeted Deglycosylation as a Means of Vaccine Focusing
Peter Kwong (Vaccine Research Center, United States)

Composition and Antigenic Effects of Individual Glycan Sites of the HIV-1 Glycan Shield
Anna-Janina Behrens (University of Oxford, United Kingdom)

Delineating the Conformational Stability of the HIV-1 Envelope Glycoprotein Trimer
Branislav Ivan (University of Zurich, Switzerland)

Development of a Soluble HIV-1 Env Trimer Immunogen Stabilized in the Pre-fusion Closed State from Strain CH505
Kai Xu (Vaccine Research Center, NIAID, NIH, United States)

Glycan-masking improves the CD4bs-specificity of Antibodies Elicited by eOD-GT8 60mer
Xuejun Chen (Vaccine Research Center/NIAID/NIH, United States)
OA22, Human Vaccine Clinical Trials: Reality Check

Chairs:
Mary Marovich (Division of AIDS, NIAID, NIH, United States)
Fred Sawe (KEMRI/Walter Reed Project, Kenya)

**UK HVC 003: A Phase I Clinical Trial Exploring a Strategy to Maximise HIV Antibody Responses using Subtype C DNA, MVA and GLA Adjuvanted gp140**
Sarah Joseph (MRC Clinical Trials Unit at UCL, United Kingdom)

**DNA/MVA HIV Vaccine Producing Virus-like Particles (VLPs) Is Well-tolerated and Induces Durable Functional Antibodies (Abs) in HVTN 094**
Susan Buchbinder (San Francisco Department of Public Health, United States)

**Delayed Boost of ALVAC®HIV and AIDSVAX® B/E gp120 Following the RV144 Regimen, Significantly Increases HIV-1 Neutralizing Antibody Responses**
Lindsay Wieczorek (U.S. Military HIV Research Program, United States)

**Characterization of HIV-1 Envelope Antibody Responses Following ALVAC-HIV and AIDSVAX B/E Prime-boost Vaccinations with Varying Late Boosts (RV306)**
Siriwat Akapirat (Armed Forces Research Institute of Medical Sciences, Thailand)

**Upper Respiratory Tract (URT) Administration of a Replication Competent Ad4-HS-Vtn Vaccine Induces Durable Neutralizing Antibody Responses in Humans**
Jinghe Huang (National Institute of Allergy and Infectious Diseases (NIAID), NIH, United States)

**HIV Vaccine Trials Network (HVTN) 910: Long-term Follow-up of HIV Vaccine-induced Seropositivity (VISP) among HIV Vaccinees**
John Hural (HIV Vaccine Trials Network, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, United States)

OA23, Power, Pleasure and Prevention

Chairs:
Jill Schwartz (CONRAD Eastern Virginia Medical School, United States)
Saiqa Mullick (WITS Reproductive Health & HIV Institute, South Africa)

**Happy Clients: A Model for Promoting Long Acting Reversible Contraceptives**
Alexandra Hoagland (Zambia Emory HIV Research Project (ZEHRP), Zambia)

**The Impact of a Randomized Evaluation of a Girl’s Empowerment Program on HSV-2 and HIV Acquisition among Vulnerable Adolescent Girls in Zambia**
Paul C. Hewett (Population Council, United States)
Scientific Program (PDF)

Effectiveness of Integrated HIV Prevention and Family Planning Services for Couples in Zambia to Prevent HIV and Unintended Pregnancy  
Mubiana Inambao (Zambia Emory HIV Research Project (ZEHRP), Zambia)  
13:30 - 13:45

HIV Prevention Method Using Life Skills Education Program among In-school Adolescents in South West Nigeria  
Olubunmi Fakunle (Public Health Department, Nigeria)  
13:45 - 14:00

The Influence of the Vaginal Ring on Sexual Experiences of Women in an HIV Prevention Clinical Trial  
Nicole Laborde (RTI International, United States)  
14:00 - 14:15

Balancing HIV Risk with Fertility Desires and Willingness to Pay for Oral PrEP to Reduce Risks: Findings from a Discrete Choice Experiment  
Sheree Schwartz (Johns Hopkins Bloomberg School of Public Health, United States)  
14:15 - 14:30

Oral  
13:00 - 14:30  
Chicago Ballroom VIII-X

OA24, Prevention: Think Global, Prevent Local  
Chairs:
Saidi Kapiga (London School of Hygiene and Tropical Medicine, Mwanza Intervention Trials Unit, Tanzania, United Republic of)
Robert C Bailey (University of Illinois at Chicago, United States)

Evaluating the Impact of the Voluntary Medical Male Circumcision (VMMC) Program in Kenya  
John Stover (Avenir Health, United States)  
13:00 - 13:15

“How I Wish This Thing Was Initiated 100 Years Ago!” Willingness to Take Daily Oral Pre-exposure Prophylaxis among Men Who Have Sex with Men in Kenya  
Robinson Karuga (LVCT Health, Kenya)  
13:15 - 13:30

PrEP Uptake and Demographic Characteristics of PrEP Users in Two Large Medical Systems in San Francisco  
Susan Scheer (San Francisco Department of Public Health, United States)  
13:30 - 13:45

Prepping 4 Love: Engaging Focus Communities in the Development of a Citywide Social Marketing Campaign  
Amy Johnson (AIDS Foundation of Chicago, United States)  
13:45 - 14:00

Studies in Orange Farm, a Township of South Africa, Revealed That Obtaining a Male Circumcision Prevalence Rate of 80% Is Difficult but Feasible  
Bertran Auvert (INSERM U1018, France)  
14:00 - 14:15

Feasibility of Conducting HIV-combination Intervention Effectiveness Trials in Fishing Communities in Uganda: A Cluster Randomized Pilot  
Monica Kuteesia (MRC/UVRI Uganda Research Unit on AIDS, Uganda)  
14:15 - 14:30
RP01, Rapporteur Session

Chairs:
Gabriella Scarlatti (Global HIV Vaccine Enterprise, United States)

Lead Rapporteur - Team A
Cynthia Derdeyn (Emory University, United States) 15:00 - 15:22

Lead Rapporteur - Team B
Raphael Landovitz (UCLA Center for Clinical AIDS Research & Education, United States) 15:22 - 15:44

Lead Rapporteur - Team C
Barbara Shacklett (University of California, United States) 15:44 - 16:06

Lead Rapporteur - Team D
Morenike Ukpong (Institute of Public Health, Obafemi Awolowo University; New HIV Vaccine and Microbicide Advocacy Society, Nigeria) 16:06 - 16:28

Closing Plenary

PL04, Bring It On: Delivering Combination Prevention

Chairs:
Robin Shattock (Imperial College, United Kingdom)
Connie Celum (University of Washington, United States)

Introduction and Tribute to Ward Cates
Myron Cohen (University of North Carolina, United States) 16:30 - 16:35

Sexual and Reproductive Health Over a Lifetime: Ward Cates’ Contribution
Helen Rees (Wits Reproductive Health and HIV Institute, South Africa) 16:35 - 17:00

Desmond Tutu Award for HIV Prevention and Human Rights
Nelly Mugo (Kenya Medical Research Institute (KEMRI), Kenya) 17:00 - 17:10

From Research to Implementation: Delivery and Rollout
Deborah Birx (Office of the U.S. Global AIDS Coordinator, United States) 17:10 - 17:40

Control of the HIV Epidemic: The Requirement for Effective Prevention
Emilio Emini (Bill & Melinda Gates Foundation, United States) 17:40 - 18:05

Omu Falobi Award
Manju Chatani (AVAC, United States) 18:05 - 18:15

Closing Remarks
Lynn Morris (National Institute for Communicable Diseases of the NHLS, South Africa)
Jeanne Marrazzo (University of Alabama at Birmingham School of Medicine, United States) 18:15 - 18:25

Handover to 2018
18:25 - 18:30
SA20, Strengthening Community Advocacy and Solidarity for HIV Vaccine Research

AIDS vaccine research is complex; the role of an AIDS vaccine advocate is challenging. Explaining the hopeful, yet slow and complicated, progress in AIDS vaccine research to non-scientific stakeholders requires someone with relatively deep knowledge of complex science, research process, and related technical issues. Likewise, the critical role of representing stakeholder concerns to AIDS vaccine researchers requires someone who can speak in language that commands scientists’ attention and respect. Through the Vaccine Advocacy Resource Group (VARG) a global team of AIDS prevention research advocates play a critical liaison role in a highly complex scientific field. Since 2014, the VARG has been convened virtually—largely through teleconferences and email—to receive research updates, discuss advocates’ perspectives and priorities, and to move forward key actions. These efforts have been impactful in terms of coalescing the team of vaccine-specific advocates, building VARG members’ skills and understanding to a certain degree, and preparing them for conferences and scientific meetings. This satellite session aims to build the capacity of community advocates at R4P around HIV Prevention Research Advocacy, particularly how it relates to vaccine research.

Chairs:
Morenike Upong (New HIV Vaccine & Microbicide Advocacy Society)
Ntando Yola (Desmond Tutu Foundation, South Africa)
Tian Johnson (African Alliance for HIV Prevention)

SA18, Beyond Viral Neutralization

It has been known for more than 30 years that Human Immunodeficiency Virus 1 (HIV-1) infection drives a very potent B cell response resulting in the production of anti-HIV-1 antibodies targeting several viral proteins, particularly its envelope glycoproteins (Env), which are exposed at the surface of viral particles and infected cells. Enthusiasm by the generation of these anti-Env antibodies was short-lived since the majority were found to be unable to efficiently neutralize viral particles. This class of antibodies were therefore called non-neutralizing antibodies. However, antiviral activities of antibodies should not be limited to viral neutralization. Through their Fc portion, antibodies can mediate several immunological responses such as antibody-dependent cellular cytotoxicity (ADCC), antibody-mediated complement activation, antibody-mediated cellular phagocytosis (ADCP), antibody-dependent cell-mediated virus inhibition (ADCVI), trancytosis inhibition, opsonization, etc. All these functions could be beneficial in fighting viral infections including HIV-1. In this satellite session, we will discuss the latest developments in the expanding field of non-neutralizing, effector function competent (nNeFC) anti-HIV-1 antibodies.

Chairs:
Andres Finzi (CRCHUM / Université de Montréal, Canada)
Beyond Viral Neutralization
Andrés Finzi (CRCHUM / Université de Montréal, Canada)
Marzena Pazgier (University of Maryland)
George Lewis (Institute of Human Virology, University of Maryland School of Medicine, United States)
Matthew Parsons (University of Melbourne, Australia)
Nicole Bernard (Research Institute of the McGill University Health Centre, Division of Clinical Immunology, Faculty of Medicine, McGill University, Canada)
Guido Ferrari (Duke University Medical Center, United States)
David Evans (University of Wisconsin)
Stylianos Bournazos (Rockefeller University, United States)

Satellites
09:00 - 12:00

Chicago Ballroom VIII


What do women really desire from an HIV prevention product, and how do we, as a field, provide the optimal environment for women to adopt and adhere to these technologies? What are the product attributes that researchers should incorporate during the development process, and how should they be packaged, branded, and distributed? What role do health care providers, community, and stakeholders play in implementation and uptake? How can private sector approaches be applied to inform public health market shaping? Following the disappointing results of some PrEP trials in African women, one thing is clear: we must begin with the end user in mind. The Microbicide Product Introduction Initiative (MPii) is a multipartner, multiyear project funded by USAID that takes a deep dive into end-user research, stakeholder engagement, and PrEP implementation by using human-centered design, research-driven branding and messaging, and public/private partnerships to engage end users and their network on what makes HIV prevention products desirable and practical to use. Team members from MPii Projects EMOTION, OPTIONS, and POWER will provide an overview of each project and discuss how research and stakeholder engagement will be woven into an integrated launch plan for optimal results in PrEP introduction. Audience engagement will be emphasized.

Chairs:
Andrea Ries Thurman (CONRAD Eastern Virginia Medical School, United States)


Kristine Torjesen (FHI 360, United States)
Ann Kim (IDEO)
Jared Baeten (University of Washington, United States)
Hasina Subedar (formerly SANC)
Saïqa Mullick (WITS Reproductive Health & HIV Institute, South Africa)
Connie Celum (University of Washington, United States)
Yogan Pillay (Department of Health, South Africa)
Andrew Schirmer (McCann)
Liz Montgomery (RTI International)
Mitchell Warren (AVAC, United States)
Cal Burns (Matchboxology)
SA21, Antibody Mediated Prevention and What It Takes to Make a HIV Vaccine?

The HVTN and the HPTN are international collaborations funded primarily by the National Institute of Allergy and Infectious Disease (NIAID) of the United States National Institutes of Health (NIH). Since its founding more than a decade ago, the HVTN has sought to characterize the safety, immunogenicity, and efficacy of HIV vaccine candidates with the goal of developing, as rapidly as possible, a safe, effective vaccine for the prevention of HIV infection globally. The HPTN research agenda is focused primarily on the use of integrated strategies, using antiretroviral therapy for prevention of transmission from the HIV infected individual, and pre-exposure prophylaxis agents for prevention of acquisition in HIV uninfected individuals, as well as interventions for substance use, behavioral risk reduction and structural interventions. Antibody Mediated Prevention (AMP) is one approach the Networks are taking to achieve these goals. The AMP Studies will demonstrate whether an intravenously infused broadly neutralizing antibody against HIV, which works well in controlled in vitro assays and NHP challenge experiments, will prevent HIV infection in men, women, and transgender individuals at high risk of HIV infection. These studies will also define what levels of neutralizing antibody are required for protection. This satellite session will provide an overview of the AMP Studies, summarize ongoing advances in preclinical work, illustrate experiences implementing the Studies in Africa and in the Americas, and address next steps. This symposium will provide HIV R4P attendees with insight into the challenges and innovations required to move forward in the development of a globally effective HIV vaccine.

Chairs:
Glenda Gray (South African Medical Research Council, South Africa)
Larry Corey (Fred Hutchinson Cancer Research Center, United States)

Antibody Mediated Prevention and What It Takes to Make a HIV Vaccine?
Julie McElrath (Fred Hutchinson Cancer Research Center, United States)
Srilatha Edupuganti (Emory University, United States)
Nyaradzo Mgodi (University of Zimbabwe Collaborative Research Program, Zimbabwe)

SA16, Implementing HIV/AIDS Combination Interventions Tailored to Populations and Geographies at Scale

The Kenya HIV Prevention Revolution Roadmap (2014) provides a framework for the future orientation of the national HIV prevention response. The Roadmap revolutionized the global HIV response, by recommending that HIV investments be assigned by risk, population, and location profiling. Modelling data demonstrated that the proposed shifts would catalyse reduction of new HIV infections and AIDS-related deaths at no added costs, thus saving lives and averting deaths. The Roadmap recommended shifts in HIV prevention programming at county levels requiring managers to focus on: a) needs of populations rather than driving available interventions blindly toward all populations; b) granulation of the epidemic at sub-national level with appropriate interventions for each sub-epidemic; c) leveraging non-health sector interventions to deliver HIV prevention for hard-to-reach populations and also address structural determinants that drive HIV vulnerability. In the last year, Kenya has made progress in reorienting its HIV program to align to these recommended shifts, which are nontraditional in the HIV response framework globally. Stakeholders including PEPFAR, the Global Fund, and UNAIDS have begun and continue to invest in this approach. This session proposes to share data, experiences, and lessons from global partners and countries in implementing these shifts.

Implementing HIV/AIDS Combination Interventions Tailored to Populations and Geographies at Scale
Nduku Kilonzo (National AIDS Control Council, Kenya)
Nelly Mugo (Kenya Medical Research Institute (KEMRI), Kenya)
Geoffrey Garnett (Bill & Melinda Gates Foundation, United States)
Peter Cherutich (Ministry of Health, Kenya)
Satellites
09:00 - 11:30
Sheraton Ballroom I

SA17, Systems Biology and Vaccines – Implications for HIV Vaccine Design

Systems biology approaches may help accelerate HIV vaccine development by identifying predictors and genetic signatures of immunogenicity and protective immune responses. Some vaccines appear to be less effective in LMIC populations, with possible factors including nutrition, concomitant infections, and the host microbiome. Systems biology approaches provide an opportunity to understand the impact of these factors on immune response to vaccines for populations most at risk for HIV. Systems biology has been used to identify gene signatures that predict CD8+ T cell and B cell responses to influenza and yellow fever vaccination. However, applications for HIV vaccine development are not well described. This session will review current systems biology methodologies, examples of their use in vaccinology and immunology, and current research relevant to HIV vaccine development. A panel discussion will focus on potential high-priority applications of omics to HIV vaccine development, including microbiome and accompanying bioinformatics.

Chairs:
Bali Pulendran (Emory Vaccine Center, United States)
Rafick Sekaly (Case Western Reserve University, United States)

Systems Biology and Vaccines - Implications for HIV Vaccine Design